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Abstract	
Toll-like	receptors	(TLRs)	recognise	pathogenic	microorganisms	through	conserved	pathogen	associated	molecular	patterns,	which	activates	the	innate	immune	response.	TLR	signalling	is	mediated	by	cytoplasmic	adaptor	proteins	via	Toll/interleukin-1	receptor	(TIR)	domains.	Sterile	α-	and	armadillo-motif-containing	protein	(SARM)	is	the	fifth	TLR	adaptor	protein	identified	in	humans	and	has	been	described	as	a	negative	regulator	of	the	innate	immune	response.	Several	pathogenic	bacteria	are	also	known	to	express	proteins	with	TIR-domains,	which	are	believed	to	be	involved	in	disruption	of	TLR	signalling.	This	raises	the	question	of	whether	SARM	functions	in	a	similar	manner,	as	phylogenetic	studies	have	shown	that	SARM	is	closely	related	to	bacterial	proteins.			In	this	project,	functional	characterisation	of	SARM	and	a	bacterial	TIR	domain	protein	from	Bacillus	anthracis	(BaTdp)	have	been	performed	using	both	recombinantly	expressed	and	purified	proteins,	as	well	as	cellular	assays.	The	TIR	domains	of	both	SARM	and	BaTdp	were	found	to	form	heterotypic	TIR-TIR	interactions	with	multiple	human	TLR	adaptors,	including	Myeloid	differentiation	factor	88	(MyD88).	SARM	and	MyD88	both	localised	to	mitochondria	when	overexpressed	in	mammalian	cells,	and	SARM	overexpression	was	associated	with	a	reduction	of	TLR2-,	TLR4-	and	MyD88-induced	cytokine	activation.	A	single	amino	acid	residue	in	the	SARM	BB-loop	motif,	G601,	was	also	identified	as	being	critical	for	SARM’s	anti-inflammatory	effect.	A	short	peptide	derived	from	this	motif	was	able	to	target	MyD88	in	vitro	and	slightly	reduce	TLR4-mediated	cytokine	activation.	Overexpression	of	BaTdp	
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in	mammalian	cells	had	no	significant	effect	on	TLR-mediated	cytokine	activation.	Instead,	the	protein	targeted	microtubular	networks	in	the	cell	and	BaTdp	expression	was	associated	with	a	significant	increase	in	cellular	autophagy	activity.		The	findings	further	enhance	our	understanding	of	the	underlying	mechanisms	by	which	SARM	suppress	the	innate	immune	response,	and	also	describe	previously	unknown	functions	of	BaTdp.			 	
	 6	
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1.1	Brief	overview	of	the	immune	system	Our	bodies	are	under	constant	attack	from	different	pathogens,	but	most	of	the	time,	we	are	unaware	of	this	because	of	our	immune	system.	The	immune	system	is	a	magnificent	biological	machine	that	provides	protection	against	invading	pathogens	via	a	wide	range	of	sophisticated	mechanisms.	There	are	two	arms	of	immunity:	the	adaptive,	and	the	innate	immune	system,	although	there	is	no	exact	boundary	between	them	as	it	is	well	known	that	one	important	function	of	innate	immunity	is	to	coordinate	the	adaptive	immune	response	(Iwasaki	and	Medzhitov,	2015).	Adaptive	immunity	provides	protection	against	specific	pathogens	through	the	use	of	antibodies	and	requires	exposure	to	the	antigen	before	protection	is	available.	Innate	immunity	on	the	other	hand	is	encoded	in	our	genome	and	is	available	from	birth.	Although	it	is	not	antigen-specific,	innate	immunity	provides	a	much	faster	and	more	robust	response	against	invading	microbes.			
1.2	Innate	immunity	
1.2.1	Introduction	to	innate	immunity	Due	to	its	immediate	availability,	the	innate	immune	response	comprises	the	first	line	of	defence	against	pathogenic	infection,	but	unlike	adaptive	immunity,	it	does	not	provide	a	long	lasting	protection.	While	adaptive	immunity	is	only	found	in	vertebrates,	innate	immunity	is	also	present	in	plants,	fungi,	insects	and	invertebrate	animals	(Hoffmann	et	al.,	1999).	Thus	the	system	has	been	strongly	conserved	through	evolution	and	appears	to	predate	the	split	between	mammals	and	plants	(Belvin	and	Anderson,	1996).	It	operates	through	
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the	use	of	phagocytes,	such	as	macrophages	(MΦ)	and	dendritic	cells	(DC),	which	either	kill	the	invading	pathogen	directly	by	engulfing	them,	or	indirectly	by	secreting	inflammatory	molecules	that	are	harmful	to	the	invader.			
1.2.2	Macrophages	in	innate	immune	defence	The	majority	of	microorganisms	that	succeed	in	penetrating	the	epithelial	layer	are	immediately	recognised	and	removed	by	macrophages.	These	cells	are	derived	from	monocytes	generated	in	the	bone	marrow	and	released	into	circulation.	They	congregate	in	strategic	positions	throughout	the	body	where	microbial	invasion	is	likely	to	occur,	or	where	debris	from	the	environment	(e.g.	dust)	tends	to	accumulate	(Geissmann	et	al.,	2010,	Murray	and	Wynn,	2011,	Wynn	et	al.,	2013).	Once	phagocytosed	by	a	macrophage,	the	pathogen	becomes	trapped	in	a	phagosome	which	then	fuses	with	a	lysosome	containing	digestive	enzymes	in	order	to	kill	the	invader.	Apoptotic	cells	are	also	cleared	with	this	mechanism,	preventing	a	build-up	of	dead	cells	in	the	system.	In	response	to	pathogen	detection,	macrophages	also	secrete	a	wide	range	of	chemicals	and	proteins	with	the	purpose	of	both	harming	the	pathogen	and	recruiting	other	immune	cells	to	the	site.		Because	of	their	potential	destructive	force,	it	is	critical	that	macrophages	and	other	immune	cells	efficiently	discriminate	between	self	and	non-self.	How	exactly	this	is	done	has	long	been	a	central	question	in	the	field	of	immunology	(Beutler,	2009),	and	the	natural	answer	would	be	that	they	possess	certain	receptors	capable	of	differentiating	self	and	non-self.	However,	at	a	glance	this	appears	to	be	slightly	contradictory	to	the	concept	of	innate	immunity.	If	millions	of	different	pathogens	exist,	all	in	continuous	evolution,	how	could	a	cell	possibly	
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recognise	them	all	without	even	encountering	them	first?	The	answer	lies	in	the	so-called	pattern	recognition	receptors	(PRRs),	which	do	not	detect	pathogens	as	a	whole,	but	rather	certain	conserved	motifs	characteristic	of	the	microbes.		
1.2.3	Pattern	recognition	receptors	Pattern	recognition	receptors	(PRRs)	play	a	critical	role	in	innate	immunity	as	they	allow	immune	cells	to	discriminate	between	self	and	non-self	(Medzhitov,	2007).	Examples	of	PRRs	include	the	Toll-like	receptors	(TLRs),	C-type	lectin	receptors	(CLRs),	Retinoic	acid-inducible	gene	(RIG)-I-like	receptors	(RLRs)	and	NOD-like	receptors	(NLRs)	(Takeuchi	and	Akira,	2010).	These	are	either	transmembrane,	cytoplasmic,	or	secreted	proteins	capable	of	recognising	pathogen-associated	molecular	patterns	(PAMPs)	(Janeway,	1989).	PAMPs	are	molecular	motifs	shared	by	multiple	microorganisms	that	are	typically	vital	for	their	survival	and	therefore	conserved	(Akira	et	al.,	2006).	As	these	motifs	are	not	exclusive	to	pathogenic	microbes,	the	term	PAMP	has	been	called	a	misnomer	(Ausubel,	2005),	and	microbe-associated	molecular	patterns	(MAMPs)	are	sometimes	used	instead	(Didierlaurent	et	al.,	2005,	Mackey	and	McFall,	2006).	The	first	identified,	and	to	date,	the	best	studied	class	of	PRRs	are	the	TLRs,	with	the	first	characterised	receptor	in	the	family,	TLR4,	initially	identified	as	a	homologue	to	the	Toll-receptor	in	Drosophila	(Medzhitov	et	al.,	1997).					
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1.2.4	Toll-like	receptors	The	TLRs	are	a	family	of	type	I	transmembrane	receptors	expressed	predominantly	on	macrophages,	mast	cells,	and	DCs	(Kawai	and	Akira,	2009).	TLRs	are	believed	to	exist	as	either	hetero-	or	homo-dimers	in	vivo	(Ozinsky	et	al.,	2000).	They	are	located	either	on	the	cell	surface	or	in	endosomal	compartments	(Akira	et	al.,	2006,	Blasius	and	Beutler,	2010)	and	play	a	central	role	in	activation	of	the	initial	innate	immune	response	upon	infection	(Beutler,	2004,	Takeda	and	Akira,	2005,	West	et	al.,	2006).	There	is	also	significant	evidence	for	their	involvement	in	directing	the	later	adaptive	immune	response	(Janeway	and	Medzhitov,	2002,	Kawai	and	Akira,	2011).	So	far,	13	functional	TLRs	have	been	identified	in	mammals	(Kawai	and	Akira,	2006),	of	which	10	are	present	in	humans.	TLRs	1,	2,	4,	5	and	6	are	expressed	on	the	cell	surface,	while	TLRs	3,	7,	8	and	9	are	expressed	inside	cellular	compartments.		TLRs	are	characterised	by	having	an	extracellular	domain	which	includes	19-25	tandem	copies	of	leucine-rich	repeats	(LRRs)	(Bell	et	al.,	2003,	Kobe	and	Kajava,	2001)	capable	of	recognising	various	PAMPs,	a	single	transmembrane	helix,	as	well	as	a	conserved	C-terminal	region	of	around	100	to	200	amino	acids	in	the	cytoplasmic	part	of	the	receptor	known	as	the	Toll/interleukin-1	receptor	(TIR)	domain	(Slack	et	al.,	2000)	(Fig.	1.1).		
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Figure	1.1	Schematic	overview	of	the	domain	organisation	of	a	Toll-like	receptor	
(TLR).	The	extracellular	part	of	the	Toll-like	receptor	contains	multiple	leucine-rich	repeats	(LRRs)	capable	of	recognising	pathogen-associated	molecular	patterns	(PAMPs).	On	the	intracellular	side,	a	Toll/interleukin-1	receptor	(TIR)	domain	is	responsible	for	mediating	downstream	signalling.		
1.2.5	Signalling	pathways	used	by	TLRs	The	TLRs	are	not	only	different	in	terms	of	expression	profiles	and	ligand	specificities,	but	also	with	regard	to	the	individual	genes	they	induce	upon	activation.	Receptor	recognition	of	PAMPs	eventually	leads	to	the	activation	of	NFκB	and	the	release	of	pro-inflammatory	cytokines,	but	the	pathways	used	to	propagate	downstream	signalling	varies	from	the	different	receptors.	Broadly	speaking,	two	different	TLR	signalling	pathways	exist:	the	myeloid	differentiation	factor	88	(MyD88)-dependent	pathway	and	the	TIR-domain-containing	adaptor	protein	inducing	IFNβ	(TRIF)-dependent	pathway	(also	known	as	the	MyD88-independent	pathway),	which	reflect	the	TLR	adaptor	protein	initially	coupled	by	the	receptor.	As	shown	in	Figure	1.2,	all	human	TLRs	characterised	to	date,	except	TLR3,	utilise	the	MyD88-dependent	pathway,	while	TLRs	3	and	4	utilise	the	TRIF-dependent	pathway.		MyD88	has	previously	been	shown	to	be	a	critical	component	of	interleukin-1	receptor	(IL-1R)	signalling	(Muzio	et	al.,	1997)	and	was	known	to	
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function	by	interacting	with	multiple	proteins	in	the	Interleukin-1	receptor-associated	kinase	(IRAK)	family.	We	now	know	that	these	interactions	are	mediated	via	a	death	domain	(DD)	located	near	the	N-terminus	of	MyD88	and	results	in	dimerised	MyD88	forming	complexes	with	IRAK4,	IRAK1	and/or	IRAK2	(Loiarro	et	al.,	2009).	Further	propagation	of	TLR	signalling	is	then	enabled	by	the	phosphorylation	of	IRAK1	and	2	by	IRAK4,	enabling	the	recruitment	of	tumour	necrosis	factor	receptor–associated	factor	6	(TRAF6),	which	in	turn	acts	as	a	platform	for	activating	several	kinases	crucial	for	the	activation	of	immune	related	transcription	factors	such	as	NFκB	(Narayanan	and	Park,	2015).		Studies	on	MyD88-deficient	mice	later	revealed	that	the	protein	is	also	required	for	proper	TLR4-signalling,	as	the	production	of	pro-inflammatory	cytokines	following	challenge	with	the	TLR4	ligand	lipopolysaccharide	(LPS)	was	impaired	in	these	animals	(Adachi	et	al.,	1998,	Kawai	et	al.,	1999).	Further	studies	also	confirmed	that	MyD88	was	a	necessary	component	for	transducing	signalling	by	TLRs	2,	5,	6,	7,	8	and	9	(Beutler	et	al.,	2005)	indicating	that	all	of	these	receptors	couple	to	MyD88	following	PAMP	recognition.	However,	while	the	effect	of	stimulating	these	receptors	were	completely	absent	in	MyD88-deficient	cells,	stimulation	of	TLR4	with	LPS	still	provoked	a	weakened	and	slightly	delayed	immune	response,	indicating	the	existence	of	a	secondary	pathway	used	by	this	receptor.	Unlike	the	other	receptors	found	to	utilise	MyD88,	stimulation	of	TLR4	was	also	found	to	result	in	the	activation	of	IRF3	(Kawai	et	al.,	1999),	mimicking	the	effect	of	TLR3-stimulation	and	suggesting	that	these	two	receptors	act	via	a	shared	pathway.	These	suspicions	were	later	
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confirmed	with	the	discovery	of	TRIF,	which	was	found	to	mediate	both	TLR3-	and	TLR4-signalling.	TLR	recruitment	of	TRIF	activates	the	dimersiation	of	IRF3	through	a	series	of	phosphorylations	and	ubiquitinations	of	intermediary	signalling	proteins,	enabling	IRF3	to	translocate	into	the	cell	nucleus	and	induce	IFNβ	(Kim	et	al.,	2013).	TRIF	also	acts	by	coupling	to	TRAF6	via	its	N-terminus,	and	to	multiple	receptor-interacting	proteins	via	its	C-terminus,	which	both	leads	to	the	activation	of	NFκB	(Narayanan	and	Park,	2015).	
	
Figure	1.2	Schematic	overview	of	signalling	pathways	used	by	TLRs	with	regard	to	
adaptor	protein.	Upon	TLR	dimerisation,	downstream	signalling	is	mediated	either	via	MyD88	or	TRIF.	TLRs	5	and	7-9	bind	directly	to	MyD88,	while	MAL	is	used	as	a	bridging	protein	by	TLR4,	as	well	as	heterodimers	of	TLR2	and	1	or	6,	to	mediate	MyD88-dependent	signalling.	TLR3	uses	TRIF	to	mediate	signalling,	while	TLR4	can	also	engage	in	TRIF-dependent	signalling	via	the	bridging	protein	TRAM.			 To	ensure	that	a	balance	exist	between	activation	and	inhibition	of	TLR	signalling,	multiple	mechanisms	exist	to	attenuate	the	TLR	immune	response	in	order	to	avoid	uncontrolled	inflammation	(Kondo	et	al.,	2012,	Liew	et	al.,	2005).	One	example	is	via	the	secretion	of	soluble	forms	of	TLRs,	which	likely	acts	by	
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inhibiting	the	ability	of	membrane-bound	TLRs	to	form	receptor	complexes	necessary	for	PAMP	recognition.	Soluble	forms	of	TLR4	(Iwami	et	al.,	2000)	and	TLR2	(LeBouder	et	al.,	2003)	have	been	identified,	and	both	of	these	proteins	were	shown	to	inhibit	the	activation	of	inflammatory	cytokines	following	cellular	stimulation	with	the	corresponding	PAMP.	Inhibition	of	signal	transduction	can	also	occur	on	the	intracellular	side	of	the	receptor	via	a	similar	mechanism,	where	variants	of	TIR-domain	proteins	block	downstream	signalling	by	interfering	with	the	ability	of	receptors	or	adaptors	to	form	complexes.	One	example	is	an	alternative	splice	variant	of	MyD88	(MyD88s),	which	is	able	to	inhibit	LPS-induced	NFκB	activation	(Janssens	et	al.,	2002)	by	forming	a	heterodimer	with	MyD88	that	blocks	the	ability	of	IRAK4	to	phosphorylate	IRAK1	(Burns	et	al.,	2003,	Janssens	et	al.,	2003),	thereby	inhibiting	further	downstream	signalling.		The	central	role	TIR	domains	play	in	TLR	signalling	has	also	made	them	important	targets	for	drug-induced	inhibition	of	TLR-mediated	immune	activation.	Multiple	groups	have	shown	that	peptides	targeting	TIR-proteins	have	the	ability	to	interfere	with	their	ability	to	form	complexes	necessary	for	signal	transduction	(Couture	et	al.,	2012,	Loiarro	et	al.,	2005,	Piao	et	al.,	2013a,	Piao	et	al.,	2013b,	Toshchakov	et	al.,	2005,	Toshchakov	et	al.,	2011).	An	established	approach	for	designing	these	peptides	is	to	model	them	after	exposed	regions	of	proteins	involved	in	TIR-domain	complex	formation.	For	example,	Toshchakov	and	colleagues	used	the	crystal	structure	of	the	TLR4	TIR-domain	to	design	a	set	of	decoy	peptides	representing	the	domain	surface	regions	(Toshchakov	et	al.,	2011).	Five	of	these	peptides	were	then	found	to	potently	inhibit	LPS-mediated	cytokine	activation.	This	strategy	is	not	only	
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useful	for	identifying	novel	peptides	with	immunosuppressive	function,	but	also	provides	insight	to	the	mechanisms	used	by	TIR-proteins	to	form	heterotypic	TIR-TIR	interactions.		
1.2.6	LRR	domains	The	TLRs	recognise	PAMPs	through	their	ectodomain	(ECD)	which	features	tandem	LRRs	that	form	structural	frameworks	capable	of	recognising	the	corresponding	ligand.	These	motifs	feature	an	11	amino	acid	long	consensus	sequence	of	LxxLxLxxN/CxL,	where	x	can	be	any	residue	and	leucine	(L),	which	is	sometimes	replaced	by	other	hydrophobic	residues	valine	(V),	isoleucine	(I)	or	phenylalanine	(F)	(Kobe	and	Kajava,	2001).	In	1993,	Kobe	and	colleagues	solved	the	first	structure	of	an	LRR	domain	when	they	crystallised	porcine	ribonuclease	inhibitor	(Fig.	1.3)	(Kobe	and	Deisenhofer,	1993),	and	since	then,	TLR	LRR	domain	structures	have	been	solved	with	human	(Bell	et	al.,	2005,	Choe	et	al.,	2005)	(Fig.	1.4)	and	mouse	TLR3	(Liu	et	al.,	2008),	human	TLR2	in	complex	with	either	TLR1	(Jin	et	al.,	2007)	or	TLR6	(Kang	et	al.,	2009),	mouse	(Kim	et	al.,	2007a)	and	human	(Park	et	al.,	2009)	TLR4,	zebrafish	TLR5	(Yoon	et	al.,	2012),	human	TLR8	(Tanji	et	al.,	2013),	as	well	as	human,	bovine,	horse	and	mouse	TLR9	(Ohto	et	al.,	2015),	among	others.	The	domains	typically	form	a	non-globular	horseshoe	shaped	molecule	with	β-sheets	running	along	the	surface	of	the	inner	curve,	while	the	surface	of	the	outside	curve	features	multiple	α-helices	(Figures	1.3	and	1.4).	
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Figure	1.3	Structure	of	LRR	
domain	of	porcine	ribonuclease	
inhibitor.	Crystal	structure	of	the	LRR	domain	of	porcine	ribonuclease	inhibitor	(Protein	data	bank;	PDB	entry	2BNH)	(Kobe	and	Deisenhofer,	1996).	α-helices	are	coloured	in	red,	β-sheets	in	yellow	and	loop-regions	in	green.	Structure	was	visualised	using	PyMOL.		 			
Figure	1.4	Structure	of	LRR	
domain	of	human	TLR3.	Crystal	structure	of	the	LRR	domain	of	human	TLR3	(Protein	data	bank;	PDB	entry	2A0Z)	(Bell	et	al.,	2005).	α-helices	are	coloured	in	red,	β-sheets	in	yellow	and	loop-regions	in	green	Structure	was	visualised	using	PyMOL.		 		 	Many	of	the	TLR	ECDs	are	known	to	form	either	homo-	or	hetero-	dimers	in	a	membranous	environment,	e.g.	Triantafilou	and	colleagues	have	shown	that	the	ECD	of	TLR2	can	associate	with	those	of	TLR1	and	6	(Triantafilou	et	al.,	2006),	while	Latz	and	colleagues	have	shown	that	the	TLR9	ECD	exists	as	a	dimer	both	before	and	after	binding	to	its	ligand	(Latz	et	al.,	2007).	In	TLRs,	ECD	binding	to	a	PAMP	triggers	a	conformational	change	in	the	receptor,	which	enables	it	to	recruit	cytoplasmic	adaptor	proteins	via	its	TIR	domain	to	further	propagate	immune	signalling.	TLR3	binds	to	double	stranded	
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RNA	(dsRNA)	(Alexopoulou	et	al.,	2001),	TLR4	mainly	binds	to	LPS	(Lien	et	al.,	2000,	Poltorak	et	al.,	1998,	Poltorak	et	al.,	2000,	Qureshi	et	al.,	1999),	TLR5	binds	to	flagellin	(Hayashi	et	al.,	2001),	TLR7	(Lund	et	al.,	2004)	and	8	(Heil	et	al.,	2004)	both	bind	to	single	stranded	RNA,	and	TLR9	binds	to	bacterial	CpG	DNA	(Bauer	et	al.,	2001,	Hemmi	et	al.,	2000,	Takeshita	et	al.,	2001).	TLR2	binds	to	a	large	set	of	PAMPs,	such	as	peptidoglycan	(Schwandner	et	al.,	1999,	Takeuchi	et	al.,	1999,	Yoshimura	et	al.,	1999),	lipoteichoic	acid	(LTA)	(Lehner	et	al.,	2001,	Schwandner	et	al.,	1999),	lipoarabinomannan	(LAM)	(Means	et	al.,	1999),	lipoproteins/lipopeptides	(Takeuchi	et	al.,	2002),	and	LPS	(Gantner	et	al.,	2003,	Girard	et	al.,	2003,	Underhill	et	al.,	1999a,	Werts	et	al.,	2001).	Its	wide	set	of	associated	PAMPs	might	be	due	to	the	fact	that	TLR2	forms	heterodimers	together	with	other	TLRs,	thereby	increasing	its	range	of	recognition	(Ozinsky	et	al.,	2000).	Figure	1.5	shows	the	ECD	of	TLR2	in	heterodimer	formation	with	the	ECDs	of	TLR1	and	TLR6.	Although	neither	the	cellular	expression	pattern	nor	exact	ligand(s)	for	TLR10	are	known,	a	recent	study	has	indicated	that	the	receptor	plays	a	functional	role	in	the	induction	of	immune	responses	to	influenza	virus	infection	(Lee	et	al.,	2014).			
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Figure	1.5	Dimerisation	of	human	TLR2	ECD	with	ECDs	of	TLR1	and	TLR6	LRR	
domains.	(A)	Crystal	structure	of	the	LRR	domains	of	human	TLR1	and	2	in	complex	with	Pam3CSK4	(Protein	data	bank;	PDB	entry	2Z7X)	(Jin	et	al.,	2007).	TLR1	is	marked	in	cyan,	TLR2	in	magenta	and	Pam3CSK4	in	orange.	(B)	Crystal	structure	of	the	LRR	domains	of	human	TLR2	and	6	in	complex	with	Pam2CSK4	(Protein	data	bank;	PDB	entry	3A79)	(Kang	et	al.,	2009).	TLR6	is	marked	in	cyan,	TLR2	in	magenta	and	Pam2CSK4	in	orange.	Structures	were	visualised	using	PyMOL.		
1.2.7	TIR	domains	Mediation	of	protein-protein	interactions	is	believed	to	be	the	main	function	of	the	TIR-domain	(Kopp	and	Medzhitov,	1999),	which	is	also	present	in	IL-1Rs	and	TLR	adaptor	proteins.	Upon	TLR	ligand	binding,	downstream	signalling	is	mediated	via	the	TIR-domain	of	the	TLR	and	TIR-containing	adaptor	proteins	by	utilisation	of	heterotypic	protein-protein	interactions	between	receptors	and	adaptor	proteins,	which	ultimately	results	in	the	activation	of	immune	related	genes	and	the	release	of	inflammatory	cytokines,	chemokines	and	interferons	(Kawai	and	Akira,	2005).	Sequence	alignment	of	the	TIR-domains	from	a	selection	of	TLRs	and	adaptor	proteins	(Fig.	1.6)	reveals	a	rather	weak	overall	sequence	similarity,	with	notable	exceptions	being	the	three	regions	referred	to	as	boxes	1,	2	and	3,	believed	to	be	important	for	signalling	
	 34	
(Slack	et	al.,	2000).	Despite	this,	structural	studies	of	TIR	domains	have	revealed	a	surprisingly	high	structural	similarity.		
	
Figure	1.6	Multi-sequence	alignment	of	human	TIR	domains.	Alignment	of	selected	TIR	domain	sequences	of	human	SARM	(residues	563-704),	MyD88	(residues	159-296),	MAL	(residues	84-230),	TRIF	(residues	393-555),	TRAM	(residues	77-225),	TLR1	(residues	639-775),	TLR2	(residues	641-784),	TLR4	(residues	632-781),	TLR5	(residues	695-835)	and	TLR6	(residues	644-780).	Residues	are	shaded	according	to	level	of	conservation.	Secondary	structure	elements	are	based	on	the	TLR1	structure	(Xu	et	al.,	2000).	The	box	1,	box	2	and	box	3	regions	are	indicated	by	red	boxes.	Alignment	was	generated	using	MAFFT	v.7.220	(Katoh	et	al.,	2005)	and	visualised	in	Jalview	(Waterhouse	et	al.,	2009).		
1.2.8	Structural	features	of	TIR	domains	The	crystal	structures	of	the	TIR	domains	from	TLRs	1	and	2	were	solved	in	the	year	2000	by	Xu	and	colleagues	and	showed	that	these	domains	contain	a	central	five-stranded	parallel	β-sheet,	surrounded	by	five	α-helices	(Fig.	1.7)	(Xu	et	al.,	2000).	The	structures	of	the	TLR10	(Nyman	et	al.,	2008)	and	TLR6	(Jang	and	Park,	2014)	TIR	domains,	those	belonging	to	adaptor	proteins	MyD88	(Ohnishi	et	al.,	2009,	Snyder	et	al.,	2013)	and	MyD88-adaptor-like	protein	(MAL)	(Lin	et	al.,	2012,	Valkov	et	al.,	2011),	as	well	as	interleukin-1	receptor	accessory	
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protein-like	(IL-1RAPL)	(Khan	et	al.,	2004)	have	also	been	solved,	and	all	share	some	common	architectural	features.		The	exposed	BB-loop,	named	for	connecting	the	strand	βB	and	helix	αB,	is	believed	to	play	an	important	role	in	signal	transduction	of	TIR	proteins.	This	motif,	located	on	the	box2	region	of	the	TIR	sequence,	comprises	approximately	10	amino	acids	(Fig.	1.8).	Mutational	studies	have	revealed	that	the	proline	residue	located	in	the	φ2	position	of	the	RDxφ1φ2G	motif	(where	x	corresponds	to	any	amino	acid	residue	and	φ	corresponds	to	a	hydrophobic	residue)	in	this	region	plays	a	crucial	role	in	the	functionality	of	TLR2	(Underhill	et	al.,	1999a,	Underhill	et	al.,	1999b),	TLR4	(Hoshino	et	al.,	1999,	Poltorak	et	al.,	1998)	and	TLR10	(Hasan	et	al.,	2005).	Xu	and	colleagues	have	also	demonstrated	that	mutations	of	the	conserved	R,	D	and	G	residues	in	the	TLR4	TIR	domain	BB-loop	resulted	in	significantly	reduced	signalling	activity	of	the	receptor	(Xu	et	al.,	2000),	further	underlining	the	functional	importance	of	this	motif.		
Figure	1.7	Structure	of	TIR	domain	
of	human	TLR1.	Crystal	structure	of	the	TIR	domain	of	human	TLR1	(Protein	data	bank;	PDB	entry	1FYV	(Xu	et	al.,	2000).	Exposed	loop	regions:	BB,	DD	and	EE,	as	well	as	N-	and	C-terminals	are	marked.	α-Helices	are	coloured	in	red,	β-sheets	in	yellow	and	loop-regions	in	green.	The	structure	was	visualised	using	PyMOL.						
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Figure	1.8	Sequence	alignment	of	human	TIR	
domain	BB	loop.	Multiple	sequence	alignment	of	the	predicted	BB-loop	sequences	of	human	SARM,	TRIF,	MyD88,	MAL,	TRAM	and	TLRs	1,	2,	4,	5	and	6,	reveals	a	strong	conservation	of	four	amino	acids:	the	arginine	(R)	residue	in	position	3,	aspartic	acid	(D)	in	position	4,	proline	in	position	7,	and	the	glycine	in	position	8.	Alignment	was	visualised	in	Jalview	(Waterhouse	et	al.,	2009).			
1.2.9	Cytosolic	TLR	adaptor	proteins	TLR	adaptor	proteins	bind	to	the	TIR	domain	of	the	TLR	and	mediate	downstream	signalling.	To	date,	five	TLR	adaptor	proteins,	listed	below,	have	been	identified	in	humans	(O'Neill	and	Bowie,	2007).	
• Myeloid	differentiation	factor	88	(MyD88)	(Medzhitov	et	al.,	1998).		
• MyD88-adaptor-like	protein	(MAL)	(Fitzgerald	et	al.,	2001)	also	known	as		TIR	domain-containing	adaptor	protein	(TIRAP)	(Horng	et	al.,	2001).		
• TIR-domain-containing	adaptor	protein	inducing	IFNβ	(TRIF)	(Yamamoto	et	al.,	2002)	also	known	as	TIR-containing	adaptor	molecule	1	(TICAM1)	(Oshiumi	et	al.,	2003a).		
• TRIF-related	adaptor	molecule	(TRAM)	(Fitzgerald	et	al.,	2003,	Yamamoto	et	al.,	2003)	also	known	as	TIR-containing	adaptor	molecule	2	(TICAM2)	(Oshiumi	et	al.,	2003b)	or	TIR	domain-containing	protein	(TIRP)	(Bin	et	al.,	2003).		
• Sterile	α-	and	armadillo-motif-	containing	protein	(SARM)	(Mink	et	al.,	2001).	
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The	TLR	adaptor	proteins	are	sometimes	also	referred	to	as	the	MyD88	family,	where	the	terms	MyD88-2,	-3,	-4,	and	-5	are	used	to	describe	MAL,	TRIF,	TRAM,	and	SARM,	respectively.	As	previously	shown	in	Figure	1.2,	signalling	downstream	of	the	TLR	is	mediated	via	the	MyD88-	or	TRIF-dependent	pathway,	while	MAL	and	TRAM	have	been	described	as	bridging	proteins,	recruiting	MyD88	and	TRIF,	respectively	(O'Neill	and	Bowie,	2007).	All	TLRs	except	TLR3	utilise	the	MyD88-dependent	pathway	(Janssens	and	Beyaert,	2002),	while	the	TRIF-dependent	pathway	is	used	by	TLRs	3	and	4	(O'Neill	and	Bowie,	2007)	(Table	1.1).	Although	the	roles	of	MyD88,	MAL,	TRIF	and	TRAM	are	comparatively	well	understood,	the	biological	functions	of	SARM	are	less	clear.			
Table	1.1.	Human	TLRs,	their	adaptors	and	ligands.	
TLR	 Localisation	 Adaptors	used	 Main	PAMPs	 PAMP	origin	
TLR2-1	heterodimer	 Cell	surface	 MAL,	MyD88	 Triacyl	lipoprotein	 Bacteria	
TLR2-6	heterodimer	 Cell	surface	 MAL,	MyD88	 Diacyl	lipoprotein	 Bacteria	
TLR3	 Endosome	 TRIF	 dsRNA	 Viruses	
TLR4	 Cell	surface	 MAL,	MyD88,	
TRAM,	TRIF	
LPS	 Bacteria	
TLR5	 Cell	surface	 MyD88	 Flagellin	 Bacteria	
TLR7	 Endosome	 MyD88	 ssRNA	 Bacteria,	viruses,	
fungi	
TLR8	 Endosome	 MyD88	 ssRNA	 Viruses	
TLR9	 Endosome	 MyD88	 DNA	 Bacteria,	viruses,	
fungi	
TLR10	 Endosome	 Unknown	 Unknown	 Unknown	Summary	of	the	localisation	and	adaptor	proteins	used	by	the	10	TLRs	identified	in	humans.					
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1.2.10	SARM	SARM	was	the	last	of	the	five	mammalian	TLR	adaptor	proteins	to	be	identified,	and	was	originally	described	as	an	ortholog	of	the	Drosophila	gene	CG7915	(Mink	et	al.,	2001),	although	the	presence	of	a	TIR-domain	was	not	initially	reported.	It	is	a	highly	conserved	protein	found	among	multiple	species,	including	horseshoe	crab	(Belinda	et	al.,	2008),	Caenorhabditis	elegans	(Couillault	et	al.,	2004),	amphioxus	(Yuan	et	al.,	2010),	zebrafish	(Jault	et	al.,	2004,	Meijer	et	al.,	2004)	and	whiteleg	shrimp	(Wang	et	al.,	2013),	suggesting	an	ancient	origin	of	this	protein.	Phylogenetic	studies	have	also	suggested	that	SARM	is	closely	related	to	bacterial	TIR-proteins	(Zhang	et	al.,	2011).		Human	SARM	was	originally	found	to	be	expressed	in	the	liver	and	kidney	(Mink	et	al.,	2001)	and	occurs	in	two	alternative	isoforms	comprised	of	either	690	or	724	amino	acids.	The	protein	contains	two	armadillo	motif	(ARM)	domains,	two	adjacent	sterile	α-motif	(SAM)	domains,	and	a	C-terminal	TIR-domain	(Fig.	1.9).	SAM	domains	are	common	protein-protein	interaction	motifs	found	in	eukaryotes	(Qiao	and	Bowie,	2005)	that	are	often	used	to	form	multimeric	complexes.	The	ARM	domain	often	occurs	as	tandem	repeats	and	is	named	after	the	domain	in	the	armadillo	protein,	the	Drosophila	ortholog	of	β-catenin,	that	is	responsible	for	protein	binding	(Riggleman	et	al.,	1989).	
	
Figure	1.9	Schematic	overview	of	human	SARM	protein	domains.	Five	individual	domains	have	been	predicted	in	human	SARM:	two	tandem	ARM	domains	and	two	SAM	domains	centrally	located	in	the	amino	acid	sequence,	as	well	as	a	TIR	domain	near	the	C-terminus.	ARM,	Armadillo	motif;	SAM,	Sterile	α-motif;	TIR,	Toll/interleukin-1	receptor	domain.	
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1.2.11	SARM	is	an	anti-inflammatory	protein	In	a	study	by	Carty	and	colleagues,	SARM	expression	was	shown	to	be	associated	with	an	inhibition	of	TLR3-	and	TLR4-	mediated	signalling	in	mammalian	cell	lines,	and	as	direct	interaction	between	SARM	and	TRIF	was	detected	by	yeast	two-hybrid	analysis,	they	speculated	that	the	mechanism	of	action	involved	a	disruption	of	TRIF-mediated	signalling	downstream	of	the	receptors	(Carty	et	al.,	2006).	SARM	was	able	to	reduce	both	NFκB	and	IRF7	activation	induced	by	TRIF	expression,	but	not	MyD88	expression,	estimated	by	luciferase	reporter	assay.	As	NFκB	activation	is	required	for	inducing	expression	of	inflammatory	cytokines	and	IRF7	is	a	key	regulator	of	interferon	induction	(Honda	et	al.,	2005),	this	suggested	that	the	anti-inflammatory	effect	of	SARM	was	restricted	to	the	TRIF-dependent	pathway.	Knockdown	of	SARM	was	also	not	associated	with	any	difference	in	IL-8	secretion	induced	by	IL-1	stimulation,	measured	by	ELISA,	further	suggesting	that	SARM	does	not	act	on	the	MyD88-dependent	pathway.	In	contrast	to	this	study,	Peng	and	colleagues	were	able	to	demonstrate	that	SARM	expression	in	HEK293	cells	was	associated	with	an	inhibition	of	activator	protein	1	(AP-1)	activity	induced	by	both	expression	of	MyD88	and	TRIF	(Peng	et	al.,	2010).	As	AP-1	is	an	important	transcription	factor	in	addition	to	NFκB	and	IRF-3	during	TLR	activation	(Sen	and	Sarkar,	2005),	these	results	indicate	that	SARM’s	anti-inflammatory	effect	is	not	restricted	to	the	TRIF	dependent	pathway.	SARM	overexpression	was	also	shown	to	reduce	phosphorylation	of	p38	in	a	dose-dependent	manner,	thus	inhibiting	the	MAPK	pathway	independently	of	TRIF	or	MyD88.	In	their	study	of	amphioxus	SARM,	Yuan	and	colleagues	showed	that	the	protein	was	able	to	suppress	IL-8	secretion	
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in	HEK293	cells	induced	by	overexpression	of	the	human	MyD88	(Yuan	et	al.,	2010).	NFκB	activation	induced	by	IL-1	stimulation	was	also	reduced	following	amphioxus	SARM	expression.	Although	these	experiments	were	not	performed	with	human	SARM,	they	can	be	considered	an	indication	that	human	SARM	may	target	the	MyD88-dependent	pathway,	as	the	protein	displays	a	strong	evolutionary	conservation	throughout	different	species.	Studies	have	shown	that	both	the	SAM-	and	TIR-	domains	of	SARM	are	required	for	negative	regulation	of	the	immune	system	both	in	human	(Carty	et	al.,	2006)	and	in	horseshoe	crab	(Belinda	et	al.,	2008),	while	deleting	the	N-terminal	portion	of	the	protein	actually	increased	the	inhibitory	effect	in	both	studies.	After	immune	activation,	SARM	expression	has	been	reported	to	be	both	upregulated	(Piao	et	al.,	2009)	and	downregulated	(de	Vos	et	al.,	2009),	causing	some	confusion	to	what	its	actual	biological	function	is	with	regard	to	the	immune	system.	It	has	been	demonstrated	that	TIR-1,	the	C.	elegans	homologue	of	human	SARM,	plays	an	important	role	in	worm	immunity,	but	here	as	a	positive	regulator.	Inactivation	of	TIR-1	by	RNA	interference	resulted	in	decreased	expression	of	antimicrobial	peptides	NLP-29	and	NLP-31,	increasing	susceptibility	to	infection	(Couillault	et	al.,	2004).	The	same	method	has	also	been	used	to	show	that	the	TIR-1	gene	is	required	for	activation	of	p38	mitogen-activated	protein	kinase	(PMK-1),	the	C.	elegans	homologue	of	mammalian	p38	mitogen-activated	protein	kinase	(MAPK),	which	is	an	important	regulator	of	the	immune	response	(Liberati	et	al.,	2004).				
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1.2.12	SARM	is	a	pro-apoptotic	protein	Besides	being	shown	to	have	an	anti-inflammatory	potential,	studies	later	also	implicated	SARM	as	being	involved	in	inducing	cell	death.	In	2005,	Chuang	and	Bargmann	showed	that	the	C.	elegans	SARM	homologue	was	highly	concentrated	at	post-synaptic	regions	of	axons,	with	the	SAM-domains	mediating	protein	localisation,	and	regulation	of	olfactory	receptor	expression	(Chuang	and	Bargmann,	2005).	Using	Northern	blot	analysis,	Kim	and	colleagues	later	showed	that	mouse	SARM	was	mainly	expressed	in	brain	tissue,	specifically	in	neurons	(Kim	et	al.,	2007b),	which	is	somewhat	contradictory	to	the	results	previously	presented	by	Mink	and	colleagues	which	did	not	indicate	any	SARM	expression	in	the	brain.	The	protein	was	observed	to	be	localised	to	the	mitochondria	where	it	associated	with	microtubules	and	cytosolic	JNK3.	As	both	mitochondria	and	JNK3	are	known	to	regulate	apoptosis	during	cellular	stress,	they	speculated	that	SARM	might	also	be	functionally	relevant	in	this	regard.	They	found	that	hippocampal	neurons	from	SARM-deficient	mice	were	protected	from	cell	death	induced	by	deprivation	of	oxygen	and	glucose,	suggesting	that	SARM	may	be	important	for	regulating	apoptosis	in	these	cells.	In	a	study	by	Chen	and	colleagues,	SARM’s	involvement	in	mouse	neuronal	morphogenesis	was	further	underlined	when	the	protein	was	shown	to	mediate	dendritic	arborisation	via	interaction	with	syndecan-2	(Sdc2)	(Chen	et	al.,	2011).	SARM	expression	in	COS-1	cells	was	also	shown	to	have	a	stabilising	function	on	tubulin	through	increased	acylation	levels.	In	2012,	a	landmark	publication	by	Osterloh	and	colleagues	conclusively	showed	that	Drosophila	and	mouse	SARM	homologues	were	important	for	injury-induced	axonal	degeneration	(Osterloh	et	al.,	2012).	This	process	had	traditionally	been	thought	
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to	be	the	result	of	a	passive	mechanism	following	the	lack	of	nutrients	to	the	cell.	However		certain	mouse	strains	had	been	found	to	display	an	unusually	strong	resistance	to	cell	death	following	axotomy	(Glass	et	al.,	1993,	Lunn	et	al.,	1989).	By	screening	for	mutations	in	Drosophila	associated	with	suppression	of	axonal	cell	death,	the	SARM	gene	was	identified	as	being	functionally	important,	and	by	using	both	Drosophila	and	mouse	SARM	knockout	(KO)	models,	they	then	showed	that	severed	axons	from	these	animals	displayed	a	dramatically	longer	viability	than	those	from	wild	type	animals,	suggesting	that	SARM	is	involved	in	an	evolutionary	conserved	axon	death	signalling	pathway.		The	mechanism	behind	SARM’s	mitochondrial	localisation	was	later	given	further	insight	when	Panneerselvam	and	colleagues	were	able	to	delineate	that	the	N-terminal	27	amino	acids	of	the	protein	are	responsible	for	directing	it	to	the	mitochondria	(Panneerselvam	et	al.,	2012a).	While	full	length	SARM	was	exclusively	co-localised	with	mitochondria	when	overexpressed	in	HEK293T	and	NIH3T3	cells,	truncated	versions	of	the	protein	lacking	this	region	did	not	display	any	specific	cellular	localisation.	Alanine	scanning	through	this	region	of	SARM	also	revealed	that	the	arginine	residue	in	position	14	of	the	protein	was	critical	for	mitochondrial	localisation.	Mutation	of	this	residue	also	resulted	in	a	significantly	reduced	pro-apoptotic	potential	in	HEK293T	cells.	A	study	by	Gerdts	and	colleagues	later	showed	both	the	SARM	TIR-	and	SAM-domains	were	required	to	promote	axonal	degeneration	(Gerdts	et	al.,	2013).	They	found	that	although	cultured	SARM-deficient	neurons	did	not	exhibit	axon	degeneration	following	injury,	wild-type	phenotype	could	be	restored	by	SARM	expression	as	expected.	However,	mutations	in	either	the	TIR-	or	SAM-domains	of	expressed	SARM	resulted	in	a	complete	loss	of	function.	
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Surprisingly,	deletion	of	the	mitochondria-targeting	N-terminal	part	of	the	protein	had	no	noticeable	effect	on	SARM’s	ability	to	promote	cell	death	in	axons.	Recently	the	mechanisms	used	to	trigger	axon	degeneration	was	further	elucidated	when	SARM	activation	was	found	to	result	in	the	rapid	breakdown	of	nicotinamide	adenine	dinucleotide	(NAD+)	after	injury	(Gerdts	et	al.,	2015),	an	effect	that	was	dependent	on	the	dimerisation	of	SARM’s	TIR-domain.	In	the	study,	SARM-induced	axon	degeneration	could	be	counteracted	by	increasing	the	synthesis	of	NAD+	in	the	cell.		
1.3	Inflammation	
1.3.1	Introduction	to	inflammation	As	discussed	in	section	1.1.2,	the	innate	immune	response	is	triggered	to	combat	invading	pathogens,	and	results	in	the	release	of	certain	molecules	at	the	site	of	infection	to	induce	inflammation	with	the	purpose	of	combating	infection.	Inflammation	is	a	general	term	referring	to	a	wide	range	of	molecular	events	taking	place	in	response	to	infection.	Although	the	precise	cellular	mechanisms	are	not	yet	fully	understood,	the	physiological	hallmarks	are	redness,	heat,	swelling	and	pain	(Barton,	2008).	An	ideal	response	would	be	one	that	is	rapid	and	strong	enough	to	fully	kill	the	invading	microorganism,	while	generating	minimal	damage	to	host	tissues.	This	is	one	of	the	areas	of	immunity	where	the	cooperation	between	innate	and	adaptive	immunity	becomes	clear:	inflammation	is	triggered	as	an	immediate	reaction	to	infection	in	order	to	contain	the	pathogen	while	the	adaptive	arm	of	the	immune	system	is	primed,	
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eventually	developing	lymphocytes	that	specifically	targets	and	clears	the	pathogen	in	question.		As	TLRs	detect	PAMPs,	they	induce	the	activation	of	NFκB	and	IFN-regulatory	factor	(IRF)	transcription	factors,	which	leads	to	the	expression	of	multiple	proinflammatory	molecules,	as	well	as	signalling	molecules	for	the	initiation	of	adaptive	immunity	(Medzhitov,	2007).	The	key	mediators	of	inflammation	are	the	cytokines,	a	broad	group	of	low	molecular	weight	proteins	with	multiple	cellular	functions.	The	cytokines	include	the	interleukins,	interferons,	chemokines,	mesenchymal	growth	factors,	adipokines	and	the	tumour	necrosis	factor	family	(Dinarello,	2007).	In	certain	cells,	inflammation	also	leads	to	pyroptosis,	a	type	of	rapid	cell	death	believed	to	prevent	bacterial	replication	(Derre	and	Isberg,	2004).		
1.3.2	Inflammatory	diseases	Although	inflammation	comprises	a	vital	tool	for	pathogen	clearance,	it	also	has	the	potential	to	cause	great	harm	to	the	host	given	a	dysregulation	of	the	inflammatory	signalling	pathways.	Cytokines	are	powerful	mediators	of	inflammation,	and	during	infection,	a	“cytokine	storm”	is	raised	to	drive	away	pathogens,	which	calms	after	the	infection	has	been	eliminated.	An	inability	of	the	cytokine	genes	to	shut	down	causes	chronic	inflammation,	which	is	a	hallmark	of	several	autoimmune	diseases	such	as	rheumatoid	arthritis	(RA),	inflammatory	bowel	disease	(IBD),	psoriasis,	systemic	lupus	erythematosus	(SLE),	and	Crohn’s	disease	(CD).		As	cytokines	are	secreted	from	immune	cells,	they	comprise	excellent	targets	for	treatment	by	monoclonal	antibody	therapy	(Feldmann,	2008),	but	the	
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vast	amount	of	different	cytokines	involved	in	inflammation	would	suggest	that	the	number	of	different	antibodies	required	would	also	be	high.	In	the	1980s,	Feldmann	and	colleagues	at	the	Kennedy	Institute	of	Rheumatology	speculated	that	out	of	all	the	different	cytokines	involved	in	inflammatory	disease,	some	of	them	were	bound	to	be	more	important	than	others,	maybe	even	regulating	the	expression	of	others.	They	found	that	when	cultured	synovial	cells	from	patients	with	RA	were	treated	with	an	antibody	targeting	the	pro-inflammatory	cytokine	tumour	necrosis	factor	α	(TNFα),	the	IL-1	production	was	significantly	reduced	in	the	cells	(Brennan	et	al.,	1989),	suggesting	that	TNFα	may	be	an	inducer	of	other	cytokines	and	may	play	an	important	regulatory	role	in	inflammatory	diseases	(Brennan	et	al.,	1992).	Later	studies	also	found	that	blocking	of	TNFα	resulted	in	a	reduction	of	synovial	GM-CSF	(Haworth	et	al.,	1991),	IL-6	and	IL-8	(Feldmann	et	al.,	1996).	The	technology	was	quickly	commercialised	with	clinical	trials	started	in	1992	(Elliott	et	al.,	1993),	and	by	the	end	of	the	1990s	the	first	generation	of	anti-TNFα	antibodies	were	approved	for	treatment	of	RA	and	CD.	Although	anti-TNFα	monoclonal	antibodies	(or	antibody-like	molecules)	provide	an	excellent	option	for	treatment	of	inflammatory	diseases,	there	is	still	high	interest	in	finding	ways	to	manipulate	the	upstream	pathways	that	initially	cause	abnormal	cytokine	activation.	Given	their	central	role	in	immune	activation,	the	TLRs	have	become	emerging	targets	for	therapeutic	treatment	(Hoffman	et	al.,	2005,	O'Neill,	2003,	O'Neill,	2006).		
1.3.3	Targeting	of	TLR	signalling	for	therapeutic	use	It	is	now	well	established	that	dysregulation	of	TLR	signalling	is	associated	with	the	pathogenesis	of	disease	(Cook	et	al.,	2004,	Netea	et	al.,	2012).	
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An	inability	of	the	receptors	to	properly	recognise	PAMPs	leaves	the	host	at	increased	risk	of	infection.	For	example,	the	individuals/mice	carrying	the	D299G	or	T399I	mutations	in	TLR4	have	both	been	shown	to	result	in	a	reduced	response	to	inhaled	LPS	(Arbour	et	al.,	2000)	compared	to	individuals/mice	with	WT	TLR4.	These	amino	acid	residues	are	both	located	in	the	extracellular	part	of	the	receptor,	suggesting	that	these	polymorphisms	may	affect	the	receptor’s	ligand	binding.	Studies	later	showed	that	these	mutations	in	the	TLR4	receptor	were	also	associated	with	a	predisposition	to	sepsis	(Agnese	et	al.,	2002,	Lorenz	et	al.,	2002)	and	systemic	inflammatory	response	syndrome	(SIRS)	(Child	et	al.,	2003)	in	patients	following	infection	with	gram-negative	bacteria.		As	TLRs	mediate	the	expression	of	inflammatory	cytokines,	it	is	reasonable	to	assume	that	these	signalling	pathways	may	contribute	to	the	pathogenesis	of	inflammatory	diseases.	As	TLR	activation	occurs	early	in	the	signalling	cascade	that	leads	to	expression	of	inflammatory	cytokines,	there	may	be	an	advantage	of	targeting	this	part	of	the	host	immune	activation.	In	2002,	Seibl	and	colleagues	showed	that	TNF	stimulation	of	synovial	cells	led	to	an	upregulation	of	TLR2	expression,	but	not	TLR4	expression	(Seibl	et	al.,	2003).	This	indicates	a	role	for	TLR2	in	the	pathogenesis	of	RA,	as	increased	levels	of	TNFα	in	synovial	fluids	are	associated	with	the	disease.	Synovial	tissue	from	patients	with	RA	also	exhibited	elevated	TLR2	expression,	especially	at	sites	of	attachment	and	invasion	into	the	cartilage	and	bone.	Leadbetter	and	colleagues	have	also	described	a	potential	link	between	TLR9	signalling	and	activation	of	adaptive	immunity	in	SLE	(Leadbetter	et	al.,	2002).	Anti-malarial	drug	hydroxychloroquine	(HCQ)	has	been	used	to	treat	SLE	for	a	long	time,	even	though	the	mechanism	of	action	was	not	fully	understood.	In	2011,	Kužnik	and	
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colleagues	showed	that	HCQ	binds	to	nucleic	acids	directly,	thereby	disrupting	their	binding	potential	to	TLR9,	and	providing	a	possible	explanation	to	the	efficacy	of	HCQ	in	treatment	of	SLE	(Kuznik	et	al.,	2011).	Targeting	of	TLR4	has	been	suggested	for	the	treatment	of	multiple	inflammatory	diseases,	and	treatment	with	E5564	(Eritoran;	a	TLR4	antagonist)	was	shown	to	inhibit	LPS-induced	cytokine	production	in	mice	(Mullarkey	et	al.,	2003,	Savov	et	al.,	2005)	and	human	blood	monocytes	(Czeslick	et	al.,	2006),	suggesting	a	possible	use	for	treatment	of	sepsis.	In	the	subsequent	clinical	trials,	E5564	was	able	to	reduce	LPS-induced	cytokine	response	in	healthy	volunteers	(Lynn	et	al.,	2003),	and	a	slight	reduction	in	mortality	in	sepsis	patients	was	also	demonstrated	in	the	phase	2	trial	(Tidswell	et	al.,	2010),	though	the	difference	was	not	statistically	significant.	In	the	phase	3	trial,	no	difference	in	overall	mortality	between	E5564	and	placebo	treatment	could	be	demonstrated	(Opal	et	al.,	2013),	resulting	in	the	discontinuation	of	development	for	this	indication.		
1.4	Pathogen	subversion	of	innate	immunity	
1.4.1	Brief	introduction	to	pathogen	subversion	of	innate	
immunity	As	discussed	previously	in	this	chapter,	the	innate	immune	system	is	incredibly	efficient	at	detecting	and	neutralising	invading	pathogens.	In	order	to	survive	in	the	host,	pathogens	have	developed	several	different	mechanisms	to	circumvent	immune	defence	surveillance	mechanisms	following	an	infection.	Phagocytes	are	often	the	first	type	of	host	immune	cells	to	encounter	pathogenic	bacteria	following	infection,	and	many	mechanisms	of	host	immune	evasion	are	
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based	around	preventing	phagocytosis.	One	example	is	how	several	Yersinia	species	utilise	type	III	secretion	systems	to	inject	multiple	effector	molecules	into	host	phagocytes	that	interfere	with	the	host	cell’s	ability	to	engulf	bacteria	(Fallman	et	al.,	1997).	These	molecules	include	YopH,	a	protein	tyrosine	phosphatase	that	antagonises	several	signalling	pathways	central	to	phagocytosis	such	as	the	β1	integrin	pathway,	and	several	proteins	known	to	cleave	or	disrupt	host	Rho	GTPases,	thereby	interfering	with	regulation	of	the	actin	cytoskeleton.		Some	bacteria	are	also	known	to	avoid	being	trapped	in	the	macrophage	phagolysosome,	thereby	avoiding	digestion	by	hydrolytic	enzymes.	
Mycobacterium	tuberculosis	does	this	by	expressing	certain	glycolipids	that	are	known	to	interfere	with	the	phagosome-lysosome	fusion	by	targeting	phosphatidylinositol	3-phosphate	(PI3P)	(Pieters,	2008),	a	critical	component	for	synthesis	of	the	phagolysosome	(Roth,	2004).		Another	common	example	employed	by	many	pathogenic	bacteria	to	avoid	detection	by	host	immune	cells	is	the	use	of	carbohydrate	capsules	to	mask	the	bacterial	surface,	inhibiting	recognition	by	innate	immune	receptors.	
Streptococcus	pneumoniae	and	Neisseria	meningitidis	are	two	examples	of	extracellular	bacteria	that	rely	on	their	capsule	to	avoid	recognition	by	host	immune	mechanisms	(Finlay	and	McFadden,	2006).		
1.4.2	Cellular	autophagy		 Autophagy	is	an	internal	housekeeping	system	that	allows	cells	to	degrade	cytoplasmic	waste	products	in	order	to	maintain	cellular	homeostasis	(Eskelinen,	2005).	The	process	involves	the	formation	of	double	membrane	
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autophagosomes	that	surround	cytosolic	components	and	fuse	with	lysosomes	in	order	to	degrade	the	target	via	various	digestive	enzymes	(Fig.	1.10).	During	cellular	starvation,	this	mechanism	enables	the	cell	to	degrade	non-essential	components	in	order	to	obtain	nutrients	(Kadowaki	et	al.,	2006),	but	it	can	also	be	used	as	a	self-defence	mechanism	to	combat	intracellular	microorganisms	(Deretic	et	al.,	2006).			
	
Figure	1.10	Overview	of	autophagosome	formation.	The	process	of	degradation	of	an	intracellular	target	via	autophagy	is	initiated	by	the	formation	of	an	isolation	membrane.	As	the	membrane	fully	engulfs	the	target	to	form	an	autophagosome,	membrane-bound	LC3	is	lipidated.	The	autophagosome	then	fuses	with	a	lysosome	to	form	an	autolysosome,	leading	to	the	release	of	LC3	bound	on	the	cytosolic	side	of	the	membrane,	which	is	recycled.	The	target	is	finally	degraded	by	digestive	enzymes	from	the	lysosome.			 The	most	direct	way	cells	utilise	autophagy	mechanisms	to	defend	against	microbes	in	the	cytosol	is	to	directly	capture	and	degrade	the	invader.	Autophagy	was	previously	considered	to	be	a	non-specific	cellular	function,	but	it	is	now	well	established	that	cells	can	target	certain	components	for	selective	degradation	by	autophagy	(Kraft	et	al.,	2010).	This	is	mediated	via	adaptor	proteins	called	sequestosome	1/p62-like	receptors	(SLRs)	(Deretic,	2011)	that	
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recognise	cytosolic	targets	and	transports	them	into	autophagosomes.	It	has	also	been	shown	that	TLR	stimulation	can	trigger	an	increase	in	autophagy	activity	(Sanjuan	et	al.,	2007,	Xu	et	al.,	2007).	Shi	and	colleagues	have	further	shown	that	stimulation	of	TLR4	with	LPS	results	in	TRAF6-mediated	ubiquitination	of	Beclin-1,	which	plays	a	key	role	in	regulating	autophagy	(Shi	and	Kehrl,	2010).	Interestingly,	many	pathogens	have	evolved	to	subvert	autophagy-related	processes	as	a	means	of	host-immune	evasion.	For	example,	pathogenic	bacteria	such	as	Anaplasma	phagocytophilum	(Niu	et	al.,	2008),	Coxiella	burnetii	(Beron	et	al.,	2002),	and	Staphylococcus	aureus	(Schnaith	et	al.,	2007),	are	all	believed	to	exploit	autophagy	in	order	to	establish	an	intracellular	protective	niche	environment	where	the	pathogen	can	further	develop.	Schnaith	and	colleagues	have	shown	that	S.	aureus	transits	into	autophagosomes	shortly	after	infection	of	mammalian	cells,	but	also	inhibits	them	from	fully	maturing	and	fusing	with	lysosomes,	eventually	escaping	from	the	compartment	into	the	cytoplasm	(Schnaith	et	al.,	2007).	The	pathogen	was	unable	to	replicate	in	an	autophagy-deficient	cell	lines,	but	the	ability	could	be	restored	by	artificially	inducing	autophagy	via	cellular	stimulation	with	rapamycin,	indicating	that	this	is	an	essential	process	for	S.	aureus	infection	of	host	cells.		
1.4.3	Pathogen	subversion	of	host	Toll-like	receptor	signalling	Given	the	central	role	TLRs	play	in	innate	immune	activation,	one	could	assume	that	pathogens	seek	to	subvert	these	pathways	as	a	means	of	immune	evasion.	Underhill	has	described	three	different	strategies	for	pathogenic	microorganisms	to	manipulate	TLRs,	or	the	effect	of	their	activation:	(a)	manipulation	of	the	PAMPs	they	display,	(b)	activation	of	other	receptors	that	
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dampen	the	effect	of	TLR	activation,	and	(c)	interference	of	TLR	signalling	(Fig.	
1.11)	(Underhill,	2004),	and	examples	of	all	three	strategies	have	been	identified.		Many	gram-negative	bacteria,	including	Escherichia	coli	and	Salmonella	
typhimurium,	are	known	to	selectively	modify	the	lipid	A	moiety	of	membrane	bound	LPS	in	order	to	hinder	detection	by	TLR4	(Raetz	et	al.,	2007).	However,	one	issue	that	makes	this	strategy	less	effective	than	expected	is	that	there	is	a	fair	deal	of	redundancy	in	the	TLR	systems.	For	example,	while	Helicobacter	
pylori	is	known	to	express	myristate-deficient	lipid	A,	not	recognised	by	TLR4	(Ernst	et	al.,	1999),	experiments	performed	by	Smith	and	colleagues	showed	that	the	organism	can	still	be	detected	via	TLR2	and	TLR5	(Smith	et	al.,	2003).	Engaging	other	receptors	in	order	to	lessen	the	effect	of	TLR	activation	is	another	strategy	that	allows	for	an	indirect	manipulation	of	the	effect	of	TLR	signalling.	A	commonly	cited	example	is	the	way	Mycobacterium	bovis	and	
Mycobacterium	tuberculosis	are	able	to	inhibit	TLR4-mediated	IL-12	production	by	expression	of	mannose-capped	lipoarabinomannans	(Nigou	et	al.,	2001).	Though	the	mechanism	of	action	is	still	not	clear,	these	molecules	are	displayed	on	the	bacterial	cell	wall	and	bind	to	the	mannose	receptor	of	host	immune	cells,	inhibiting	the	effect	of	TLR4	activation.		Pathogens	may	also	inhibit	TLR	signalling	through	direct	interference	with	the	molecules	used	to	direct	downstream	immune	activation.	This	is	often	accomplished	through	the	use	of	molecular	mimics,	i.e.	molecules	that	share	a	high	degree	of	homology	with	host	proteins	and	peptides.	Multiple	pathogens	are	known	to	inhibit	NFκB	activation	(Tato	and	Hunter,	2002),	though	targeting	of	TLR	signalling	further	upstream	has	also	been	described.	For	example,	Kaposi	
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sarcoma-associated	herpesvirus	has	been	shown	to	block	TLR3-signalling	through	the	use	of	RTA,	which	was	found	to	specifically	degrade	TLR	adaptor	molecule	TRIF	when	overexpressed	in	mammalian	cells	(Ahmad	et	al.,	2011).	The	mechanism	is	believed	to	involve	the	ubiquitin-proteasome	pathway,	as	both	proteasome	inhibitors	and	knockdown	of	host	ubiquitin	expression	was	found	to	combat	this	effect.	Vaccinia	viral	proteins,	A46R	and	A52R,	have	both	been	shown	to	suppress	TLR4	signalling	(Bowie	et	al.,	2000).	The	amino	acid	sequences	of	these	proteins	show	a	high	similarity	to	mammalian	TIR	domains,	and	A46R	was	later	shown	to	target	the	BB-loop	motif	of	TLR2	and	TLR4	(Stack	and	Bowie,	2012).	A52R	has	been	shown	to	interact	directly	with	IRAK2	and	TRAF6	(Harte	et	al.,	2003),	proteins	critical	for	TLR	signalling	downstream	of	TLR	adaptors.	A	large	number	of	TIR	domain	proteins	have	also	been	identified	in	bacterial	species	(Spear	et	al.,	2009),	many	of	which	are	from	pathogenic	species.		
	
Figure	1.11	Microbial	strategies	for	TLR	manipulation.	Microorganisms	may	manipulate	their	endogenous	PAMPs	in	order	to	avoid	TLR	recognition	(A),	stimulate	other	receptors	that	lead	to	a	dampened	immune	response	(B),	or	directly	interfere	with	TLR	signalling	(C).	Figure	adapted	from	(Underhill,	2004).	
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1.4.4	Bacterial	TIR	domain	proteins	Bacterial	homologues	of	the	TIR	domains	found	in	proteins	of	multicellular	organisms	were	first	noted	by	Koonin	and	colleagues	in	2002,	where	TIR	proteins	in	Streptomyces,	Rhizobium,	Synechocystis,	Caulobacter,	
Bacillus	and	Anabaena	were	described	(Koonin	and	Aravind,	2002).	At	this	stage,	little	was	known	about	their	function,	but	speculation	regarding	a	role	in	programmed	cell	death	was	raised.		In	2006,	Newman	and	colleagues	identified	more	than	200	bacterial	Tdps	through	bioinformatics	homology	searches,	and	postulated	that	these	may	constitute	a	previously	unidentified	virulence	factor	(Newman	et	al.,	2006).	They	characterised	one	of	these	proteins,	identified	from	the	Salmonella	enterica	serovar	Enteritidis	genome,	and	found	that	overexpression	of	this	protein	(named	TlpA	for	TIR-like	protein	A)	in	mammalian	cells	resulted	in	strong	inhibition	of	TLR4-mediated	immune	signalling.	TlpA	KO	bacteria	also	showed	significantly	reduced	lethality	in	mouse	infection.	Though	the	exact	mechanism	of	action	was	not	known,	Newman	and	colleagues	postulated	that	pathogens	may	utilise	Tdps	to	suppress	host	immune	signalling	by	mimicking	eukaryote	signalling	molecules.	They	also	noted	that	Tdps	were	found	in	many	highly	pathogenic	bacteria.		Cirl	and	colleagues	later	characterised	a	Tdp	from	the	uropathogenic	E.	
coli	strain	CFT073	(named	TcpC	for	TIR	domain	containing	protein	C)	and	one	from	Brucella	melitensis	(named	TcpB)	(Cirl	et	al.,	2008).	In	vitro	studies	showed	that	both	of	these	proteins	impaired	TLR	signalling	and	the	release	of	inflammatory	cytokines	such	as	TNFα	and	IL-6	during	infection	of	host	cells,	and	that	both	of	them	interacted	with	MyD88.	In	vivo	studies	in	mice	also	confirmed	a	
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role	for	TcpC	in	pathogenesis,	as	the	bacterial	burden	of	mutants	lacking	this	protein	was	significantly	lower	compared	to	infection	with	wild	type	bacteria.	As	TcpC	was	found	to	be	secreted	into	the	growth	medium	from	cultured	bacteria,	they	proposed	a	mechanism	of	action	where	TcpC	is	secreted	by	the	pathogen,	followed	by	internalisation	by	host	cells	where	it	impairs	immune	signalling	by	binding	to	the	cytosolic	TLR	adaptor	MyD88.	Experiments	with	cultured	macrophages	confirmed	that	recombinantly	expressed	and	purified	TcpC	TIR	domain	protein	was	taken	up	by	the	host	cell,	which	consequently	interfered	with	TLR-mediated	TNF	activation.		Salcedo	and	colleagues	were	studying	TcpB	(which	they	referred	to	as	Btp1	for	Brucella	TIR	protein	1)	at	the	same	time,	and	discovered	that	the	protein	interferes	with	TLR2	signalling,	down-modulating	maturation	of	infected	DCs	(Salcedo	et	al.,	2008).	Radhakrishnan	and	colleagues	later	found	that	the	protein	shares	a	rather	high	sequence	similarity	(53%)	with	TLR	adaptor	protein,	MAL	(Radhakrishnan	et	al.,	2009).	As	MAL	had	previously	been	found	to	play	a	role	in	DC	maturation	(Horng	et	al.,	2001),	they	hypothesised	that	TcpB	functions	by	mimicking	properties	of	this	protein.	TcpB	was	found	to	interfere	with	both	TLR2-	and	TLR4-	signalling,	though	unlike	MAL,	no	direct	binding	to	any	of	the	TLRs	was	observed.	They	were	also	unable	to	detect	any	association	with	MAL,	which	led	them	to	believe	that	TcpB	acts	on	targets	downstream	of	MAL,	and	they	did	find	that	TcpB	interacted	with	multiple	phosphoinositides	(PtdIns)	in	a	similar	fashion	to	MAL.	A	point	mutation	of	the	highly	conserved	glycine	residue	G158	located	in	the	TIR	domain	BB-loop	of	TcpB	(Fig.	1.13)	resulted	in	a	reduced	ability	to	suppress	immune	signalling	by	the	protein,	again	highlighting	the	importance	of	this	motif	for	protein	function.	The	crystal	
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structure	of	the	TcpB	TIR	has	been	solved	by	multiple	groups	(Alaidarous	et	al.,	2014,	Kaplan-Turkoz	et	al.,	2013,	Snyder	et	al.,	2014),	and	interestingly	it	displays	a	very	similar	overall	fold	to	the	TIR	domains	of	human	TIR	domain	proteins	(Fig.	1.12),	with	root	mean	square	deviation	(RMSD)	values	of	2.5-3.0	Å	for	the	TIR	domain	structures	of	human	MyD88,	MAL	and	TLR2	(Alaidarous	et	al.,	2014,	Snyder	et	al.,	2014).	This	feature	further	strengthens	the	hypothesis	that	these	proteins	subvert	mammalian	TLR	signalling	by	mimicking	the	function	of	endogenous	TIR	domain	proteins.	However,	some	regions	adopt	a	markedly	different	conformation,	such	as	the	exposed	BB-loop.	In	bacterial	TIR	proteins,	this	region	typically	lacks	certain	residues	that	are	strongly	conserved	in	human	TIR	domain	sequences,	such	as	R,	D	and	P	residues	in	positions	3,	4	and	7	(Fig.	
1.13).	 	
	
Figure	1.12	Bacterial	TIR	domain	from	Brucella	melitensis	show	structural	
homology	with	human	TIR	domains.	Superposition	of	the	TIR	domain	crystal	structures	of	TcpB	(Protein	data	bank;	PDB	entry	4LQC)	(Snyder	et	al.,	2014),	MyD88	(Protein	data	bank;	PDB	entry	4DOM)	(Snyder	et	al.,	2013)	and	TLR2	(Protein	data	bank;	PDB	entry	1FYW)	(Xu	et	al.,	2000)	show	high	overall	structural	similarity.	TcpB	is	coloured	in	cyan,	MyD88	in	magenta	and	TLR2	in	orange.	C-	and	N-terminals,	and	exposed	BB-	DD-	and	EE-loop	regions	are	marked.	Structures	were	visualised	using	PyMOL.	
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Figure	1.13	Sequence	alignment	of	human	and	bacterial	TIR	domain	BB	loop.	Multiple	sequence	alignment	of	the	predicted	BB-loop	regions	of	the	TIR	domains	of	human	TLR4	and	SARM,	Salmonella	enterica	TlpA,	Brucella	melitensis	TcpB,	uropathogenic	Escherichia	coli	CFT073	TcpC,	Paracoccus	denitrificans	PdTlp,	Yersinia	
pestis	YpTdp	and	Bacillus	anthracis	BaTdp.	Alignment	was	visualised	in	Jalview	(Waterhouse	et	al.,	2009).		Although	these	findings	clearly	indicate	a	role	for	bacterial	Tdps	in	host	immune	evasion,	it	is	important	to	point	out	that	Tdps	have	also	been	identified	in	non-pathogenic	bacteria.	For	example,	a	Tdp	expressed	by	Paracoccus	
denitrificans	(named	PdTlp	for	P.	denitrificans	TIR	like	protein)	has	previously	been	characterised,	and	in	vitro	interactions	with	human	TLR4	and	mouse	MyD88	(Low	et	al.,	2007)	as	well	as	human	MyD88	(Chan	et	al.,	2009)	have	been	described.	It	is	possible	that	the	immune	evasive	effect	of	certain	bacterial	Tdps	may	just	be	a	side	effect,	while	their	main	function	is	to	mediate	regular	protein	interactions.	In	2009,	Spear	and	colleagues	identified	more	than	900	bacterial	Tdps,	and	concluded	that	a	majority	of	these	were	not	from	pathogenic	strains	(Spear	et	al.,	2009).	It	is	not	reasonable	to	suggest	that	the	exclusive	function	of	bacterial	Tdps	is	to	enable	host	immune	evasion,	though	in	some	cases	this	may	be	an	important	function	and	the	presence	of	such	a	protein	in	a	pathogenic	organism	certainly	warrants	some	interest.	In	their	study,	Spear	and	colleagues	identified	Tdps	in	Yersinia	pestis,	and	Bacillus	anthracis,	two	extremely	virulent	
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pathogens	that	are	both	among	the	six	agents	classified	as	Category	A	bioterrorism	agents	by	the	United	States	Centers	for	Disease	Control	and	Prevention	(CDC).		
1.4.5	Yersinia	pestis	
Yersinia	pestis	is	the	causative	agent	of	bubonic,	pneumonic	and	septicemic	plague.	These	comprise	a	family	of	diseases	that	are	believed	to	have	killed	more	than	100	million	people	over	the	course	of	history	through	three	major	pandemics	(Perry	and	Fetherston,	1997).	The	first	one	recorded	is	known	as	the	Justinian	plague	and	occurred	between	the	sixth	and	eighth	century,	originating	in	Africa	and	spreading	to	the	Mediterranean	via	Egypt.	The	second	pandemic	is	widely	known	as	the	Black	Death,	which	originated	in	Asia	during	the	1300s	and	later	spread	into	Europe,	eventually	killing	approximately	one	third	of	the	European	population.	The	most	recent,	and	still	on-going,	plague	pandemic	started	in	China	during	the	1800s	and	spread	to	various	continents	via	shipping	routes	from	Hong	Kong,	killing	approximately	12	million	people	so	far,	mainly	in	India	and	China.	The	disease	has	a	high	mortality	rate	(Crook	and	Tempest,	1992)	and	is	mainly	transmitted	via	blood.	It	typically	spreads	to	humans	via	fleas	that	previously	have	bitten	infected	rodents,	though	infection	via	inhalation	is	also	known	to	be	possible	(Franz	et	al.,	1997).		
Y.	pestis	is	a	rod	shaped	gram-negative	bacterium	that	despite	lacking	a	traditional	capsule	develops	a	cellular	envelope	when	exposed	to	temperatures	above	33°C	(Brubaker,	1972),	such	as	in	the	human	blood	stream.	The	cellular	wall	is	covered	in	LPS,	which	can	be	recognised	by	TLR4	in	humans	to	initiate	inflammation.	The	Y.	pestis	genome	was	first	sequenced	in	2001	by	Parkhill	et	al.	
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(Parkhill	et	al.,	2001),	and	in	2009,	bioinformatics	analysis	by	Spear	et	al.	revealed	a	TIR	domain	containing	protein	(Spear	et	al.,	2009).		
1.4.6	YpTdp	(Y.	pestis	TIR	domain	protein)	The	Y.	pestis	TIR	domain	protein	(YpTdp),	named	y2426	by	Deng	and	colleagues	in	their	mapping	of	the	Y.	pestis	KIM	genome	(Deng	et	al.,	2002),	is	a	358	amino	acid	protein	found	in	all	Y.	pestis	strains.	The	TIR	domain	(YpTIR)	spans	residues	S130-A285.		YpTIR	has	previously	been	studied	in	vitro	by	Rana	et	al.,	and	was	found	to	form	dimers	in	solution.	Pull	down	assays	confirmed	that	YpTIR	interacts	with	the	MyD88	TIR	domain,	and	a	P173H	mutation	in	the	predicted	BB-loop	region	of	the	amino	acid	sequence	resulted	in	a	loss	of	binding,	but	not	a	loss	of	dimerisation	(Rana	et	al.,	2011).	These	results	suggest	that	YpTIR	interacts	with	MyD88	via	its	BB-loop,	but	that	the	dimerisation	interface	is	likely	located	at	another	part	of	the	protein.	Cell	based	assays	in	HEK293	cells	later	showed	that	YpTdp	was	able	to	significantly	reduce	LPS-mediated	NFκB	signalling,	although	the	isolated	TIR	domain	was	not	(Spear	et	al.,	2012).	Introduction	of	the	P173H	mutation	in	YpTdp	resulted	in	a	loss	of	ability	to	reduce	immune	signalling	following	LPS	stimulation,	consistent	with	the	hypothesis	that	the	anti-inflammatory	function	is	a	result	of	competitive	TIR-TIR	interactions.	It	is	possible	that	the	non-TIR	regions	of	the	protein	are	still	required	for	proper	folding	or	cellular	localisation	of	YpTdp.	A	Y.	pestis	KO	strain	lacking	YpTdp	was	also	generated,	but	this	strain	was	only	shown	to	have	a	minor	increase	in	virulence	during	mouse	infection	(Spear	et	al.,	2012).	It	seems	that	although	YpTdp	is	responsible	for	downregulation	of	host	immune	signalling	following	
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infection,	this	is	a	very	subtle	effect,	and	the	protein	may	also	possess	other	functions.	It	is	not	clear	if	MyD88	is	the	only	TIR	domain	protein	that	YpTdp	interacts	with,	and	if	it	interacts	with	other	proteins,	whether	this	is	done	via	different	mechanisms	or	not.		
1.4.7	Bacillus	anthracis	
Bacillus	anthracis	is	a	gram-positive	bacterium	best	known	for	being	the	causative	agent	of	anthrax	(Dixon	et	al.,	1999).	It	has	an	unusual	infection	cycle	(Fig.	1.14)	where	the	bacterium	forms	tightly	packed	spores	that	are	highly	resistant	against	environmental	stress,	and	can	lay	dormant	in	this	state	for	long	periods	of	time	(Mock	and	Fouet,	2001).	Only	when	the	spores	are	introduced	to	a	suitable	environment	do	they	initiate	vegetative	growth.	The	developed	bacilli	on	the	other	hand	are	rather	fragile	and	quickly	lose	viability	when	removed	from	the	host	(Lindeque	and	Turnbull,	1994),	forcing	them	to	undergo	sporulation	in	order	to	survive.	The	spores	are	typically	found	in	the	soil	and	infect	herbivores	via	ingestion,	although	cutaneous	infection	or	via	inhalation	are	also	possible.	In	the	rare	cases	when	humans	are	infected,	it	is	usually	from	eating	the	meats	of	infected	animals,	or	through	an	insect	bite.	Once	the	spores	have	entered	the	host,	they	are	rapidly	engulfed	by	macrophages	and	transported	to	lymph	nodes	(Lincoln	et	al.,	1965),	and	it	is	at	this	stage	that	the	germination	process	is	initiated	(Shafa	et	al.,	1966).	It	is	not	clear	exactly	how	B.	
anthracis	spores	survive	in	the	phagolysosome,	or	how	it	eventually	escapes	from	the	macrophage,	but	the	pathogen	eventually	enters	the	bloodstream	where	it	releases	three	key	toxins	(Stanley	and	Smith,	1961)	named	protective	
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antigen	(PA),	lethal	factor	(LF)	and	edema	factor	(EF).	Individually,	none	of	these	proteins	are	toxic,	but	in	combination	they	have	the	ability	to	cause	severe	injury	or	death	(Beall	et	al.,	1962).		
	
Figure	1.14	Schematic	overview	of	Bacillus	anthracis	infection	cycle.	Dormant	B.	
anthracis	spores	typically	enter	the	host	animal	via	ingestion	or	inhalation	and	are	engulfed	by	macrophages.	Inside	the	cell,	the	spores	germinate	into	vegetative	bacilli	and	eventually	escape	from	the	cell	and	enter	the	bloodstream	where	they	produce	multiple	toxins.	Host	death	leads	to	sporulation	as	the	bacteria	are	exposed	to	air.		Interestingly,	despite	being	a	gram-positive	bacterium	(which	do	not	express	LPS),	a	study	by	Hsu	et	al.	showed	that	exposing	BMDMs	to	both	live	and	heat-killed	B.	anthracis	resulted	in	a	strong	TLR4-mediated	immune	response	(Hsu	et	al.,	2004).	Further	characterisation	revealed	that	it	is	a	through	a	molecule	known	as	anthrolysin	O	(ALO),	a	cholesterol-dependent	cytolysin,	that	TLR4	recognises	the	pathogen	(Park	et	al.,	2004).	ALO	is	a	hemolytic	toxin,	which	was	discovered	in	2003	when	Shannon	et	al.	showed	that	B.	anthracis	secreted	large	amounts	of	this	molecule	when	grown	in	rich	medium,	though	barely	a	detectable	amount	when	grown	in	Lysogeny	broth	(LB)	(Shannon	et	al.,	2003).				
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1.4.8	BaTdp	(B.	anthracis	TIR	domain	protein)	The	genome	of	B.	anthracis	was	first	mapped	by	Read	and	colleagues	in	2003,	and	revealed	a	high	similarity	to	other	Bacillus	strains	(Read	et	al.,	2003).	In	their	2009	systematic	search	for	bacterial	TIR	domain	proteins,	Spear	et	al.	identified	a	protein	in	the	B.	anthracis	genome	that	was	predicted	to	contain	a	TIR	domain	(Spear	et	al.,	2009).	Although	this	protein	has	not	previously	been	characterised,	Bergman	and	colleagues	have	shown	that	its	gene	(GBAA4098)	is	upregulated	more	than	2-fold	between	one	and	two	hours	post	infection	during	growth	in	mouse	macrophages	(Bergman	et	al.,	2007),	suggesting	a	possible	role	in	infection.	The	protein	is	273	amino	acids	long	with	the	predicted	TIR	domain	spanning	residues	D126-R266,	thus	comprising	the	majority	of	the	protein.		
	
1.5	Aims	of	project	The	overall	aim	of	this	project	was	to	functionally	characterise	human	SARM,	as	well	as	a	selection	of	bacterial	Tdps,	in	order	to	increase	our	understanding	of	the	roles	these	proteins	play	with	regard	to	innate	immune	suppression.	SARM	has	for	some	time	been	known	to	possess	an	anti-inflammatory	potential,	but	reports	on	which	pathways	it	acts	on	are	conflicting.	This	study	attempted	to	clarify	whether	SARM	exclusively	targets	the	TRIF-dependent	pathway	or	also	suppresses	MyD88-mediated	immune	activation,	as	well	as	identify	functionally	important	regions	of	the	protein.	BaTdp	is	a	novel	protein	that	has	not	previously	been	studied,	though	the	presence	of	a	TIR	indicates	a	function	in	TLR-mediated	host	immune	evasion.	This	study	aimed	to	explore	the	precise	function	of	BaTdp.	
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1.6	Significance	of	research	The	significance	of	the	research	presented	here	stems	from	two	different	aspects.	Firstly,	it	advances	our	knowledge	in	the	field	of	TLR	signalling,	and	inhibition	of	these	pathways.	As	dysregulation	of	TLR	signalling	has	been	implicated	in	multiple	immune	related	diseases,	a	better	understanding	of	the	underlying	mechanisms	behind	these	pathways	can	support	the	development	of	novel	therapeutic	strategies	for	targeting	autoimmune	diseases.	Secondly,	the	technical	protocols	that	have	been	developed	throughout	this	study	may	provide	support	for	researchers	studying	TIR	domain	proteins	in	the	future.	As	these	proteins	have	emerged	as	attractive	molecules	to	be	studied	from	multiple	perspectives,	generation	of	high	quality	protein	could	likely	pose	a	serious	bottleneck	for	progression	of	research.		
1.7	Overview	of	study	This	thesis	contains	seven	chapters.	Following	the	general	introduction	to	TIR	domain	proteins	given	here,	in	chapter	2,	a	phylogenetic	study	of	TIR	domain	proteins	will	be	presented	in	order	to	quantify	the	abundance	of	these	proteins	in	different	kingdoms,	as	well	as	confirm	the	previously	reported	strong	relationship	between	SARM	and	bacterial	TIR	proteins.	Although	this	type	of	study	has	been	performed	before	(Spear	et	al.,	2009,	Zhang	et	al.,	2011),	continuous	advances	in	genomic	sequencing	of	species	warrant	a	new	investigation	of	this	topic.	In	chapter	3,	the	details	behind	recombinant	expression	and	purification	of	TIR	domains	from	seven	different	TIR	domain	proteins	(SARM,	BaTdp,	YpTdp,	MyD88,	MAL,	TRIF	and	TRAM)	are	accounted	
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for.	These	proteins	were	used	in	multiple	protein-protein	interaction	studies,	the	details	of	which	will	be	presented	in	chapter	4.	In	chapters	5	and	6,	functional	studies	of	SARM	and	BaTdp	in	a	cellular	environment	will	be	shown,	with	specific	focus	on	cellular	localisation,	TLR-mediated	immune	activation	and	pro-apoptotic	effect.	Finally,	a	concluding	discussion	of	all	findings	will	be	presented	in	chapter	7.	Figure	1.15	summarises	a	workflow	of	this	project,	showing	experimental	strategies	under	each	aim.		
	
Figure	1.15	Overview	of	specific	aims	of	the	study	and	experimental	strategies	
used.	 		 	
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Chapter	2		
Phylogenetic	study	of	TIR-domain	proteins	
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2.1	Introduction	As	discussed	in	chapter	1,	the	innate	immune	system	is	an	ancient	defence	mechanism	that	appears	to	predate	the	point	in	evolution	where	plants	and	animals	diverged.	In	animals	and	insects,	the	TLRs	serve	as	one	of	the	key	PRRs	for	microbes,	and	mediate	downstream	signalling	via	their	TIR	domains.	The	Toll-pathway	was	initially	discovered	in	Drosophila.	The	Toll	protein	was	described	as	a	membrane	protein	with	an	extracellular	domain	displaying	similar	features	to	those	of	the	human	LRR	proteins	such	as	leucine-rich	α2-glycoprotein	(LRG)	(Hashimoto	et	al.,	1988)	and	membrane	receptor	platelet	glycoprotein	1b	(Keith	and	Gay,	1990).	A	135-amino	acid	long	motif	of	the	cytoplasmic	part	of	the	receptor	was	later	found	to	bear	close	resemblance	to	the	region	located	in	the	cytoplasmic	part	of	human	IL-1R	that	is	essential	for	signal	transduction	(Gay	and	Keith,	1991,	Heguy	et	al.,	1992).	Lemaitre	and	colleagues	later	showed	that	mutations	in	the	Toll	gene	resulted	in	dramatically	reduced	survival	following	pathogen	infection,	demonstrating	that	this	gene	plays	a	key	role	in	innate	immunity	(Lemaitre	et	al.,	1996).		As	genome	sequencing	technology	advanced,	TIR	domains	from	various	organisms	continued	to	be	discovered.	These	were	not	only	present	in	receptors,	but	also	in	cytoplasmic	proteins,	suggesting	that	mediation	of	protein-protein	interactions	downstream	of	the	receptors	appeared	to	be	the	main	function	of	these	TIR	domains.	TIR	domain	proteins	also	appeared	to	be	surprisingly	widespread	in	many	organisms,	for	example,	the	sea	urchin	genome	has	been	reported	to	contain	more	than	200	TIR	domain	proteins	(Rast	et	al.,	2006).		The	first	report	of	TIR	domains	in	prokaryotic	proteins	were	made	by	Koonin	and	colleagues	in	2002,	where	9	different	bacterial	proteins	were	
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identified	(Koonin	and	Aravind,	2002).	This	was	a	surprising	finding,	as	prokaryotes	are	not	known	to	have	an	innate	immune	system,	prompting	the	authors	to	question	the	purpose	of	these	proteins.	As	TIR	domains	have	thus	far	only	been	reported	in	crown-group	eukaryotes,	they	also	hypothesised	possible	evolutionary	scenarios	for	mammalian	Tdps.	These	included	mitochondrial	acquisition	with	subsequent	loss	in	eukaryotic	lineages,	or	horizontal	gene	transfer	(HGT)	from	a	bacterial	source.	Later	studies	(Newman	et	al.,	2006,	Spear	et	al.,	2009)	greatly	expanded	on	the	number	of	known	bacterial	Tdps,	clearly	showing	that	these	were	widespread	among	prokaryotes	and	were	likely	to	have	important	functions.	Certain	bacterial	Tdps,	such	as	TcpB	and	TcpC	(Cirl	et	al.,	2008)	had	also	been	described	as	contributors	to	pathogenesis,	leading	to	speculation	on	whether	bacterial	Tdps	may	serve	as	a	class	of	virulence	factors,	or	some	other	form	of	host-pathogen	interaction.	Similarly	to	many	bacterial	TIR	domain	proteins,	human	SARM	is	also	known	to	suppress	TLR-mediated	immune	activation	(Carty	et	al.,	2006,	Peng	et	al.,	2010).		Systematic	homology	searches	for	TIR	proteins	have	been	performed	before	(Newman	et	al.,	2006,	Spear	et	al.,	2009,	Zhang	et	al.,	2011),	but	as	the	number	of	proteins	reported	continues	to	increase	as	new	genomic	sequencing	data	are	being	made	available,	one	of	the	aims	of	this	thesis	was	to	conduct	a	phylogenetic	analysis	of	the	TIR	domain	proteins.	In	this	chapter	phylogenetic	mapping	of	TIR	domain	proteins	is	presented	based	on	information	available	in	the	NCBI	protein	database.	In	total,	more	than	10,000	TIR	domain	proteins	were	identified,	of	which	3967	were	of	metazoan	origin,	2749	from	plants,	and	3417	of	bacterial	origin.	By	using	techniques	based	multiple	sequence	alignments,	our	
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analysis	affirmed	that	SARM	appears	to	be	evolutionary	related	to	bacterial	proteins.		
2.2	Materials	and	methods	
2.2.1	Database	search		 Amino	acid	sequences	of	human	TIR	domains	from	TLRs1-10,	MyD88,	MAL,	TRIF,	TRAM,	SARM,	and	SIGIRR,	as	well	as	Dictyostelium	discoideum	TirA,	C.	
elegans	Tir-1	and	bacterial	TIR	domain	sequences	from	TcpB,	PdTlp,	BaTdp,	and	YpTdp		were	used	as	seeds	for	performing	PSI-BLAST	searches	(Altschul	et	al.,	1997)	against	the	NCBI	non-redundant	(NR)	protein	database.	Up	to	five	iterations	were	used	with	default	parameters,	using	an	inclusion	threshold	of	0.005.	Duplicate	sequences	were	eliminated	using	Jalview	(Waterhouse	et	al.,	2009).	TIR	domains	and	TIR-like	domains	were	defined	by	batch	conserved	domain	search	(CD-search)	(Marchler-Bauer	and	Bryant,	2004,	Marchler-Bauer	et	al.,	2011)	against	Pfam	v27.0	(Finn	et	al.,	2014)	and	SMART	v6.0	(Schultz	et	al.,	1998).		
2.2.2	Multiple	sequence	alignment		 Large	scale	multiple	sequence	alignment	was	performed	with	MAFFT	v7.215	(Katoh	et	al.,	2002,	Katoh	and	Standley,	2013)	using	FFT-NS-2	function	with	default	parameters	(BLOSUM62	scoring	matrix,	gap	penalty	1.53,	offset	value	0,	maxiterate	1000).	Sequences	with	more	than	30%	gaps	were	removed	from	the	final	alignment.		
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2.2.3	Phylogenetic	reconstruction		 The	multiple	sequence	alignment	was	used	to	generate	a	Newick	format	phylogenetic	tree	by	approximately	maximum	likelihood	method	with	FastTree	v2.1.8	(Price	et	al.,	2010),	using	default	parameters.	The	tree	was	visualised	in	Dendroscope	v3.2.10	(Huson	and	Scornavacca,	2012)	with	colouring	based	on	taxonomic	identifiers.		
2.2.4	Extraction	of	taxonomic	information		 The	NCBI	taxonomy	database	(Sayers	et	al.,	2009)	was	downloaded	from	the	NCBI	website	and	was	used	to	extract	taxonomic	information	for	sequences	in	the	multiple	sequence	alignment	based	on	their	Genbank	ID-number.	Information	was	stored	and	edited	in	an	MS	Excel	file.		
2.2.5	Cluster	analysis	of	sequences		 TIR	domain	sequences	were	labelled	based	on	their	taxonomic	information	and	clustered	in	3D	based	on	sequence	homology	with	Cluster	analysis	of	sequences	(CLANS)	software	(Frickey	and	Lupas,	2004)	until	data	points	were	in	equilibrium.	A	P-value	cut-off	of	10-10	was	used.	This	was	followed	by	transposition	into	2D	for	visualisation	purpose	and	colouring	based	on	taxonomic	identifiers.						
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2.3	Results	
2.3.1	TIR	domain	proteins	are	widespread	among	organisms		 The	sequences	from	multiple	known	TIR	domains	(Table	2.1)	were	used,	both	from	human	and	other	species,	as	seeds	for	performing	PSI-BLAST	searches	against	the	NCBI	non-redundant	protein	database.	Typically,	between	1000-10000	proteins	were	matched	to	each	query	sequence,	although	the	overlap	between	different	searches	was	as	expected,	very	high.	After	removal	of	duplicate	sequences,	a	total	of	13,731	unique	proteins	were	identified.		
Table	2.1	Sequences	used	as	seeds	for	PSI-BLAST.	
Species	 Protein	 Protein	ID	 Amino	acids	
Homo	Sapiens	 TLR1	 CAG38593.1	 639-775	
Homo	Sapiens	 TLR2	 AAH33756	 643-784	
Homo	Sapiens	 TLR3	 AAH59372	 758-862	
Homo	Sapiens	 TLR4	 AAY82270	 676-814	
Homo	Sapiens	 TLR5	 AAI09119	 695-832	
Homo	Sapiens	 TLR6	 BAA78631	 644-780	
Homo	Sapiens	 TLR7	 AAQ88659	 893-1034	
Homo	Sapiens	 TLR8	 AAQ88663	 882-1020	
Homo	Sapiens	 TLR9	 AAQ89443	 872-1009	
Homo	Sapiens	 TLR10	 AAQ88667	 636-774	
Homo	Sapiens	 MyD88	 NP_002459	 176-305	
Homo	Sapiens	 MAL	 NP_001034750	 86-168	
Homo	Sapiens	 TRIF	 BAC44839	 395-527	
Homo	Sapiens	 TRAM	 AAO74498	 81-174	
Homo	Sapiens	 SARM	 NP_055892	 561-700	
Homo	Sapiens	 SIGIRR	 CAG33619	 167-304	
Dictyostelium	discoideum	 TirA	 XP_636358	 821-915	
Caenorhabditis	elegans	 Tir-1	 NP_001021253	 578-718	
Yersinia	pestis	 YpTdp	 WP_002213208	 139-240	
Brucella	melitensis	 TcpB	 AAL52855	 121-233	
Bacillus	anthracis	 BaTdp	 WP_000291405	 128-255	
Paracoccus	denitrificans	 PdTlp	 WP_041530013	 23-133	Summary	of	the	TIR	domain	sequences	used	for	identification	of	other	TIR	domain	proteins	by	sequence	homology	searches.		
	 A	presence	of	at	least	one	TIR-	or	TIR-like	domain	in	each	sequence	was	then	verified	by	conserved	domain	search	(CD-search)	against	Pfam	and	SMART	
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databases.	Taxonomic	information	corresponding	to	each	sequence	was	also	extracted	from	the	NCBI	taxonomy	database	for	the	purpose	of	classifying	each	protein	based	on	origin.	A	total	of	10,455	unique	proteins	were	identified,	of	which	almost	4000	were	from	animals,	and	around	3000	each	from	bacteria	and	plants	(Table	2.2).		
Table	2.2	TIR	domain	proteins	identified	by	origin.	
Type	of	organism	 Number	of	TIR	domain	proteins	
identified	
Metazoa	(animals)	 3967	
Bacteria	 3417	
Streptophyta	(plants)	 2749	
Archaea	 70	
Peronosporales	(moulds)	 58	
Saprolegniales	(moulds)	 46	
Isochrysidales	(Algae)	 46	
Florideophyceae	(Algae)	 36	
Chlorophyta	(Algae)	 14	
Cryptophyta	(Algae)	 12	
Dictyosteliida	(slime	molds)	 8	
Albuginales	(moulds)	 6	
Ichthyosporea	(Protists)	 6	
Fungi	 2	
Pelagophyceae	(Algae)	 2	
Unknown	 18	Summary	of	the	TIR	domains	identified	through	sequence	homology	search	against	human	and	bacterial	TIR	domain	sequences.			
2.3.2	The	glycine	residue	in	the	TIR	domain	BB-loop	is	highly	
conserved	In	order	to	estimate	phylogenetic	relationships,	a	multiple	sequence	alignment	containing	the	TIR	domain	sequences	was	generated	using	MAFFT.	Due	to	the	large	dataset,	the	fast	progressive	FFT-NS-2	option	was	used,	which	utilises	the	FFT	algorithm	and	a	linear-space	DP	algorithm	and	is	suitable	for	aligning	many	(or	long)	sequences	(Katoh	et	al.,	2002).	In	Figure	2.1,	a	consensus	sequence	is	shown	with	the	degree	of	conservation	for	each	amino	
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acid	indicated.	In	general,	most	residues	were	not	strongly	conserved,	with	the	most	common	residue	typically	present	in	less	than	50%	of	sequences.	Although	some	notable	exceptions	stood	out.	For	example,	a	leucine	(L)	residue	located	in	the	A-helix,	a	glycine	(G)	residue	in	the	BB-loop	region,	and	a	glutamic	acid	(E)	residue	in	the	C-helix	all	showed	around	80%	conservation.	
	
Figure	2.1	Amino	acid	residue	conservation	from	multiple	sequence	alignment	of	
TIR	domains.	Sequences	of	identified	TIR	domains	were	aligned	using	MAFFT	(Katoh	et	al.,	2002)	and	the	conservation	of	each	individual	amino	acid	residue	was	calculated	using	Jalview	(Waterhouse	et	al.,	2009).	Consensus	sequence	is	indicated.	Secondary	structural	elements	based	on	the	TLR1	crystal	structure	(Xu	et	al.,	2000)	are	indicated	below.	Graphs	were	visualised	in	Graphpad	Prism	5.	
		
	 72	
2.3.3	SARM	is	closely	related	to	bacterial	TIR	proteins		 To	calculate	the	predicted	evolutionary	relationships	between	the	proteins,	FastTree	v2.1.8	was	used	to	construct	a	phylogenetic	tree	based	on	the	multiple	sequence	alignment	generated	in	section	2.3.2.	FastTree	uses	a	combination	of	neighbour-joining,	minimum	evolution	and	maximum	likelihood	to	generate	an	approximately	maximum	likelihood	tree,	making	it	dramatically	faster	than	maximum	likelihood	programs	such	as	PhyML	with	subtree	pruning	and	regrafting	moves	or	RAxML.	Furthermore,	it	was	also	much	more	accurate	than	minimum-evolution	methods	such	as	neighbor	joining,	BIONJ	or	FastME	(Price	et	al.,	2010).	As	shown	in	Figure	2.2,	the	TIR	domain	proteins	are	generally	divided	into	three	main	branches,	corresponding	to	animal,	plant,	and	bacterial	origin.	One	exception	however,	is	a	small	group	of	animal	proteins,	which	appear	evolutionary	closer	to	bacterial	TIR	proteins	than	other	animal	TIR	proteins.	SARM	homologs	make	up	the	majority	of	these	proteins.	These	results	are	consistent	with	those	reported	by	Zhang	and	colleagues	in	2011,	where	the	apparent	bacterial	origin	of	SARM	was	first	suggested	(Zhang	et	al.,	2011).	
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Figure	2.2	TIR	domains	phylogenetic	tree.	Phylogenetic	tree	was	generated	by	approximately	maximum	likelihood	based	on	aligned	TIR	domain	proteins	using	FastTree	(Price	et	al.,	2010)	and	visualised	using	Dendroscope	(Huson	and	Scornavacca,	2012).	Taxonomic	information	was	used	to	colour	the	branches	into	red,	cyan,	green	and	purple	for	metazoa	(animals),	bacteria,	streptophyta	(plants),	and	archaea,	respectively.	For	clarity,	only	the	four	largest	taxonomic	groups	are	indicated.			 While	phylogenetic	trees	are	useful	tools	for	predicting	the	evolutionary	relationships	of	proteins	based	on	sequence	alignment,	it	is	often	difficult	to	extract	meaningful	information	from	them	when	working	with	large	datasets.	As	the	number	of	sequences	used	for	analysis	increases,	so	does	the	alignment	complexity	and	the	computational	power	needed	for	inferring	phylogenetic	reconstructions.	CLANS	clustering	software	was	designed	to	overcome	these	challenges,	and	it	utilises	BLAST	to	conduct	all	against	all	homology	searches	
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from	a	sequence	dataset,	followed	by	calculating	pairwise	attraction	values.	Unlike	with	traditional	phylogenetic	reconstruction,	an	increasing	number	of	sequences	analysed	actually	increases	the	accuracy	of	the	model,	as	it	is	then	based	on	a	larger	set	of	pairwise	relationships.	After	random	placement	either	in	a	2D	or	3D	space,	sequences	are	then	moved	iteratively	based	on	their	attraction	values	towards	other	sequences	until	equilibrium	has	been	reached.		 As	shown	in	Figure	2.3,	CLANS	clustering	of	TIR	domain	proteins	resulted	in	a	pattern	similar	to	that	seen	during	phylogenetic	reconstruction.	Plant	TIR	domains	formed	two	tightly	bound	clusters,	while	animal	and	bacterial	proteins	were	predominantly	divided	into	a	number	of	separate	clusters.	SARM	homologues	were	again	an	obvious	exception	as	they	were	located	in	the	middle	of	the	general	bacterial	cluster.	A	second	cluster	of	metazoan	TIR	proteins	could	also	be	identified	among	the	bacterial	proteins.	This	mainly	contained	TIR	domain	proteins	from	water-living	invertebrates	such	as	Strongylocentrotus	
purpuratus	(purple	sea	urchin),	Saccoglossus	kowalevskii	(acorn	worm),	Aplysia	
californica	(California	sea	hare),	Lottia	gigantean	(owl	limpet),	Crassostrea	gigas	(pacific	oyster)	and	Nematostella	vectensis	(starlet	sea	anemone),	among	others.	Of	the	previously	characterised	bacterial	Tdps,	the	Y.	pestis	YpTdp	which	previously	has	been	described	as	a	minor	virulence	factor	(Spear	et	al.,	2012),	is	the	only	one	that	appeared	close	to	SARM	in	the	diagram.	Bacterial	TIR	proteins	from	Salmonella	(TlpA),	Brucella	(TcpB),	Paracoccus	(PdTlp)	and	Escherichia	(TcpC)	species	all	appeared	in	the	same	cluster,	indicating	a	high	degree	of	sequence	homology.		
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Figure	2.3	CLANS	clustering	of	TIR	domains.	By	using	CLANS	clustering	(Frickey	and	Lupas,	2004),	TIR	domain	proteins	were	separated	based	on	pairwise	sequence	similarities.	Plant	proteins	(green)	formed	two	tight	clusters,	while	bacterial	(blue)	and	animal	(red)	proteins	were	wider	dispersed.	Proteins	of	archaeal	origin	(purple)	did	not	form	any	obvious	clusters.	Relative	positions	of	human	TLRs,	MyD88,	MAL,	TRIF,	TRAM	and	SARM	are	indicated,	as	well	as	positions	of	bacterial	proteins	YpTdp,	BaTdp,	TcpB,	PdTlp,	TlpA	and	TcpC.	For	clarity,	only	the	four	largest	taxonomic	groups	are	indicated.	
	
2.4	Discussion		 From	the	data	presented	in	this	chapter,	it	is	clear	that	the	TIR	domain	is	a	common	protein	domain	among	animals,	plants	and	bacteria.	More	than	10,000	TIR	domain	proteins	were	identified	here,	noticeably	higher	than	in	previously	presented	studies	(Spear	et	al.,	2009,	Zhang	et	al.,	2011).	This	is	likely	in	part,	due	to	the	use	of	less	stringent	inclusion	criteria,	as	well	as	the	increased	amount	of	genomic	information	in	publicly	available	sequence	databases.	As	expected,	phylogenetic	analysis	indicated	that	animal,	plant,	and	bacterial	TIR	domain	proteins	were	generally	observed	to	form	separate	branches.	Consistent	with	
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previous	reports,	SARM	homologues	from	various	animals	appeared	together	with	the	bacterial	branch,	suggesting	a	different	evolutionary	origin	than	those	of	other	human	TLR	adaptor	proteins.	As	SARM	is	the	only	TLR	adaptor	that	has	been	shown	to	negatively	regulate	TLR	signalling	(Peng	et	al.,	2010,	Carty	et	al.,	2006),	this	fits	in	well	with	the	overall	view	of	the	protein	as	being	functionally	unique	among	human	Tdps.	The	vast	majority	of	the	non-mammalian	proteins	identified	have	not	yet	been	characterised,	and	are	only	described	as	hypothetical	proteins	based	on	genomic	information.	It	is	not	clear	whether	these	are	expressed	by	their	hosts,	and	if	so,	what	their	function	would	be.			 It	is	noteworthy	that	the	glycine	residue	located	in	the	exposed	BB-loop	region	of	the	domain	shows	a	very	high	degree	of	conservation	(~80%),	suggesting	that	it	plays	a	functionally	important	role.	As	discussed	previously	in	chapter	1,	the	BB-loop	region	has	repeatedly	been	described	as	being	functionally	important	for	TLR	signalling.	When	this	observation	is	combined	with	the	information	presented	here,	the	BB-loop	glycine	residue	appears	as	a	natural	target	for	mutagenesis	studies,	which	forms	part	of	this	thesis	work.	 		 	
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Chapter	3	
Expression	and	purification	of	TIR	domain	proteins	
	 	
	 78	
3.1	Introduction		 From	the	results	presented	in	chapter	2,	we	confirmed	and	expanded	on	the	results	from	previous	studies	(Spear	et	al.,	2009,	Zhang	et	al.,	2011)	showing	that	TIR	domain	proteins	are	a	large	family	of	proteins	present	in	animals,	bacteria,	and	plants.	As	bacteria	do	not	express	any	native	TLRs,	it	appears	that	the	functions	of	bacterial	TIR-proteins	differ	from	animal	and	plant	TIR-proteins.	In	animals,	TIR-proteins	are	mainly	used	to	mediate	signalling	in	response	PAMP	recognition	by	TLRs.	Interestingly,	SARM	appeared	to	be	more	closely	related	to	bacterial	TIR-proteins	than	other	animal	proteins,	suggesting	a	unique	evolutionary	history	and	function	for	this	protein.	It	is	possible	that	SARM	and	the	bacterial	TIR	proteins	share	a	common	mechanism	of	action.		 In	order	to	study	the	function	of	SARM	and	other	TIR	proteins,	we	first	needed	to	generate	protocols	for	robust	recombinant	expression	and	purification.	The	products	need	to	be	pure,	stable	and	functional,	and	the	amount	generated	needs	to	be	sufficient	for	conducting	suitable	downstream	analyses.	The	most	basic	assay	for	probing	TIR-TIR	interactions	in	this	study	was	the	GST	pull	down,	where	some	100-200	µg	protein	is	used	per	tube,	meaning	that	purification	yields	in	at	least	the	milligram-range	per	litre	expression	culture	would	be	ideal.			 Previous	studies	utilising	recombinantly	expressed	TIR	proteins	have	typically	focussed	on	expressing	the	isolated	TIR	domains	instead	of	the	full	length	proteins,	sometimes	citing	an	inability	to	generate	sufficient	soluble	expression	of	the	full	length	construct	(Spear	et	al.,	2012).	The	purification	strategies	employed	typically	involve	affinity	chromatography	for	protein	capture,	followed	by	other	types	of	chromatography	for	polishing.	For	example,	
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Xu	and	colleagues	were	able	to	purify	histidine-tagged	versions	of	the	human	TIR	domains	of	both	TLR1	and	TLR2	through	a	combination	of	nickel-agarose,	cation	exchange	and	gel	filtration	chromatography	(Xu	et	al.,	2000).	Rana	and	colleagues	used	a	similar	strategy,	excluding	the	ion	exchange	purification,	to	isolate	the	YpTdp	TIR	domain	(Rana	et	al.,	2011).		 In	this	chapter,	the	methods	used	to	express	and	purify	the	SARM	TIR-domain,	as	well	as	a	range	of	other	human	and	bacterial	TIR-domains	are	described.	Although	the	protocols	presented	here	are	specific	to	the	proteins	used	in	this	study,	we	believe	that	they	can	be	adapted	to	suit	virtually	any	TIR-domain	that	needs	to	be	purified	in	further	studies.	In	total,	7	different	TIR	domains	were	successfully	cloned,	expressed	and	purified	with	yields	in	the	range	of	milligram	per	litre	bacterial	cell	culture,	which	was	enough	to	support	the	functional	assays	presented	in	later	chapters.	
	
3.1.1	Chromatography		 The	most	common	technique	used	for	protein	purification,	and	the	one	used	almost	exclusively	in	this	study,	is	column	chromatography.	It	allows	proteins	to	be	separated	from	a	complex	mixture	based	on	multiple	different	attributes,	such	as	size,	charge,	or	hydrophobicity.	Three	different	types	of	chromatography	were	used	in	this	study,	ion-exchange	chromatography	(IEXC),	size-exclusion	chromatography	(SEC),	and	affinity	chromatography.	In	IEXC,	the	stationary	phase	is	either	positively	or	negatively	charged	and	thereby	separates	proteins	based	on	charge.	Proteins	bound	to	the	column	can	be	eluted	both	by	changing	the	pH	of	the	mobile	phase,	or	by	introducing	salt	into	the	buffer.	SEC	
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uses	a	porous	material	for	stationary	phase	where	smaller	molecules	can	freely	enter	and	exit	the	pores,	while	the	larger	molecules	do	not.	This	results	in	a	separation	of	molecules	based	on	size,	with	larger	proteins	being	eluted	from	the	column	faster	than	smaller	ones.	Affinity	chromatography	is	a	broad	term	used	to	describe	techniques	where	the	target	protein	interacts	specifically	with	the	stationary	phase.	One	example	used	in	this	study	is	the	purification	of	proteins	fused	to	glutathione	S-transferase	(GST)	by	utilising	the	high	affinity	interaction	between	GST	and	its	substrate	glutathione.	A	stationary	phase	featuring	immobilised	glutathione	captures	the	GST-fusion	protein	with	high	specificity,	and	the	target	protein	can	later	be	released	by	introducing	reduced	glutathione	(GSH)	in	the	mobile	phase,	which	disrupts	the	interaction	by	competitively	binding	to	the	target	protein.	Immobilised	metal-ion	affinity	chromatography	(IMAC)	is	another	special	type	of	affinity	chromatography	that	utilises	immobilised	metal	ions	such	as	nickel	or	cobalt	for	separation.	Histidine	binds	covalently	to	these	ions,	so	by	introducing	a	terminal	tag	comprising	multiple	histidine	residues	to	the	protein,	it	can	be	separated	with	high	specificity	from	a	mixture.	Protein	elution	is	performed	by	introducing	imidazole	to	the	mobile	phase,	which	displaces	the	bound	His-tagged	protein	by	competitively	binding	to	the	metal	ions,	thus	releasing	the	protein.		
3.1.2	Protein	tags		 As	described	in	the	previous	section,	introducing	tags	such	as	GST	or	hexahistidine	to	the	target	protein	can	facilitate	purification	greatly	by	providing	an	affinity	handle	that	can	be	utilised	for	high	specificity	purification.	However,	this	is	not	the	only	purpose	of	introducing	tags	to	the	target	protein.	Tags	can	
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also	be	incorporated	to	provide	improved	expression	yield,	or	protein	stability,	as	well	as	a	basis	for	detection	by	antibodies	or	fluorescence,	among	others.	Six	different	tags	have	been	used	in	this	study,	and	a	brief	summary	of	their	main	features	is	listed	in	Table	3.1.	For	proteins	expressed	in	E.	coli,	the	His-	and	GST-tags	were	mainly	used	for	purification	and	antibody-based	detection	during	Western	blots.	During	pull	down	interaction	assays	(data	presented	in	chapter	4),	the	GST-tag	also	served	the	purpose	of	immobilising	the	bait	protein	onto	a	resin.	Some	proteins	expressed	in	bacteria	were	also	incorporated	with	a	tag	comprised	of	the	B1	immunoglobulin	domain	of	Streptococcal	protein	G	(GB1).	The	main	purposes	of	this	tag	were	to	increase	expression	yield	and	prevent	protein	aggregation.		
Table	3.1	Protein	tags	used	in	this	study.	 	
Tag	 Size	 Main	purpose	 Basis	for	detection	
His	 0.8	kDa	 Purification,	detection	 Antibody	
GST	 26	kDa	 Purification,	detection,	stability,	expression	yield	 Antibody	
GB1	 6	kDa	 Stability,	expression	yield	 N/A	
GFP	 27	kDa	 Detection	 Fluorescence,	antibody	
FLAG	 1	kDa	 Detection	 Antibody	
V5	 1	kDa	 Detection	 Antibody			 For	proteins	overexpressed	in	mammalian	cells	(data	presented	in	chapters	5	and	6),	the	Green	fluorescent	protein	(GFP)	tag	was	mainly	used	as	a	fluorescent	reporter-tag,	allowing	visualisation	of	cellular	localisation	of	the	target	fusion-protein.	The	smaller	FLAG-	and	V5-tags	were	both	primarily	used	for	protein	detection	during	Western	blot,	but	could	also	be	used	during	cellular	
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localisation	studies	by	incubating	permeabilised	cells	with	antibodies	specific	for	these	motifs.	
	
3.2	Materials	and	methods	
3.2.1	Generation	of	plasmids	for	bacterial	expression		 The	oligonucleotide	primers	(Eurofins	MWG	Operon)	used	for	amplification	of	sequences	coding	for	all	proteins	generated	by	bacterial	expression	used	in	this	study	are	listed	in	Table	3.2.	DNA	sequences	of	the	respective	genes	were	amplified	by	standard	PCR	protocols	and	digested	with	indicated	restriction	enzymes,	after	which	the	digested	fragment	was	ligated	into	a	plasmid	previously	digested	with	the	same	set	of	enzymes.	The	resulting	plasmids	were	transfected	into	Top10	chemically	competent	E.	coli	cells	and	the	cloned	DNA	prepared	from	individual	colony	cultures	using	a	plasmid	miniprep	kit	(Invitrogen).	The	sequences	of	all	plasmids	were	confirmed	by	DNA	sequencing	(Source	BioScience).	The	original	plasmid	coding	for	MyD88	was	provided	by	Prof.	Andrew	Bowie,	Trinity	College	Dublin,	while	plasmids	coding	for	TRAM,	MAL	and	TRIF	were	provided	by	Dr.	Tom	Monie,	University	of	Cambridge.	DNA	coding	for	BaTdp	was	from	Dr.	Abigail	Spear,	Defence	Science	and	Technology	Laboratory	(DSTL).	Plasmid	coding	for	YpTIR	was	from	Dr.	Rohini	Rana.	To	generate	GST-tagged	SARM	BB-loop	expression	constructs,	Oligonucleotides	(Eurofins	MWG	Operon)	5’-GATCCGTCTTCATTGATGTGGAGAAGCTGGAAGCAGGCAAGTTCGAGGACAAATAG-3’	and	5’-	AATTCTATTTGTCCTCGAACTTGCCTGCTTCCAGCTTCTCCACATCAATGAAGACG-3’	were	melted	at	95°C	for	10	min	and	annealed	by	cooling	the	heat	block	slowly	to	
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room	temperature	over	45	min.	The	resulting	sequence	fragment,	coding	for	amino	acids	V591-K606,	was	inserted	into	a	pGEX-6p-1	vector	between	the	BamHI	and	EcoRI	restriction	sites.	A	construct	coding	for	GB1-tagged	SARM	BB-loop	was	generated	by	similar	methodology	using	oligonucleotides	5’- GATCCGTCTTCATTGATGTGGAGAAGCTGGAAGCAGGCAAGTTCGAGGACAAAC-3’	and	5’- TCGAGTTTGTCCTCGAACTTGCCTGCTTCCAGCTTCTCCACATCAATGAAGACG-3’	that	were	inserted	into	a	GEV2	vector	between	the	BamHI	and	XhoI	restriction	sites.	
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Table	3.2	Nucleotide	primers	used	for	plasmid	generation.	
Construct	 Residues	 Nucleotide	sequence	(5’-3’)	 Vector	
His-SARM-ST	 409-700	 GATCCATATGGTGCCCAGCTGGAAGGAG	
GATCGAATTCCTACTGCAGGAAGCGGATGATCTTC	
pET-28a	
His-SARM-ST-C	 409-724	 GATCCATATGGTGCCCAGCTGGAAGGAG	
GATCGAATTCTTAGGTTGGACCCATGGGTGC	
pET-28a	
His-SARM-TIR	 559-700	 GATCCATATGGGGGACACTCCAGATGTCTTC	
GATCGAATTCTTAGGTTGGACCCATGGGTGC	
pET-28a	
His-SARM-TIR-C	 559-724	 GATCCATATGGGGGACACTCCAGATGTCTTC	
GATCGAATTCTTAGGTTGGACCCATGGGTGC	
pET-28a	
GST-SARM-ST	 409-700	 GATCGGATCCGTGCCCAGCTGGAAGGAG	
GATCGAATTCCTACTGCAGGAAGCGGATGATCTTC	
pGEX-6p-1	
GST-SARM-ST-C	 409-724	 GATCGGATCCGTGCCCAGCTGGAAGGAG	
GATCGAATTCTTAGGTTGGACCCATGGGTGC	
pGEX-6p-1	
GST-SARM-TIR	 559-700	 GATCGGATCCGGGGACACTCCAGATGTCTTC	
GATCGAATTCCTACTGCAGGAAGCGGATGATCTTC	
pGEX-6p-1	
GST-SARM-TIR-C	 559-724	 GATCGGATCCGGGGACACTCCAGATGTCTTC	
GATCGAATTCTTAGGTTGGACCCATGGGTGC	
pGEX-6p-1	
GB1-SARM-ST	 409-700	 GATCGGATCCGTGCCCAGCTGGAAGGAG	
GATCCTCGAGCTGCAGGAAGCGGATGATC	
GEV2	
GB1-SARM-TIR	 559-700	 GATCGGATCCGGGGACACTCCAGATGTCTTC	
GATCCTCGAGCTGCAGGAAGCGGATGATC	
GEV2	
GST-TRIF-TIR368-537	 368-537	 GATCGGATCCTCATCTACTCCTTGTTCAGCTCAC	
GATCGAATTCCTACTTTCGGGCCTGAAGCCT	
pGEX-6p-1	
GST-TRIF-TIR368-613	 368-613	 GATCGGATCCTCATCTACTCCTTGTTCAGCTCAC	
GATCGAATTCCTACACCTGGCCCCCAAAGGGCAT	
pGEX-6p-1	
GST-TRIF-TIR368-700	 368-700	 GATCGGATCCTCATCTACTCCTTGTTCAGCTCAC	
GATCGAATTCCTACCCTCTCTGGTTCCACATGT	
pGEX-6p-1	
GB1-BaTIR	 126-266	 GATCGGATCCGATAACACTAAAGTATTCA	
GATCCTCGAGCCTTAATTCTTTCATAATA	
GEV2	Underlined	sequences	CATATG,	GAATTC,	GGATCC	and	CTCGAG	correspond	to	restriction	sites	NdeI,	EcoRI,	BamHI	and	XhoI	respectively. 
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3.2.2	Site-directed	mutagenesis		 Site-directed	mutagenesis	of	SARM	plasmids	was	performed	using	QuikChange®	Lightning	Site-directed	Mutagenesis	Kit	(Stratagene),	following	the	manufacturer’s	instructions.	Oligonucleotide	primers	(Eurofins	MWG	Operon)	hSARM_G601A_F	(Fw)	5’-GAGAAGCTGGAAGCAGCCAAGTTCGAGGACAAA-3’	and	hSARM_G601A_R	(Rev)	5’-TTTGTCCTCGAACTTGGCTGCTTCCAGCTTCTC-3’	were	used	to	insert	a	Gly601Ala	mutation	in	the	pET28a	SARM	expression	vectors.	The	underlined	bases	indicate	the	mutagenesis	site.	Mutagenesis	was	confirmed	by	DNA	sequencing	(Eurofins	MWG	Operon).		
3.2.3	Generation	of	chemically	competent	cells		 E.	coli	BL21(DE3)	and	TOP10	used	for	plasmid	cloning	or	protein	expression	were	made	competent	using	a	protocol	modified	from	(Sambrook	et	al.,	1989).	A	single	bacterial	colony	was	used	to	inoculate	5	mL	of	LB	and	grown	overnight	at	37°C.	The	starter	culture	was	then	used	to	inoculate	100	mL	LB,	which	was	grown	at	37°C	until	optical	density	(OD)	reached	0.4.	The	culture	was	chilled	on	ice	and	cells	were	harvested	by	centrifugation	at	5,000	x	g	for	10	min	at	4°C.	Cells	were	then	gently	washed	in	40	mL	pre-chilled	sterile	100	mM	CaCl2,	before	being	centrifuged	again	and	resuspended	in	5	mL	100	mM	CaCl2.	Cells	were	incubated	on	ice	for	at	least	1	hour,	after	which	3	mL	of	sterile	40%	glycerol	was	added	(final	concentration	15%	glycerol).	Finally,	the	cells	were	mixed	gently	and	divided	into	100	µL	aliquots	which	were	flash	frozen	in	liquid	nitrogen	and	stored	at	-80°C	until	used.			
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3.2.4	Bacterial	transformation		 100	µL	aliquots	of	previously	frozen	chemically	competent	E.	coli	cells	were	thawed	on	ice	prior	to	the	addition	of	plasmid	(typically	1	µL	with	a	concentration	of	approximately	0.1-1	µg/mL).	The	mixture	was	incubated	on	ice	for	30	min,	after	which	the	cells	were	heat	shocked	in	a	42°C	water	bath	for	45	seconds.	The	cells	were	then	chilled	on	ice	and	250	µL	LB	without	antibiotics	added.	The	cells	were	allowed	to	grow	at	37°C	for	1	hour	after	which	they	were	streaked	on	a	plate	of	LB	agar	supplemented	with	appropriate	antibiotics	and	incubated	at	37°C	overnight.	For	plasmid	amplification	cloning,	TOP10	(GE	Healthcare)	E.	coli	cells	were	used,	while	protein	expression	was	conducted	in	BL21(DE3)	(GE	Healthcare)	E.	coli	cells.		
3.2.5	Protein	expression	in	E.	coli	BL21(DE3)		 Unless	stated	otherwise,	the	following	protocol	was	used	for	protein	expression.	Single	colonies	of	cells	transformed	with	bacterial	expression	plasmid	as	described	in	section	3.2.4	were	used	to	inoculate	small	scale	(5-50	mL)	starter	cultures	of	either	LB	or	terrific	broth	(TB)	supplemented	with	appropriate	antibiotics	and	grown	at	25-30°C	overnight.		The	starter	cultures	were	used	to	inoculate	large	scale	(1-12	L,	depending	on	protein	expression	level)	cultures	and	cells	were	grown	at	37°C	until	the	optical	density	at	600	nm	(OD600)	reached	0.6.	At	this	stage,	cells	were	chilled	briefly	to	rapidly	decrease	the	culture	temperature	to	approximately	25°C,	and	the	temperature	of	the	incubators	was	decreased	to	25°C.	Protein	expression	was	induced	by	adding	IPTG	(Melford	Laboratories)	to	a	final	concentration	of	0.5	mM,	and	the	cultures	
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were	incubated	overnight.	The	following	day,	cells	were	harvested	by	centrifugation	at	5,000	x	g	for	15	min	and	the	cell	pellets	either	resuspended	in	lysis	buffer	for	immediate	protein	purification	as	described	in	sections	3.2.8,	
3.2.9,	3.2.11	and	3.2.12,	or	frozen	at	-80°C	for	future	use.		
3.2.6	Preservation	of	E.	coli	clones	in	glycerol	stocks		 In	order	to	avoid	the	need	for	repeated	transformation	of	cells	with	the	same	plasmid,	glycerol	stocks	were	routinely	generated.	A	single	bacterial	colony	from	bacteria	transformed	with	a	selected	plasmid	was	picked	from	a	freshly	streaked	LB	agar	plate	and	grown	overnight	at	37°C	in	5	mL	of	LB	medium	supplemented	with	appropriate	antibiotics.	In	a	cryogenic	vial	(Nunc),	500	µL	of	cell	culture	was	mixed	with	300	µL	of	sterile	glycerol	from	a	40%	stock	solution	to	make	the	final	concentration	of	glycerol	15%.	Following	flash	freezing	in	liquid	nitrogen,	the	cells	were	stored	at	-80°C.	In	order	to	use	the	cells,	the	frozen	surface	was	scraped	with	a	pipette	tip	that	was	dipped	in	LB	medium	afterwards,	thus	avoiding	repeated	freezing	and	thawing	of	the	vial	content	which	may	cause	degradation	of	cell	viability.		
3.2.7	Chromatographic	purification		 Automated	chromatographic	separations	of	proteins	were	performed	with	a	ÄKTA	purifier	FPLC	system	(GE	Healthcare).	All	buffers	were	filtered	through	a	0.22	µm	pore	size	filter	before	used.	Protein	samples	were	clarified	either	by	filtration	or	high	speed	centrifugation	before	being	loaded	on	the	column.	Elution	was	monitored	by	UV	absorbance	at	280	nm.	Manual	
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chromatographic	separation	was	performed	using	a	basic	gravity	flow	column	setup	and	elution	was	verified	by	SDS-PAGE.		
3.2.8	Purification	of	His-tagged	SARM	proteins		 Pelleted	cells	were	suspended	in	5	volumes	of	ice-cold	buffer	A	[40	mM	Tris-HCl,	200	mM	NaCl,	10	mM	imidazole,	pH	7.5]	supplemented	with	one	cOmplete	EDTA-free	protease	inhibitor	cocktail	tablet	(Roche)	and	approx.	1	mg/mL	lysozyme	(Sigma),	lysed	by	sonication	using	a	Vibra-Cell	VCX-500	sonicator	(Sonics).	The	samples	were	then	centrifuged	at	50,000	x	g	for	one	hour	to	remove	cell	debris	and	residual	unbroken	cells.	The	supernatants	were	applied	to	Talon®	metal	affinity	resin	(Clontech)	(5	mL	resin	per	1	L	culture)	equilibrated	with	buffer	A	and	the	proteins	allowed	to	batch	bind	for	1	hour	at	4°C.	The	resin	was	then	washed	with	10	column	volumes	(CVs)	of	buffer	A,	followed	by	protein	elution	with	5	CVs	buffer	B	[40	mM	Tris-HCl,	200	mM	NaCl,	300	mM	imidazole,	pH	7.5].	Purified	proteins	were	concentrated	to	approximately	15	mL	using	Amicon	ultra	centrifugal	devices	(10	kDa	MWCO)	(Millipore),	and	were	buffer	exchanged	into	buffer	C	[20	mM	Tris-HCl,	5	mM	DTT,	1	mM	EDTA,	pH	7.0]	using	a	HiPrep	26/10	desalting	column	(GE	Healthcare).	The	samples	were	then	either	flash	frozen	in	liquid	nitrogen	and	stored	at	-80°C,	or	further	purified	by	anion-exchange	chromatography	with	MonoQ	resin	(GE	Healthcare)	using	a	linear	gradient	of	sodium	chloride	(0-1	M)	in	buffer	C	for	elution.	The	eluted	protein	was	finally	concentrated	to	a	volume	of	approximately	500	μL	and	purified	by	gel	filtration	with	a	Superdex	200	10/300	GL	column	(GE	Healthcare)	equilibrated	with	buffer	D	[20	mM	Tris-HCl,	300	mM	NaCl,	5	mM	DTT,	1	mM	EDTA,	pH	7.0],	followed	by	concentration	of	the	protein	
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to	approximately	1	mg/mL	and	flash	freezing.	Buffers	used	for	purification	of	proteins	described	in	this	chapter	are	listed	in	Table	3.3.		
Table	3.3	Buffers	used	for	protein	purification	in	this	study.	 	
Buffer	 Composition	
Buffer	A	 40	mM	Tris-HCl,	200	mM	NaCl,	10	mM	imidazole,	pH	7.5	
Buffer	B	 40	mM	Tris-HCl,	200	mM	NaCl,	300	mM	imidazole,	pH	7.5	
Buffer	C	 20	mM	Tris-HCl,	5	mM	DTT,	1	mM	EDTA,	pH	7.0	
Buffer	D	 20	mM	Tris-HCl,	300	mM	NaCl,	5	mM	DTT,	1	mM	EDTA,	pH	7.0	
Buffer	E	 40	mM	Tris-HCl,	pH	7.5,	200	mM	NaCl,	1	mM	EDTA,	5	mM	DTT	
Buffer	F	 50	mM	Tris-HCl,	pH	8.0,	10	mM	GSH	
Buffer	G	 20	mM	Tris-HCl,	pH	7.5	
Buffer	H	 20	mM	Tris-HCl,	250	mM	NaCl,	2	mM	β-mercaptoethanol	(BME),	pH	7.0	
Buffer	I	 20	mM	Tris-HCl,	150	mM	NaCl,	pH	7.0		
3.2.9	Purification	of	GST-tagged	SARM	proteins		 Pelleted	cells	were	resuspended	in	5	volumes	of	ice-cold	buffer	E	[40	mM	Tris-HCl,	pH	7.5,	200	mM	NaCl,	1	mM	EDTA,	5	mM	DTT]	supplemented	with	one	cOmplete	EDTA-free	protease	inhibitor	cocktail	tablet	(Roche)	and	approx.	1	mg/mL	lysozyme	(Sigma),	lysed	by	sonication	using	a	Vibra-Cell	VCX-500	sonicator	(Sonics)	after	which	the	samples	were	centrifuged	at	50,000	x	g	for	one	hour	to	remove	cell	debris	and	residual	unbroken	cells.	The	supernatant	was	applied	to	Glutathione	Sepharose	High	Performance	resin	(GE	Healthcare)	(5	mL	resin	per	1	L	culture)	equilibrated	with	buffer	E	and	the	proteins	batch	bound	for	one	hour	at	4°C.	The	resin	was	then	washed	with	10	CVs	of	Buffer	E,	followed	by	protein	elution	with	2	CVs	buffer	F	[50	mM	Tris-HCl,	pH	8.0,	10	mM	GSH].	Protein	purity	was	assessed	by	SDS-PAGE,	and	the	sample	was	dialysed	
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overnight	against	100	times	the	sample	volume	of	lysis	buffer	using	a	Spectra/Por®	4	Dialysis	membrane	(12-14	kDa	MWCO)	(Spectrum	Labs).	The	purified	protein	was	either	concentrated,	flash	frozen	in	liquid	nitrogen	and	stored	at	-80°C,	or	subjected	to	proteolysis	by	PreScission	protease	(GE	Healthcare)	in	order	to	remove	the	GST-tag.		
3.2.10	Cleavage	of	GST-tag	from	SARM	fusion	proteins		 Purified	GST-tagged	SARM	proteins	were	incubated	at	4°C	with	PreScission	enzyme	at	an	enzyme	to	substrate	ratio	of	1:50	(w/w)	overnight,	cleaving	the	substrate	between	the	Q/G	position	of	the	LEVLFQ/GP	recognition	motif.	The	sample	mixture	was	then	subjected	to	reverse	affinity	chromatography	with	Glutathione	Sepharose	High	Performance	resin	(GE	Healthcare).	The	untagged	SARM,	present	in	the	flow-through,	was	subsequently	concentrated	to	6	mL	and	further	purified	by	gel	filtration	with	a	HiLoad	26/60	Superdex	75	column	(GE	Healthcare),	equilibrated	with	buffer	D.	Protease	efficiency	and	protein	purity	was	assessed	by	SDS-PAGE.			
3.2.11	Purification	of	GST-tagged	MyD88-TIR,	TRIF-TIR,	MAL,	
and	TRAM		 MAL,	TRAM,	and	the	TIR	domains	from	MyD88	(MyD88-TIR,	residues	F163-P296)	and	TRIF	(TRIF-TIR,	residues	S368-K537,	S368-V613	or	S368-G700)	were	expressed	as	GST-fusion	proteins.	Pelleted	cells	were	suspended	in	10	volumes	of	ice-cold	buffer	E	supplemented	with	one	cOmplete	EDTA-free	protease	inhibitor	cocktail	tablet	(Roche)	and	approx.	1	mg/mL	lysozyme	
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(Sigma),	lysed	by	sonication	using	a	Vibra-Cell	VCX-500	sonicator	(Sonics)	after	which	the	samples	were	centrifuged	at	50,000	x	g	for	one	hour	to	remove	cell	debris	and	residual	unbroken	cells.	The	supernatant	was	applied	to	Glutathione	Sepharose	High	Performance	resin	(GE	Healthcare)	equilibrated	with	buffer	E	and	the	proteins	were	allowed	to	batch	bind	for	one	hour	at	4°C.	Resin	was	then	washed	with	10	CVs	of	lysis	buffer,	followed	by	protein	elution	with	2	CVs	buffer	F.	Protein	purity	was	assessed	by	SDS-PAGE,	and	for	GST-TRAM,	a	second	purification	step	was	employed	using	anion-exchange	chromatography	with	MonoQ	resin	(GE	Healthcare)	using	a	linear	gradient	of	sodium	chloride	(0-1	M)	in	buffer	C	for	elution.	Samples	were	finally	buffer	exchanged	into	buffer	G	[20	mM	Tris-HCl,	pH	7.5]	and	concentrated	to	approximately	1	mg/mL	using	Amicon	ultracentrifugal	devices	(10	kDa	MWCO)	(Millipore).	Purified	proteins	were	flash	frozen	in	liquid	nitrogen	and	stored	at	-80°C	until	use.	Free	GST	to	be	used	as	negative	control	during	GST	pull	down	interaction	assays	was	also	expressed	in	BL21	(DE3)	cells	using	a	pGEX-6p-1	vector	and	purified	as	described	above.		
3.2.12	Purification	of	GB1-tagged	proteins		 SARM-TIR	and	the	TIR	domains	from	MyD88,	YpTdp	(YpTIR,	residues	S130	to	A285)	and	BaTdp	(BaTIR,	residues	D126	to	R266)	were	expressed	using	a	GEV2	vector	with	an	N-terminal	GB1	tag	and	a	C-terminal	His	tag.	BL21	(DE3)	
E.	coli	cells	were	grown	at	37°C	until	OD600	reached	0.6.	Protein	expression	was	then	induced	with	1	mM	IPTG	(Melford	Laboratories)	for	YpTIR	or	0.5	mM	for	MyD88-TIR,	BaTIR,	and	SARM-TIR	for	four	hours	at	25°C.	Cells	were	harvested	by	centrifugation	at	5,000	x	g	for	15	minutes	and	were	stored	at	-80°C	until	usage.	Pelleted	cells	were	suspended	in	10	volumes	of	ice-cold	buffer	H	[20	mM	
	 92	
Tris-HCl,	250	mM	NaCl,	2	mM	β-mercaptoethanol	(BME),	pH	7.0]	supplemented	with	one	cOmplete	EDTA-free	protease	inhibitor	cocktail	tablet	(Roche)	and	approx.	1	mg/mL	lysozyme	(Sigma),	lysed	by	sonication	using	a	Vibra-Cell	VCX-500	sonicator	(Sonics)	after	which	the	samples	were	centrifuged	at	50,000	x	g	for	one	hour	to	remove	cell	debris	and	residual	unbroken	cells.	The	supernatants	were	applied	to	Talon®	metal	affinity	resin	(Clontech)	(5	mL	resin	per	1	L	culture)	equilibrated	with	buffer	H	and	were	left	batch	bound	for	1	hour	at	4°C.	Resin	was	then	washed	with	10	CVs	of	lysis	buffer,	followed	by	protein	elution	with	5	CVs	buffer	H	supplemented	with	150	mM	imidazole.	Purified	protein	was	concentrated	and	buffer	exchanged	to	approximately	15	mL	in	buffer	I	[20	mM	Tris-HCl,	150	mM	NaCl,	pH	7.0]	using	Amicon	ultra	centrifugal	devices	(10	kDa	MWCO)	(Millipore),	followed	by	flash	freezing	in	liquid	nitrogen.	Protein	was	stored	at	-80°C	until	use.	For	MyD88-TIR,	a	further	purification	step	using	size-exclusion	chromatography	on	a	HiLoad	26/60	Superdex	75	column	(GE	Healthcare)	was	performed	before	concentration	and	freezing	of	the	protein.		
3.2.13	Purification	of	SARM	BB-loop	peptide		 The	predicted	SARM	BB-loop	sequence	(V591-K606)	was	expressed	as	a	GST-	or	GB1-fusion	protein	and	purified	as	described	in	sections	3.2.9	and	
3.2.12.	The	GST-tag	was	cleaved	by	adding	PreScission	protease	at	a	1:1000	(w/w)	ratio	and	incubating	the	sample	over	night	at	4°C.	The	2	kDa	BB-loop	peptide	was	isolated	from	the	26	kDa	GST-tag	by	filtration	through	a	10	kDa	MWCO	Amicon	ultra	centrifugal	device	unit.	The	peptide	was	precipitated	by	adding	ice	cold	acetone	to	the	sample	to	an	80%	total	concentration	and	incubation	over	night	at	-20°C.	Precipitated	peptide	was	collected	by	
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centrifugation	at	12,000	x	g	for	10	min,	followed	by	decanting	the	supernatant	and	letting	the	sample	air	dry	at	room	temperature	until	all	solvent	had	evaporated.	The	peptide	was	finally	dissolved	in	20	mM	Tris-HCl,	150	mM	NaCl,	pH	7.5	and	clarified	from	any	remaining	insoluble	matter	by	centrifugation	at	20,000	x	g	for	20	min.		
3.2.14	UV-spectroscopy		 The	concentration	of	each	purified	protein	was	determined	by	UV-spectroscopy	using	a	DU	730	spectrophotometer	(Beckman)	by	measuring	sample	absorbance	at	280	nm.	Extinction	coefficients	were	estimated	with	ProtParam	(Wilkins	et	al.,	1999)	from	the	ExPASy	webserver.	Protein	concentrations	were	calculated	from	the	absorbance	values	by	applying	Beer-Lambert’s	law.		
3.2.15	SDS-PAGE		 NuPAGE®	4-12%	Bis-Tris	precast	1.0	mm	thick	gels	(Invitrogen)	were	used	for	SDS-PAGE	analysis	with	an	XCell	SureLock	Mini-Cell	Electrophoresis	System	(Invitrogen).	Protein	samples	were	mixed	at	a	1:1	ratio	(v/v)	with	LDS	sample	loading	buffer	(2X)	(Invitrogen)	and	boiled	at	95°C	for	5	minutes	before	loading	on	the	gel.	After	separation,	gels	were	either	used	for	Western	blot	analysis,	or	Coomassie-stained	with	InstantBlue	(Expedon)	in	order	to	visualise	the	protein	bands	directly.			
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3.2.16	Western	blot		 Proteins	from	unstained	SDS-PAGE	gels	were	transferred	to	an	Amersham	Hybond-P	Polyvinylidene	difluoride	(PVDF)	membrane	(GE	healthcare)	using	an	XCell	II	Blot	Module	(Invitrogen).	Membranes	were	then	incubated	with	5%	blocking	solution	[5%	milk	in	PBS	supplemented	with	0.1%	Tween	20	(PBST)]	at	room	temperature	for	1	hour,	followed	by	incubation	with	an	appropriate	dilution	of	primary	antibody	in	blocking	solution,	following	manufacturer’s	instruction,	for	1	hour	at	room	temperature.	For	His-tagged	proteins,	monoclonal	anti-polyHistidine	antibody	produced	in	mouse	(Sigma)	was	used	(1:	5000	dilution	in	5%	blocking	solution)	and	for	GST-tagged	proteins,	monoclonal	Anti-Glutathione-S-Transferase	antibody	produced	in	mouse	(Sigma)	was	used	(1:5000	dilution	in	5%	blocking	solution).	After	three	cycles	of	washing	in	PBST	for	5	minutes	each,	the	membrane	was	incubated	with	a	secondary	antibody,	anti-Mouse	IgG	(whole	molecule)-Alkaline	Phosphatase	antibody	produced	in	goat	(Sigma)	diluted	1:5000	with	5%	blocking	solution,	at	room	temperature	for	1	hour.	The	membrane	was	finally	washed	with	PBST	five	times	for	5	minutes	each,	after	which	proteins	were	detected	with	SIGMAFAST	BCIP®/NBT	(Sigma)	following	manufacturer’s	instructions.		
3.2.17	In-gel	digestion	and	analysis	of	GST-TRIF-TIR	by	mass	
spectrometry			 The	SDS-PAGE	gel	band	of	GST-TRIF-TIR	was	excised	and	cut	into	1	mm	cubes.	These	were	then	subjected	to	in-gel	digestion,	using	a	ProGest	Investigator	in-gel	digestion	robot	(Genomic	Solutions)	using	standard	protocols	
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(Shevchenko	et	al.,	1996).	Briefly	the	gel	cubes	were	destained	by	washing	with	acetonitrile	and	subjected	to	reduction	and	alkylation	before	digestion	with	trypsin	at	37°C.	The	peptides	were	extracted	with	10%	formic	acid.	The	digest	solution	(0.5	mL)	was	applied	to	the	MALDI	target	along	with	alpha-cyano-4-hydroxycinnamic	acid	matrix	(0.5	mL,	10	mg/mL	in	50:50	acetonitrile:0.1%	TFA)	and	allowed	to	dry.	MALDI	MS	were	acquired	using	a	4800	MALDI	TOF/TOF	Analyser	(Applied	Biosystems)	equipped	with	a	Nd:YAG	355	nm	laser	calibrated	using	a	mixture	of	peptides.	The	most	intense	peptides	(up	to	15)	were	selected	for	MSMS	analysis	and	the	combined	MS	and	MSMS	data	were	analysed,	using	GPS	Explorer	(Applied	Biosystems)	to	interface	with	the	Mascot	2.1	search	engine	(Matrix	Science),	against	the	UniProt	(Swiss-Prot	and	TREMBL	combined)	database	(April	2009).	No	species	restriction	was	applied.	The	data	was	searched	with	tolerances	of	100	ppm	for	the	precursor	ions	and	0.5	Da	for	the	fragment	ions,	trypsin	as	the	cleavage	enzyme,	assuming	up	to	one	missed	cleavage,	carbamidomethyl	modification	of	cysteines	as	a	fixed	modification	and	methionine	oxidation	selected	as	a	variable	modification.	Sample	preparation	and	analysis	was	performed	by	Dr.	Catherine	Botting	in	the	Biomedical	Sciences	Research	Complex	(BSRC)	Mass	Spectrometry	and	Proteomics	Facility,	University	of	St	Andrews.		
3.3	Results	
3.3.1	Generation	of	SARM	expression	constructs		 Initial	purification	strategies	focused	on	expression	of	the	full	length	human	SARM	protein	in	a	bacterial	expression	system.	Despite	multiple	attempts	
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at	optimising	growth	conditions	with	regard	to	temperature,	induction	parameters	and	time,	no	soluble	protein	expression	was	obtained	(data	not	shown).	This	is	why	we	decided	to	generate	truncated	versions	of	the	protein.	As	mentioned	in	chapter	1,	human	SARM	harbours	five	predicted	protein	domains	in	its	sequence:	two	parallel	ARM	domains,	two	parallel	SAM	domains,	and	a	TIR	domain	located	near	the	C-terminus.	Additionally,	an	intact	N-terminus	has	previously	been	shown	to	be	required	for	mitochondrial	localisation	in	the	cell	(Panneerselvam	et	al.,	2012a),	although	as	purified	proteins	would	not	be	used	in	a	cellular	environment,	this	motif	was	excluded.	Interactions	with	other	TIR	domain	proteins	are	believed	to	be	mediated	by	the	SARM	TIR	domain,	so	this	domain	was	featured	in	all	constructs	designed.	An	overview	of	the	sequences	used	for	plasmid	generation	is	shown	in	Figure	3.1.	All	sequences	were	subcloned	into	a	pET28a	vector	for	expression	as	a	His-tagged	fusion	protein	and	into	pGEX-6p-1	for	expression	as	a	GST-tagged	fusion	protein.	Additionally,	the	smallest	SARM-TIR	sequence	was	also	subcloned	into	the	GEV2	vector	for	expression	as	a	double	tagged	protein	with	an	N-terminal	GB1-tag	and	a	C-terminal	His-tag.					
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Figure	3.1	SARM	protein	sequences	cloned	into	expression	vectors.	Four	different	SARM	sequences	were	subcloned	into	expression	constructs.	SARM-ST-C	(residues	409-724)	covered	both	SAM-	and	TIR-domains	as	well	as	the	C-terminus,	while	SARM-ST	(residues	409-700)	was	identical	with	the	exception	of	the	C-terminus	being	truncated.	SARM-TIR-C	(residues	559-724)	covered	the	TIR-domain	and	the	C-terminus,	while	SARM-TIR	(residues	559-700)	did	not	include	the	C-terminus.	All	sequences	were	subcloned	into	pET28a-	and	pGEX-6p-1	vectors.	The	SARM-TIR	sequence	was	also	subcloned	into	the	GEV2-vector.		
3.3.2	Expression	and	purification	of	His-tagged	SARM-TIR		 For	SARM	proteins	fused	with	only	a	His-tag,	the	construct	featuring	only	the	SARM	TIR-domain	was	the	one	that	generated	the	highest	level	of	protein	expression,	as	estimated	by	Western	blot	analysis	(data	not	shown).	Despite	this,	the	overall	expression	yield	was	low	and	it	was	clear	from	the	beginning	that	being	able	to	generate	large	quantities	of	high-quality	protein	would	be	difficult.	Multiple	attempts	at	optimisation	of	expression	and	purification	strategies,	produced	a	maximal	yield	of	around	200	µg	pure	His-SARM-TIR	per	L	TB	culture.	In	this	case	the	protein	was	isolated	by	IMAC,	followed	by	ion	exchange	chromatography,	as	shown	in	Figure	3.2A.	Protein	precipitation	was	a	frequent	problem,	which	is	why	it	was	also	important	to	verify	that	the	protein	was	in	a	monodispersed	state.	Analytical	size	exclusion	chromatography	displayed	a	single	main	peak	near	the	expected	retention	volume	for	monomeric	SARM-TIR,	confirming	that	it	had	not	aggregated	(Fig.	3.2B).	A	G601A	mutant	version	of	the	
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protein	was	also	purified	using	identical	methodology,	resulting	in	protein	with	similar	purity	and	yield	(Fig.	3.2C-D).		
	
Figure	3.2	Purification	of	His-tagged	SARM-TIR.	(A)	SDS-PAGE	of	samples	taken	from	various	stages	of	the	purification	process	of	His-SARM-TIR.	M,	molecular	weight	marker;	lane	1,	soluble	fraction	of	cell	lysate;	lane	2,	flow	through	during	IMAC;	lane	3,	eluted	fraction	during	IMAC;	lane	4,	eluted	fraction	during	IEXC.	(B)	Chromatogram	of	His-SARM-TIR	analysed	by	SEC	using	a	Superdex	200	10/300	GL	column.	(C)	Purification	of	His-SARM-TIR	(G601A).	M,	molecular	weight	marker;	lane	1,	soluble	fraction	of	cell	lysate;	lane	2,	flow	through	during	IMAC;	lane	3,	eluted	fraction	during	IMAC;	lane	4,	eluted	fraction	during	IEXC.	(D)	Chromatogram	of	His-SARM-TIR	(G601A)	analysed	by	SEC	using	a	Superdex	200	10/300	GL	column.		
3.3.3	Expression	and	purification	of	GST-tagged	SARM-SAM-TIR		 As	SARM	protein	tagged	with	only	a	small	histidine-tag	appeared	difficult	to	express,	fusion	proteins	with	a	range	of	tags	designed	for	improved	solubility,	stability,	and	expression	yield	were	generated.	By	fusing	different	SARM-sequences	to	GST,	expression	yields	were	dramatically	increased.	Fusion	
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proteins	featuring	the	isolated	SARM	TIR-domain,	or	both	SAM-	and	TIR-domains	both	expressed	well	in	BL21	(DE3)	E.	coli	cells.	Following	GST	affinity	chromatography	on	glutathione	Sepharose	resin,	pure	fusion	protein	was	isolated	with	a	purification	yield	of	approximately	2	mg/L	TB	culture	(Fig.	3.3).		
	
Figure	3.3	Purification	of	GST-tagged	SARM-SAM-TIR.	SDS-PAGE	analysis	of	samples	taken	during	the	purification	of	GST-SARM-ST.	M,	molecular	weight	marker;	lane	1,	soluble	fraction	of	cell	lysate;	lane	2	flow	through	during	affinity	chromatography;	lane	3,	eluted	fraction	after	affinity	chromatography.		
3.3.4	Expression	and	purification	of	GB1-tagged	YpTIR		 The	protocol	for	purification	of	GB1-YpTIR	was	adapted	from	(Rana	et	al.,	2011),	with	main	difference	being	that	the	final	buffer	exchange	was	made	by	diafiltration	instead	of	gel	filtration	chromatography,	and	resulted	in	pure	protein	after	a	single	IMAC	purification	step	(Fig.	3.4A)	with	a	purification	yield	of	approximately	5	mg/L	LB	culture.	Analytical	SEC	(Fig.	3.4B)	confirmed	that	the	protein	was	in	a	monodispersed	state.	At	just	6	kDa,	the	GB1-tag	is	notably	smaller	than	the	GST-tag,	making	it	a	much	more	suitable	tag	for	functional	studies	using	for	example	nuclear	magnetic	resonance	(NMR).	The	protein	also	contains	a	C-terminal	His-tag	for	convenient	purification,	as	well	as	detection	
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during	Western	blot	analysis	using	an	anti-His	primary	antibody.	A	P173H	mutant	version	of	the	protein	was	also	expressed	and	purified	using	the	same	protocol,	resulting	in	similar	yield	and	purity.		
	
Figure	3.4	Purification	of	GB1-tagged	YpTIR.	(A)	SDS-PAGE	of	samples	taken	from	various	stages	of	the	purification	process	of	GB1-YpTIR.	M,	molecular	weight	marker;	lane	1,	soluble	fraction	of	cell	lysate;	lane	2,	flow	through	during	IMAC;	lane	3,	eluted	fraction	during	IMAC.	(B)	Chromatogram	of	GB1-YpTIR	analysed	by	SEC	using	a	Superdex	200	10/300	GL	column.		
3.3.5	Expression	and	purification	of	GB1-tagged	BaTIR		 The	TIR	domain	from	BaTdp	was	successfully	produced	as	a	GB1-fusion	protein	using	an	almost	identical	protocol	to	the	one	used	to	express	and	purify	YpTIR.	The	only	minor	modification	in	the	protocol	involved	using	0.5	mM	IPTG	for	induction	of	protein	expression	instead	of	1	mM.	Small	scale	cultures	were	used	to	optimise	the	expression	conditions	and	these	parameters	resulted	in	slightly	better	expression	based	on	SDS-PAGE	analysis	(data	not	shown).	After	IMAC	purification	(Fig.	3.5),	the	purification	yield	was	approximately	3	mg/L	LB	culture.	Minor	contaminations	were	seen	during	SDS-PAGE	analysis,	but	as	this	protein	was	not	used	for	assays	requiring	a	high	purity	(e.g.	NMR),	this	was	not	a	major	concern.	
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Figure	3.5	Purification	of	GB1-tagged	BaTIR.	SDS-PAGE	of	samples	taken	from	various	stages	of	the	purification	process	of	GB1-BaTIR.	M,	molecular	weight	marker;	lane	1,	soluble	fraction	of	cell	lysate;	lane	2,	flow	through	during	IMAC;	lane	3,	eluted	fraction	during	IMAC.		
3.3.6	Expression	and	purification	of	GB1-tagged	SARM-TIR		 The	TIR	domain	from	SARM	was	also	successfully	produced	as	a	GB1-fusion	protein,	using	an	identical	protocol	as	that	used	for	expression	and	purification	of	GB1-BaTIR.	Purification	yield	was	approximately	2	mg/L	for	this	construct,	although	the	purity	was	noticeably	lower	than	other	GB1-tagged	proteins	following	IMAC	purification	(Fig.	3.6).			
	
Figure	3.6	Purification	of	GB1-tagged	SARM-TIR.	SDS-PAGE	of	samples	taken	from	various	stages	of	the	purification	process	of	GB1-SARM-TIR.	M,	molecular	weight	marker;	lane	1,	soluble	fraction	of	cell	lysate;	lane	2,	flow	through	during	IMAC;	lane	3,	eluted	fraction	during	IMAC.	
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3.3.7	Cleavage	of	GST-tag	from	GST-SARM-SAM-TIR		 To	verify	that	the	GST-tag	could	be	successfully	cleaved	and	isolated	from	GST-SARM-SAM-TIR	protein,	PreScission	protease	was	incubated	with	the	protein	at	a	1:50	(w/w)	ratio	and	the	mixture	was	incubated	at	4°C	overnight	under	gentle	agitation.	The	following	day	the	sample	was	loaded	on	a	HiLoad	26/60	Superdex	75	column	and	three	individual	protein	fractions	could	be	eluted.	Samples	from	the	three	fractions	were	analysed	by	SDS-PAGE	(Fig.	3.7).			
	
Figure	3.7	Purification	and	digestion	of	GST-tagged	SARM-SAM-TIR.	(A)	SDS-PAGE	analysis	of	cleavage	of	GST-tag	from	GST-SARM-SAM-TIR	using	PreScission	enzyme.	Substrate	was	incubated	with	the	enzyme	at	a	1:50	ratio	(w/w)	at	4°C	overnight.	(B)	Separation	of	cleaved	SARM-SAM-TIR	by	SEC,	resulting	in	three	separate	protein	peaks.	(C)	SDS-PAGE	analysis	of	eluted	fractions	from	SEC	separation	of	proteins	following	digestion	of	GST-SARM-SAM-TIR.	M,	molecular	weight	marker;	lanes	1,	2,	and	3	contains	samples	taken	from	the	three	different	peaks	obtained.			 Interestingly,	the	monomeric	molecular	weights	of	the	three	species	separated	are	34	kDa	for	SARM-SAM-TIR,	46	kDa	for	PreScission	protease,	and	26	kDa	for	GST,	so	the	observation	that	SARM-ST	was	the	first	protein	to	elute	from	the	column	indicates	that	the	protein	was	not	in	monomeric	form.	At	the	same	time,	the	retention	volume	at	which	the	protein	eluted	did	not	indicate	that	the	protein	had	aggregated.	It	is	known	that	SARM	forms	dimers	when	expressed	
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in	vivo	(Gerdts	et	al.,	2015),	so	it	is	possible	that	the	protein	was	in	dimeric	form	here.		
3.3.8	Generation	of	TRIF	expression	constructs		 As	full	length	TRIF	did	not	express	well	in	a	bacterial	expression	system,	despite	being	fused	with	a	GST-tag	which	usually	improves	expression,	truncated	versions	of	the	protein	were	designed.	Using	the	structure	prediction	software	Phyre2	(Kelley	and	Sternberg,	2009),	we	found	that	large	parts	of	TRIF	are	predicted	to	be	disordered,	in	particular	the	region	between	amino	acids	V122-Q392,	which	is	why	the	N-terminal	part	of	the	protein	was	not	included	in	any	of	the	constructs	generated.	The	TRIF	TIR	domain	is	predicted	to	cover	amino	acid	residues	S380-P530	(Watters	et	al.,	2007),	so	this	region	was	included	in	all	three	constructs.	A	summary	of	the	TRIF	expression	constructs	generated	is	shown	in	Figure	3.8.		
	
Figure	3.8	TRIF	proteins	sequences	cloned	into	expression	vectors.	Three	different	TRIF	sequences	were	subcloned	into	expression	constructs.	The	smallest	construct	covered	only	the	TRIF	TIR-domain	(residues	368-537).	Longer	constructs	covering	either	residues	368-633	or	368-700	were	also	generated.	Sequences	were	subcloned	into	a	pGEX-6p-1	vector.	
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3.3.9	Expression	and	purification	of	GST-tagged	MyD88-TIR,	
MAL,	TRIF-TIR,	and	TRAM		 Our	previous	experience	indicated	that	full	length	MyD88	and	TRIF	expressed	poorly	in	bacterial	systems,	so	truncated	versions	of	these	proteins	were	expressed.	Purification	of	MyD88-TIR	had	already	been	successfully	demonstrated	by	Rana	and	colleagues	(Rana	et	al.,	2011),	so	no	optimisation	of	the	expression	construct	was	required.	All	proteins	could	be	purified	using	a	single	GST	affinity	chromatography	step,	followed	by	buffer	exchange	(Fig.	3.9A-
D).	For	GST-TRAM,	a	slight	impurity	of	free	GST	was	detected,	which	was	removed	by	ion	exchange	chromatography	purification	step	(data	not	shown).	Yields	were	approximately	1	mg	purified	protein/L	LB	culture	for	all	four	adaptor	proteins,	sufficient	for	conducting	interaction	assays	with	SARM.	During	SDS-PAGE	analysis,	the	protein	band	for	GST-TRIF	showed	an	apparent	molecular	weight	of	approximately	10	kDa	lower	than	expected,	so	the	band	was	excised	and	analysed	by	mass	spectrometry	to	confirm	its	identity.		
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Figure	3.9	Purification	of	GST-tagged	MyD88-TIR,	MAL,	TRIF-TIR,	and	TRAM.	SDS-PAGE	analysis	of	samples	taken	during	the	purifications	of	GST-MyD88-TIR	(residues	163-296)	(A),	GST-TRIF-TIR	(residues	368-700)	(B)	GST-MAL	(C)	and	GST-TRAM	(D).	M,	molecular	weight	marker;	lane	1,	soluble	fraction	of	cell	lysate;	lane	2,	flow	through	during	affinity	chromatography;	lane	3,	eluted	fraction	after	affinity	chromatography.		
3.3.10	In-gel	digestion	and	MALDI	TOF/TOF	analysis	of	GST-
TRIF-TIR		 Following	trypsin	digestion	of	the	excised	GST-TRIF-TIR	protein	band	from	the	SDS-PAGE	gel,	analysis	of	the	resulting	peptide	mixture	by	mass	spectrometry	(Fig.	3.10)	indicated	the	presence	of	two	proteins,	GST	and	TRIF,	thus	confirming	that	the	protein	had	been	expressed	as	expected.	The	overall	sequence	coverage	of	TRIF-TIR	was	70%	with	both	the	N-	and	C-terminals	covered,	confirming	that	the	protein	had	not	been	subjected	to	degradation.	Proteins	running	slightly	faster	or	slower	than	expected	during	SDS-PAGE	are	not	uncommon,	and	possible	reasons	for	this	phenomenon	may	include	non-
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uniform	binding	of	SDS	during	sample	preparation	or	post-translational	modifications	(for	non-bacterial	expression	systems),	but	this	analysis	conclusively	confirms	the	protein	identity.		
	
Figure	3.10	MS	analysis	of	GST-TRIF-TIR	gel	band.	Peptide	mass	map	obtained	by	MALDI	TOF/TOF	analysis	of	peptide	mix	resulting	from	in-gel	trypsin	digestion	of	protein	band	suspected	to	contain	GST-TRIF-TIR.	Ion	signals	marked	with	a	star	were	matched	to	either	GST	(red)	or	TRIF	(blue).		
3.3.11	Expression	and	purification	of	GB1-tagged	MyD88-TIR		 As	MyD88-TIR	protein	would	later	be	used	for	applications	where	the	GST-tag	would	be	inappropriate,	a	protein	construct	with	the	smaller	GB1-tag	was	also	purified.	Following	IMAC	purification,	the	purity	was	still	slightly	lower	than	required	for	high	performance	assays	such	as	NMR	and	SPR.	Thus,	the	protein	was	submitted	to	an	additional	SEC	step	(Fig.	3.11A).	This	resulted	in	the	isolation	of	a	single	protein	species.	The	final	product	was	also	tested	by	analytical	SEC	to	ensure	that	the	protein	was	monodispersed	(Fig.	3.11B).	The	final	purification	yield	was	approximately	2	mg/L	LB	culture.		
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Figure	3.11	Purification	of	GB1-MyD88-TIR.	(A)	SDS-PAGE	of	samples	taken	from	various	stages	of	the	purification	process	of	GB1-MyD88-TIR.	M,	molecular	weight	marker;	lane	1,	soluble	fraction	of	cell	lysate;	lane	2,	flow	through	during	IMAC;	lane	3,	eluted	fraction	during	IMAC;	lane	4,	pooled	fractions	after	SEC.	(B)	Chromatogram	of	GB1-MyD88-TIR	analysed	by	SEC	using	a	Superdex	200	10/300	GL	column.		
3.3.12	Expression	and	purification	of	free	GST		 Free	GST	was	readily	expressed	in	BL21	(DE3)	E.	coli	and	purified	by	GST	affinity	chromatography	followed	by	a	buffer	exchange	to	remove	the	free	reduced	glutathione	used	to	elute	the	protein.	This	protein	was	later	used	as	a	negative	control	during	interaction	assays	with	GST-tagged	fusion	proteins.	The	purity	of	the	end	product	was	assessed	by	SDS-PAGE	(Fig.	3.12),	and	the	yield	was	approximately	10	mg	purified	protein/L	LB	culture.				
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Figure	3.12	Purification	of	GST.	SDS-PAGE	analysis	of	samples	taken	during	purification	of	GST.	M,	molecular	weight	marker;	lane	1,	soluble	fraction	of	cell	lysate;	lane	2,	flow	through	during	affinity	chromatography;	lane	3,	eluted	fraction	during	affinity	chromatography.		
3.3.13	Expression	and	purification	of	SARM	BB-loop		 The	predicted	SARM	BB-loop	sequence	(V591-K606)	was	expressed	as	both	a	GST-	and	GB1-fusion	protein.	Difficulties	in	cleaving	the	GB1-tag	(data	not	shown)	made	us	focus	mainly	on	the	GST	fusion	construct.	GST-SARM-BB	was	purified	by	GST	affinity	chromatography	(Fig.	3.13A)	with	a	purification	yield	of	approximately	20	mg/L	LB	culture.	Following	buffer	exchange	to	remove	reduced	glutathione,	cleavage	of	the	GST	tag	could	be	performed	by	adding	PreScission	protease	and	incubating	the	mixture	at	4°C	overnight.	Cleavage	trials	at	various	ratios	of	protease	to	substrate	(Fig.	3.13B)	showed	that	the	fusion	protein	could	be	fully	digested	at	a	1:1000	(w/w)	ratio,	indicating	that	the	cleavage	site	was	fully	exposed.		
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Figure	3.13	Purification	and	digestion	of	GST-tagged	SARM	BB-loop.	(A)	SDS-PAGE	analysis	of	samples	taken	during	the	purification	of	GST-SARM-BB-loop.	M,	molecular	weight	marker;	lane	1,	soluble	fraction	of	cell	lysate;	lane	2,	flow	through	during	affinity	chromatography;	lane	3,	eluted	fraction	after	affinity	chromatography.	(B)	SDS-PAGE	analysis	of	samples	taken	during	the	cleavage	of	GST-SARM-BB-loop	with	PreScission	protese.	Protease	to	substrate	ratios	(w/w)	are	indicated	above.	M,	molecular	weight	marker.			 To	isolate	the	released	BB-loop	peptide	from	the	GST	fusion	protein,	a	natural	solution	would	be	to	re-apply	the	mixture	to	a	Glutathione	Sepharose	column	and	collect	the	flow	through,	but	we	found	that	it	was	actually	easier	to	simply	filter	the	solution	through	a	10	kDa	MWCO	filter.	Both	the	GST-tag	and	added	protease	were	unable	to	penetrate	the	filter,	while	the	BB-loop	peptide	went	through	with	ease.	The	small	size	of	the	peptide	also	meant	that	concentrating	it	by	ultrafiltration	would	be	difficult,	so	instead	we	precipitated	the	peptide	by	diluting	the	sample	into	ice	cold	acetone	at	a	1:5	ratio	(vol/vol)	and	incubating	the	mixture	overnight	at	-20°C.	The	following	day,	the	peptide	had	precipitated	fully	and	could	be	collected	by	centrifugation	and	reconstituted	in	buffer	containing	20	mM	Tris-HCl,	150	mM	NaCl,	pH	7.5.	The	purification	process	was	monitored	by	SDS-PAGE,	as	shown	in	Figure	3.14.	A	G601A	mutant	
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version	of	the	peptide	was	also	generated	using	an	identical	protocol	for	purification	(data	not	shown).	
	
Figure	3.14	Isolation	of	SARM	BB-loop	peptide	from	cleaved	GST-tag.	SDS-PAGE	of	samples	taken	from	purification	of	untagged	SARM	BB-loop	peptide.	M,	molecular	weight	marker;	lane	1,	purified	GST-SARM-BB;	lane	2,	cleaved	GST-SARM-BB;	lane	3,	isolated	SARM-BB;	lane	4,	reconstituted	SARM-BB	following	overnight	precipitation.		
3.3.14	Summary	of	purifications	of	TIR	domain	proteins		 In	total,	7	different	TIR-domains	were	successful	expressed	and	purified	using	three	different	vector	systems	and	various	truncations.	A	summary	of	the	methods	used	and	approximate	yields	obtained	are	listed	in	Table	3.4.		
Table	3.4	Summary	of	TIR-domain	protein	purifications.	
Protein	 Culture	media	 Purification	steps	 Yield	(mg/L)	
His-SARM-TIR	 TB	 IMAC,	IEXC	 0.2	
His-SARM-ST	 TB	 IMAC,	IEXC	 0.2	
GST-SARM-TIR	 TB	 Affinity	 2	
GST-SARM-ST	 TB	 Affinity	 2	
GB1-SARM-TIR	 LB	 IMAC	 2	
GB1-MyD88-TIR	 LB	 IMAC,	SEC	 2	
GST-MyD88-TIR	 LB	 Affinity	 1	
GST-TRIF-TIR	 LB	 Affinity	 1	
GST-MAL	 LB	 Affinity	 1	
GST-TRAM	 LB	 Affinity,	IEXC	 1	
GB1-YpTIR	 LB	 IMAC	 5	
GB1-BaTIR	 LB	 IMAC	 3		
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3.4	Discussion	In	this	chapter,	the	expression	and	purification	processes	used	for	all	the	recombinant	proteins	used	in	this	study	are	described.	Although	our	initial	efforts	were	targeted	towards	purifying	full	length	SARM,	it	was	not	at	all	surprising	that	this	could	not	be	done	successfully.	In	the	past,	members	of	our	lab	have	attempted	to	express	and	purify	multiple	full	length	TIR	domain	proteins,	and	for	the	most	part	this	has	proven	to	be	extremely	challenging.	Smaller	TIR	proteins	such	as	MAL	and	TRAM,	where	the	TIR	domain	makes	up	the	majority	of	the	protein,	appear	fairly	stable	and	easy	to	isolate.	The	larger	proteins	on	the	other	hand	have	been	difficult	to	work	with.	Judging	by	the	available	literature,	other	labs	are	experiencing	the	same	issues,	as	all	TIR	domain	proteins	that	have	been	crystallised	so	far	contain	only	the	TIR	domain	(See	section	1.2.8	for	a	list	of	examples).	Functional	studies	are	ideally	performed	with	proteins	that	are	either	untagged,	or	feature	a	minimal	tag	such	as	hexahistidine	as	larger	tags	may	interfere	with	downstream	assays	(Bornhorst	and	Falke,	2000,	Crowe	et	al.,	1994).	Tao	and	Tong	have	previously	given	a	detailed	example	of	the	protocols	they	used	to	purify	and	crystallise	the	TIR	domains	from	TLR1	and	TLR2	(Tao	and	Tong,	2009),	and	their	work	was	used	as	inspiration	for	parts	of	the	work	presented	here.	Although	the	expression	yield	of	His-tagged	SARM-TIR	was	relatively	low,	purification	with	IMAC	and	IEXC	was	successful	and	this	resulted	in	a	pure	protein	in	sufficient	quantity	for	conducting	pull	down	interaction	assays,	which	will	be	discussed	in	chapter	4.		The	addition	of	fusion	partners	such	as	GST	and	GB1	greatly	improved	both	the	expression	yield	and	stability	of	proteins	purified.	While	large	affinity	
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tags	are	sometimes	viewed	upon	with	scepticism	due	to	fear	that	they	will	cause	interference	during	downstream	functional	assays	(Terpe,	2003),	there	is	no	denying	that	they	can	improve	the	efficiency	of	protein	expression	and	purification	dramatically.	Although	neither	the	GST-	nor	GB1-tagged	versions	of	SARM-TIR	were	used	to	a	great	extent	in	experiments	described	in	the	following	chapters,	the	work	presented	here	can	be	viewed	as	an	example	of	how	the	addition	of	a	tag	can	improve	purification	yield	when	working	with	a	challenging	protein.	The	GB1-tagged	proteins	in	particular	appeared	stable	and	were	associated	with	high	expression	yields,	and	the	TIR-domains	of	SARM,	MyD88,	YpTdp,	and	BaTdp	could	all	be	purified	easily	as	GB1-fusion	proteins.	As	this	tag	is	noticeably	smaller	than	other	tags	typically	used	for	improving	protein	expression	and	stability,	such	as	GST,	Maltose-binding	protein	(MBP),	or	thioredoxin	(Trx),	the	GB1-tag	can	be	expected	to	interfere	less	with	functional	assays.	Huth	and	colleagues	developed	this	tag	with	the	explicit	purpose	of	having	a	minimally	sized	tag	that	provides	a	high	level	of	overall	protein	stability	to	be	used	for	NMR	analysis	(Huth	et	al.,	1997).	It	has	also	been	used	successfully	previously	for	purification	of		TIR-domain	proteins	(Rana	et	al.,	2011)	and	the	results	presented	here	further	support	its	suitability	for	purification	of	recombinantly	expressed	TIR	domains.	Throughout	the	study,	noticeable	contaminations	were	sometimes	seen	in	the	purified	protein	samples,	e.g.	together	with	GB1-BaTIR	and	GB1-SARM-TIR.	This	was	especially	apparent	when	purification	was	done	using	only	a	single	purification	step,	as	contaminants	may	have	bound	to	the	column	together	with	the	target	protein.	It	is	possible	that	the	protein	purity	in	these	cases	could	have	
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been	improved	with	the	introduction	of	additional	chromatographic	separation	steps,	or	a	fundamentally	different	purification	methodology	such	as	with	the	filtration	and	precipitation	of	SARM	BB-loop	peptide	described	in	section	3.3.13.	However,	the	downstream	applications	of	the	proteins,	which	will	be	discussed	in	chapter	4,	mainly	determined	the	level	of	purity	that	was	considered	acceptable.	Small	contaminations	were	not	a	concern	for	proteins	used	for	pull	downs	only	as	this	assay	is	not	dependent	on	protein	purity,	and	is	even	routinely	performed	with	crude	cell	lysates.		In	this	thesis	work,	only	soluble	expression	of	proteins	was	pursued,	even	though	many	of	the	proteins	purified	could	be	expressed	with	high	yield	as	insoluble	inclusion	bodies.	This	was	a	deliberate	choice,	as	we	did	not	want	to	attempt	to	perform	protein	refolding.	The	main	problem	with	refolding	inclusion	bodies	when	studying	a	novel	protein	is	that	no	assay	for	determining	protein	activity	is	available,	as	the	function	of	the	protein	is	unknown.	Although	functional	protein	is	always	soluble,	soluble	protein	is	not	necessarily	functional.	However,	as	the	function	of	SARM	and	other	TIR-proteins	become	better	known,	recombinant	expression	as	inclusion	bodies	may	comprise	a	perfectly	viable	strategy	for	generation	of	large	quantities	of	protein.	The	aim	of	the	work	presented	in	this	chapter	was	to	generate	protocols	for	robust	generation	of	TIR	domain	proteins,	which	was	accomplished.	The	following	chapter	will	describe	the	functional	assays	that	the	proteins	were	used	for.		 	
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Chapter	4		
Interaction	studies	of	TIR-domain	proteins	
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4.1	Introduction	The	previous	chapter	described	how	different	TIR-domain	proteins	were	recombinantly	cloned,	expressed	and	purified.	In	this	chapter,	multiple	methods	were	used	to	characterise	interactions	between	these	proteins.	It	has	been	shown	that	human	SARM	interacts	with	TRIF	(Carty	et	al.,	2006),	and	the	interaction	appeared	stronger	in	PAMP-stimulated	cells,	suggesting	that	SARM’s	ability	to	downregulate	TRIF-dependent	signalling	is	mediated	by	a	direct	interaction	between	the	proteins.	A	study	by	Ulrichts	and	colleagues	also	indicated	possible	interactions	between	the	TIR	domains	of	SARM	and	both	MyD88	and	TRAM	(Ulrichts	et	al.,	2007),	and	Peng	and	colleagues	later	showed	that	SARM	is	able	to	inhibit	MyD88-mediated	AP-1	activation	(Peng	et	al.,	2010).	However,	no	previous	study	has	shown	a	definitive	analysis	of	the	precise	heterotypic	TIR-TIR	interaction	profile	of	SARM	or	identified	which	amino	acids	in	SARM	might	be	important	for	TIR-TIR	complex	formation.	The	TIR	domain	of	YpTdp	is	known	to	interact	with	the	human	MyD88	TIR	domain	(Rana	et	al.,	2011),	and	a	proline	residue	in	the	predicted	BB-loop	of	YpTIR	(P173)	was	shown	to	be	critical	for	binding	capability.	As	YpTdp	expression	in	human	cells	was	also	associated	with	a	mild	inhibition	of	TLR4-mediated	immune	activation	(Spear	et	al.,	2012),	it	is	possible	that	YpTdp	functions	via	competitive	binding	to	MyD88.	However,	it	is	not	known	whether	the	protein	is	also	able	to	interact	with	other	human	TLR	adaptor	proteins.	As	BaTdp	is	a	protein	that	has	not	previously	been	characterised,	it	is	not	known	whether	it	is	able	to	interact	with	human	TIR	domain	proteins.	The	overall	aim	of	the	experiments	presented	in	this	chapter	was	to	further	elucidate	if	and	how	SARM	interacts	with	other	human	TLR	adaptor	
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proteins,	using	a	wide	range	of	qualitative	techniques	for	monitoring	protein-protein	interactions.	We	also	wanted	to	investigate	whether	BaTdp	is	able	to	interact	with	human	TIR-proteins	or	not,	as	this	might	be	an	indication	of	BaTdp	targeting	TLR	signalling	pathways.			
4.1.1	Methods	for	investigating	protein-protein	interactions	Many	different	assays	for	investigating	protein-protein	interactions	have	been	developed,	each	with	its	own	set	of	advantages	and	drawbacks.	In	this	study,	four	different	experimental	techniques	were	used	to	probe	interactions	between	TIR	domain	proteins:	GST	pull	down	assay,	NMR,	surface	plasmon	resonance	(SPR),	and	hydrogen/deuterium	exchange	mass	spectrometry	(HDXMS).	Brief	explanations	of	how	these	techniques	are	used	to	investigate	protein-protein	interactions	are	given	below.		
4.1.2	Pull	down	assay	A	pull	down	assay	is	used	to	detect	a	direct	interaction	between	one	protein	immobilised	on	affinity	resin	and	other	potential	partners	which	are	in	solution.	By	washing	the	resin	multiple	times	in	buffer,	non-interacting	proteins	are	removed	and	the	ones	remaining	bound	to	the	protein	complex	on	the	resin	can	be	assumed	to	have	interacted	with	the	immobilised	protein.	Western	blot	analysis	is	usually	used	for	protein	detection.	A	specific	type	of	pull	down	assay	is	the	GST	fusion	pull	down,	first	described	by	Kaelin	and	colleagues	(Kaelin	et	al.,	1991),	which	exploits	the	highly	specific	interaction	between	GST	and	glutathione.	In	GST	fusion	pull	down,	a	
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GST-tagged	fusion	protein	(the	bait)	is	immobilised	on	glutathione	Sepharose	beads,	after	which	a	protein	(or	a	mixture	of	proteins)	in	solution	(the	prey)	is	mixed	with	the	beads.	Stringent	washing	of	the	resin	then	removes	all	non-interacting	proteins.	Any	protein	remaining	on	the	beads	can	be	eluted	either	with	an	elution	buffer	containing	a	high	concentration	of	reduced	glutathione,	or	simply	by	mixing	the	beads	in	SDS-PAGE	loading	buffer	and	boiling	the	sample,	thus	denaturing	all	proteins	and	releasing	them	from	the	resin.	Western	blot	analysis	with	antibodies	specific	to	the	prey	protein	can	then	be	used	to	evaluate	whether	an	interaction	was	observed	or	not.	A	schematic	figure	of	the	process	is	shown	in	Figure	4.1.		
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Figure	4.1	Schematic	overview	of	the	GST	pull	down	assay.	A	GST	fusion	protein	is	captured	on	glutathione	resin	and	incubated	together	with	a	prey	protein,	or	mixture	of	proteins.	Non-interacting	proteins	are	removed	by	collecting	and	washing	the	resin	multiple	times	in	wash	buffer,	followed	by	eluting	and	denaturing	all	bound	proteins	by	mixing	the	resin	in	SDS-PAGE	sample	buffer	and	boiling	the	sample	at	95°C.	The	protein	content	of	the	sample	is	then	analysed	by	Western	blot.	As	a	negative	control,	unconjugated	GST	is	captured	on	the	resin	instead	of	the	GST	fusion	protein,	followed	by	the	same	procedure.		 Kaelin	and	colleagues	(1991)	originally	described	the	method	as	a	technique	for	discovering	novel	interacting	proteins	using	a	cell	lysate	as	prey.	Others	have	later	developed	the	method	to	be	used	for	confirming	suspected	interactions	by	using	recombinantly	expressed	and	purified	proteins	as	prey	(Grgurevich	et	al.,	1999,	Hunter	et	al.,	1999,	Posern	et	al.,	1998).	
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It	is	imperative	to	always	include	a	negative	control	sample	in	the	assay	consisting	of	immobilised	GST	protein	as	bait	with	the	same	prey	protein	as	the	one	used	for	the	main	analysis.	If	an	interaction	is	detected	with	this	setup,	it	indicates	that	the	prey	protein	is	interacting	with	either	the	GST-tag	or	the	glutathione	resin,	and	not	necessarily	with	the	bait	protein.	The	main	benefit	of	this	assay	is	that	it	is	simple	to	perform	and	does	not	require	access	to	any	advanced	equipment.	Results	are	quickly	obtained	and	are	simple	to	interpret.	Multiple	samples	can	also	be	processed	in	parallel	and	analysed	on	a	single	membrane	during	Western	blotting.	On	the	downside,	data	obtained	with	pull	down	assays	are	not	quantitative	and	no	internal	control	of	protein	quality	exists.	Therefore,	it	is	not	possible	to	determine	if	a	negative	result	is	due	to	lack	of	interaction	or	misfolded	protein.	It	is	not	required	to	use	a	setup	based	on	GST-tagged	proteins.	Other	protein	tags	and	corresponding	affinity	resins	have	also	been	used	with	similar	methodology,	e.g.	His-tagged	proteins	(Chen	and	Hai,	1994,	Janknecht	et	al.,	1991)	and	proteins	tagged	with	MBP	(Bedouelle	and	Duplay,	1988,	di	Guan	et	al.,	1988,	Maina	et	al.,	1988).	However,	the	highly	specific	nature	of	the	GST-glutathione	interaction	makes	this	an	excellent	choice,	and	it	was	the	only	one	used	in	this	study.	The	important	parameters	to	consider	when	designing	a	pull	down	assay	include	the	reaction	buffer,	the	wash	buffer,	and	the	amounts	of	bait	and	prey	proteins	to	use.	There	are	no	ideal	conditions	to	use,	instead	optimisation	needs	to	be	done	for	each	protein	complex	analysed.	If	a	biological	reaction	is	assayed,	it	is	reasonable	to	assume	that	the	reaction	buffer	should	somewhat	mimic	physiological	conditions	with	regard	to	pH	and	salinity.	For	the	wash	buffer,	
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detergents	such	as	NP-40	can	also	be	included	for	a	more	stringent	wash,	thus	minimising	non-specific	interactions.		
4.1.3	Nuclear	magnetic	resonance	(NMR)	NMR	spectroscopy	is	a	technique	widely	used	for	obtaining	structural	information	of	proteins,	with	the	first	NMR	spectrum	of	a	protein,	ribonuclease,	being	reported	by	Saunders	and	colleagues	more	than	50	years	ago	(Saunders	et	al.,	1957).	As	of	May	2015,	more	than	9000	protein	structures	solved	by	NMR	have	been	deposited	in	the	protein	data	bank	(PDB),	making	it	the	second	most	common	technique	for	structure	determination	after	X-ray	crystallography.	The	main	benefit	is	that	NMR	spectra	are	recorded	from	proteins	in	solution.	This	allows	analysis	of	protein	structure	and	dynamics,	and	circumvents	the	issue	of	obtaining	well	diffracting	crystals	required	for	X-ray	crystallography.	The	NMR	technique	is	also	routinely	used	for	mapping	protein-protein	interactions	in	solution,	which	was	the	application	used	in	this	study.	Although	the	detailed	physical	principles	behind	NMR	are	outside	the	scope	of	this	thesis,	a	simplified	explanation	of	what	is	measured	and	how	to	interpret	the	data	is	given	below.			
4.1.4	Brief	overview	of	the	NMR	phenomenon	Most	atoms	in	a	protein	or	peptide	have	a	nuclear	spin,	which	induces	a	magnetic	dipole	moment	(Keeler,	2010).	When	introduced	to	an	external	magnetic	field	aligned	along	the	z-axis,	interactions	can	be	observed	as	the	dipoles	from	nuclei	spins	will	be	oriented	differently	around	the	static	external	field.	Transitions	between	energy	states	will	occur,	and	by	applying	
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electromagnetic	radiation	at	frequencies	that	exactly	match	the	difference	in	two	energy	states,	resonance	is	generated.	These	frequencies	are	referred	to	as	chemical	shifts	and	are	measured	in	parts	per	million	(ppm),	and	a	plot	of	signal	intensity	against	frequency	is	the	basis	for	a	1D	NMR	spectrum.	However,	different	nuclei	will	resonate	at	different	frequencies,	so	a	2D	spectrum	can	also	be	generated	to	display	the	intensities	of	two	types	of	nuclei	(e.g.	1H	and	15N).		
4.1.5	Characterising	protein-protein	interactions	by	NMR	When	the	interface	of	a	specific	protein	is	monitored	by	a	2D	NMR	spectrum,	changes	in	the	protein	interface,	e.g.	because	of	binding	to	a	second	protein,	will	result	in	detectable	changes	in	the	spectrum.	By	utilising	different	isotopic	labelling	patterns	(e.g.	1H,	14N	for	one	protein	and	1H,	15N	for	the	other),	spectrum	peaks	can	be	isolated	from	a	single	protein	in	a	mixture	of	two.	A	typical	experiment	based	on	chemical	shift	perturbation	mapping	involves	generating	a	protein	labelled	with	15N	by	expressing	it	in	E.	coli	bacteria	grown	in	minimal	medium	containing	only	this	nitrogen	isotope.	After	purification,	the	protein	is	subjected	to	NMR	spectroscopy	and	a	15N-1H	heteronuclear	single-quantum	correlation	(HSQC)	2D	spectrum	is	recorded.	Subsequent	spectra	are	then	recorded	after	an	unlabelled	interacting	protein	is	titrated	into	the	sample	mixture,	and	the	interaction	can	be	characterised	by	mapping	chemical	shift	changes	(Zuiderweg,	2002).	As	every	amino	acid	residue	except	proline	contains	a	backbone	NH-group,	each	peak	in	the	2D	HSQC	should	correspond	to	one	amino	acid	residue	in	the	protein	sequence.	By	monitoring	the	moving	peaks	following	titration	of	ligand,	it	is	possible	to	identify	the	binding	site(s)	on	the	labelled	protein.	
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Binding	affinity	can	also	be	deduced	from	correlating	the	distance	of	peak	movement	to	the	ligand	concentration.			In	general,	NMR	is	a	powerful	technique	for	studying	protein-protein	interactions	with	high	sensitivity,	although	there	are	some	limitations	associated	with	its	use.	The	quality	of	spectra	obtained	will	depend	on	the	tumbling	speed	of	the	target	molecule,	and	as	tumbling	speed	is	dependent	on	molecular	size,	it	is	difficult	to	use	NMR	to	study	large	(>50	kDa)	molecules.	Tumbling	speed	is	also	affected	by	temperature,	but	many	proteins	display	low	stability	at	above	room	temperature.	The	sample	also	needs	to	be	homogenous	and	of	relatively	high	purity,	which	is	not	the	case	in	some	of	the	other	techniques	used	in	this	study.		
4.1.6	Surface	plasmon	resonance	(SPR)	The	underlying	physical	principles	behind	SPR	are	complex,	but	a	basic	understanding	of	the	phenomenon	is	sufficient	to	appreciate	how	it	can	be	used	to	monitor	protein-protein	interactions.	Surface	plasmons	(SPs)	are	electromagnetic	waves	propagated	along	the	surface	of	a	conducting	element,	such	as	a	metal	surface,	as	they	interact	with	the	free	electrons	of	the	conductor	(Barnes	et	al.,	2003,	Homola	et	al.,	1999).	The	speed	at	which	the	waves	travel	will	depend	on	the	refractive	index	of	the	medium	adjacent	to	the	surface.	By	coupling	a	light	wave	to	the	SPs,	resonance	can	be	observed	when	the	frequency	of	the	free	oscillating	SPs	on	the	surface	matches	that	of	the	applied	light.	Any	changes	in	the	refractive	index	of	the	adjacent	surface	can	then	be	monitored,	as	they	cause	a	change	in	the	angle	of	incidence	at	which	resonance	is	observed.		
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	 In	the	1980s	Liedberg	and	colleagues	showed	how	this	technique	could	be	used	to	monitor	the	interaction	between	an	antibody	and	antigen.	By	immobilising	human	IgG	on	a	thin	silver	film,	they	were	able	to	observe	the	interaction	with	anti-human-IgG	in	real	time	by	injecting	it	into	the	flow	cell	(Liedberg	et	al.,	1983).	Injection	of	anti-rabbit-IgG	also	resulted	in	a	change	of	resonance	angle,	but	not	as	high	as	with	the	anti-human-IgG.	This	demonstrates	that	the	technique	is	quantitative	in	nature,	as	this	sample	is	expected	to	bind	weakly	to	the	human	IgG.	Many	platforms	for	conducting	SPR	experiments	exist,	and	the	one	used	in	this	study	was	the	Biacore	AB	system	(GE	Healthcare).		 Biacore	technology	uses	gold	plated	chips	with	a	dextran	matrix	surface	where	ligands	can	be	immobilised	using	multiple	different	chemical	coupling	techniques.	In	this	study	we	have	used	CM5	chips,	which	allow	for	ligand	immobilisation	via	amine	coupling	to	the	matrix.	A	typical	experiment	involves	the	immobilisation	of	a	protein	or	peptide	(the	ligand)	to	the	chip	surface,	either	directly	or	indirectly	via	a	coupling	molecule	such	as	an	antibody,	followed	by	injections	of	another	protein	or	peptide	(the	analyte)	at	different	concentrations	over	the	surface	(Piliarik	et	al.,	2009).	Any	changes	in	refractive	index	are	recorded	in	real	time	and	plotted	as	a	sensorgram.	Analysis	of	kinetic	data	can	then	be	performed	by	fitting	the	response	curves	in	the	sensorgram	against	theoretical	models.	Background	changes	in	refractive	index,	for	example	due	to	changes	in	buffer	composition,	are	corrected	for	by	subtracting	the	response	recorded	from	a	reference	cell	located	immediately	upstream	from	the	sample	cell	on	the	chip	(Myszka,	1999).	A	schematic	figure	of	the	setup	used	for	studying	protein-protein	interactions	using	SPR	is	shown	in	Figure	4.2.		
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Figure	4.2	Schematic	overview	of	the	configuration	of	a	SPR	sensor.	A	ligand	is	immobilised	on	the	surface	of	a	metal	film.	A	light	source	located	on	the	opposite	side	of	the	film	enables	light	waves	to	couple	with	SPs	propagating	along	the	metal	surface,	and	the	angle	at	which	resonance	is	observed	is	measured	by	a	detector.	When	the	ligand	interacts	with	an	analyte	protein	or	peptide,	the	refractive	index	changes	and	the	speed	at	which	SPs	move	is	slowed	down,	causing	a	change	in	the	resonance	angle.	This	change	is	monitored	by	the	detector	and	plotted	in	the	form	of	a	sensorgram,	the	shape	of	which	is	used	to	characterise	the	protein-protein	interaction.			 The	main	advantage	of	using	SPR	for	characterising	protein-protein	interactions	is	that	it	allows	analysis	of	unlabelled	proteins,	while	still	providing	quantitative	binding	data	with	high	sensitivity.	On	the	downside,	the	equipment	is	expensive	and	samples	cannot	be	analysed	in	parallel,	although	sample	runs	can	be	automated.	As	binding	is	based	on	a	molar	ratio	between	the	ligand	and	analyte,	while	the	changes	in	refractive	index	is	based	on	changes	in	mass	on	the	chip	surface,	it	can	also	be	difficult	to	study	analytes	with	a	small	molecular	weight.		 			
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4.1.7	Hydrogen/deuterium	exchange	mass	spectrometry	
(HDXMS)	HDXMS	is	a	powerful	technique	that	can	be	used	to	map	interactions	and	conformational	changes	of	proteins	and	peptides	(Clarke	and	Itzhaki,	1998,	Englander	et	al.,	1996,	Hoofnagle	et	al.,	2003).	It	utilises	the	amide	groups	of	exposed	amino	acid	residues	that	constantly	exchange	hydrogen	atoms	with	a	water	based	solvent.	By	diluting	a	protein	into	a	D2O	based	buffer,	an	exchange	from	protons	to	deuterions	is	initiated	at	exposed	residues,	a	reaction	which	can	be	quenched	by	lowering	the	pH	of	the	solution	to	below	2.5,	where	the	chemical	exchange	is	minimal	(Connelly	et	al.,	1993).	As	deuterions	are	1	Da	heavier	than	protons,	the	extent	of	the	exchange	can	later	be	evaluated	by	mass	spectrometry.	The	hydrogen	exchange	will	be	significantly	slower	if	a	proton	is	removed	from	the	protein	surface	or	if	a	more	stable	hydrogen	bond	is	formed	(Resing	et	al.,	1999),	e.g.	if	the	protein	is	interacting	with	another	protein	at	a	specific	site.	It	is	this	feature	which	allows	characterisation	of	a	protein-protein	interaction	interface.	A	general	overview	of	the	workflow	of	a	practical	experiment	is	shown	in	Figure	4.3.		
	
Figure	4.3	Schematic	overview	of	the	characterisation	of	a	protein-protein	
interaction	by	HDXMS.	Proteins	are	diluted	into	a	D2O	based	buffer	and	incubated	for	different	lengths	of	time,	followed	by	quenching	the	reaction	by	lowering	the	pH	to	2.5	and	the	temperature	near	0°C.	The	proteins	are	immediately	digested	by	pepsin	and	the	resulting	peptide	fragments	separated	by	HPLC	and	analysed	by	MS.	
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Before	MS	analysis,	the	deuterated	protein	is	digested	by	a	protease	and	the	resulting	peptide	fragments	are	separated	on	a	reverse	phase	HPLC	column.	As	pepsin	displays	maximum	proteolytic	activity	at	pH	2.0	(Johnston	et	al.,	2007),	it	is	a	good	choice	for	this	application,	although	other	non-specific	proteases	could	theoretically	be	used.	To	minimise	the	amount	of	back	exchange,	the	temperature	is	kept	as	close	to	0°C	as	possible	and	the	analysis	is	performed	immediately	after	quenching	(Thevenon-Emeric	et	al.,	1992,	Zhang	and	Smith,	1993).	For	a	typical	experiment,	the	analysed	protein	is	diluted	into	D2O	buffer	with	or	without	the	potential	ligand	and	the	exchange	reactions	are	quenched	at	different	time	points,	followed	by	pepsin	digestion	and	MS	analysis.	A	slower	deuteration	rate	for	a	specific	peptide	when	mixed	with	the	ligand	would	indicate	that	this	part	of	the	protein	binds	to	the	ligand.	Results	can	be	visualised	by	plotting	the	average	number	of	deuterions	exchanged	against	time	for	the	different	peptide	fragments,	and	if	a	protein	structure	is	available,	a	heat	map	can	also	be	generated	showing	the	interacting	parts	of	the	protein.	This	technique	provides	a	way	to	characterise	the	nature	of	an	interaction	with	high	precision,	exactly	mapping	the	interaction	interface	between	two	proteins.	Unlike	the	case	with	NMR,	the	size	of	the	protein	studied	is	not	a	limiting	factor	when	characterising	protein	interactions	by	HDXMS	(Smith,	1998,	Smith	et	al.,	1997).	However,	the	analysis	requires	access	to	expensive	equipment,	and	a	successful	experiment	will	depend	on	optimising	multiple	parameters,	including	reaction	pH,	time,	as	well	as	reaction	temperature	(Englander	and	Kallenbach,	1983).	It	is	also	not	possible	to	run	multiple	samples	in	parallel,	making	it	a	low	throughput	technique.	
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4.2	Materials	and	methods	
4.2.1	GST	pull	down	interaction	assay		 100	μg	of	purified	GST-tagged	bait	protein	was	incubated	with	50	μL	Glutathione	Sepharose	High	Performance	resin	(GE	Healthcare),	equilibrated	with	binding	buffer	[20	mM	Tris-HCl,	150	mM	NaCl,	5	mM	DTT,	1	mM	EDTA,	0.1%	Tergitol®	Type	NP-40,	pH	7.5].	The	total	volume	was	normalised	to	300	μL	for	each	sample.	After	being	batch	bound	at	4°C	for	one	hour,	the	sample	was	centrifuged	at	1,000	x	g	for	30	seconds	and	the	supernatant	was	discarded.	The	resin	was	washed	three	times	in	20	CVs	binding	buffer	and	suspended	in	300	μL,	after	which	200	μg	His-tagged	prey	protein	was	added	to	the	reaction	mixture,	which	was	incubated	at	4°C	for	two	hours.	Unbound	proteins	were	removed	by	washing	the	resin	four	times	in	20	CVs	binding	buffer,	after	which	the	beads	were	mixed	with	an	equal	volume	of	2X	SDS-page	sample	buffer,	and	analysed	by	SDS-PAGE	and	subsequent	Western	blot	using	an	anti-polyhistidine	primary	antibody	(Sigma).		
4.2.2	Expression	and	purification	of	15N-labelled	GB1-MyD88-
TIR	and	SARM-BB	peptide		 For	2D	NMR	analyses,	GB1-MyD88-TIR	or	SARM-BB	were	expressed	in	minimal	M9	media	supplemented	with	15N-labeled	NH4Cl	(Sigma)	and	purified	as	described	in	sections	3.2.12	and	3.2.13.	Proteins	were	concentrated	to	approx.	200	μM,	and	D2O	was	added	to	the	purified	proteins	to	a	10%	final	concentration	for	spectrometer	field	lock.			
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4.2.3	NMR		 Experiments	were	recorded	using	a	Bruker	Avance	III	600	spectrometer	(at	600	MHz)	at	280	or	303	K.	Spectra	of	15N-labelled	proteins	were	recorded,	followed	by	the	addition	of	increasing	amounts	of	unlabelled	interacting	protein	to	the	sample	mixture	and	any	changes	to	the	spectra	were	monitored	at	each	titration	point.	Up	to	4X	molar	equivalents	was	added.	Spectra	were	recorded	and	analysed	with	the	help	of	Dr.	Jan	Marchant	or	Dr.	Yingqi	Xu	at	the	Cross-faculty	NMR	centre,	Imperial	College	London.		
4.2.4	Surface	Plasmon	Resonance		 The	SPR	analysis	was	performed	on	a	Biacore	2000	system	(GE	Healthcare)	at	25°C	using	a	CM5	chip	with	proteins	immobilised	via	amine	coupling.	Suitable	immobilisation	buffers	were	determined	by	diluting	the	proteins	used	into	10	mM	sodium	acetate	buffers	with	varying	pH,	followed	by	injection	over	the	inactive	chip	surface	at	a	flow	rate	of	10	µL/min	and	monitoring	the	response.	The	ligand	proteins	were	diluted	to	a	concentration	of	30	µg/mL.	Protein	immobilisations	were	performed	by	first	activating	the	chip	surface	by	injecting	70	µL	EDC/NHS	mixture	[0.4	M	1-Ethyl-3-(3-dimethylaminopropyl)	carbodiimide	hydrochloride	(EDC)	mixed	1:1	with	0.1	M	N-Hydroxysuccinimide	(NHS)],	followed	by	70	µL	of	the	protein	to	be	immobilised	and	finally	70	µL	of	1	M	ethanolamine-HCl,	pH	8.5	to	block	the	remaining	active	sites	on	the	chip.	The	running	buffer	during	immobilisation	was	PBS.	Protein	interactions	were	then	determined	by	diluting	the	analytes	to	different	concentrations	and	injecting	them	over	the	chip	surface	at	a	flow	rate	of	
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30	µL/min.	The	resulting	sensorgrams	were	analysed	by	Biaevaluation	4.1.1	software	(GE	healthcare).	Regeneration	of	chip	surface	was	performed	by	injecting	small	amounts	of	10	mM	glycine,	pH	2.1,	10	mM	NaOH,	or	100	mM	NaOH	until	a	stable	baseline	was	achieved.		
4.2.5	Hydrogen/deuterium	exchange	mass	spectrometry		 Proteins	and	peptides	were	purified	as	described	in	sections	3.2.12	and	
3.2.13.	Deuterated	buffers	were	prepared	by	completely	drying	water-based	solutions	under	vacuum	using	a	CVE-100D	centrifugal	evaporator	(EYELA),	followed	by	reconstituting	the	dried	salts	in	D2O.	The	hydrogen/deuterium	exchange	reaction	was	initiated	by	diluting	1	µL	each	of	GB1-MyD88-TIR	and	SARM-BB,	both	at	a	concentration	of	approximately	1	mg/mL,	into	18	µL	of	deuterated	buffer.	The	reaction	was	quenched	at	indicated	time	points	(0,	0.5,	1,	2,	5	and	10	min)	by	adding	30	µL	ice-cold	0.08%	(v/v)	trifluoroacetic	acid	(TFA)	(Sigma)	in	order	to	lower	the	pH	to	2.5	and	kept	on	ice	to	minimise	deuterium	back	exchange,	until	further	analysis.	Proteins	were	then	digested	on	an	online	2.1	x	30	mm	immobilised	pepsin-column	(Porozyme,	ABI)	using	0.05%	formic	acid	in	water	as	running	buffer	at	100	µL/min.	Resulting	peptides	were	passed	through	a	2.1	x	5	mm	C18	guard	column	(Acquity	BEH	C18	VanGuard	Pre-column,	1.7	µm,	Waters),	followed	by	separation	by	ultra	performance	liquid	chromatography	(UPLC)	on	a	1.0	x	100	mm	C18	reverse	phase	column	(Acquity	UPLC	BEH	C18,	1.7	µm,	Waters)	using	a	8-40%	gradient	of	ACN	in	0.1%	formic	acid	at	40	µL/min.	Mass	spectrometric	analysis	was	performed	on	a	SYNAPT	G2-Si	High	Definition	Mass	Spectrometer	(Waters).	Peptides	from	undeuterated	samples	were	identified	using	ProteinLynx	Global	Server	software	(Waters),	and	
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deuterium	uptake	was	analysed	using	DynamX	software	(Waters).	Triplicate	samples	were	used	throughout	all	experiments.	Experiments	and	data	analysis	was	performed	under	supervision	of	Dr.	Jeremy	Wang	or	Ms	Madhubrata	Ghosh,	Chemical	Biology	and	Drug	Discovery	Lab,	Department	of	Biological	Sciences,	National	University	of	Singapore.		
4.3	Results	
4.3.1	YpTIR	interacts	with	multiple	human	TLR	adaptors		 Previous	studies	have	indicated	that	the	TIR	domain	of	YpTdp	suppresses	MyD88-dependent	TLR	signalling	(Spear	et	al.,	2012)	and	binds	directly	to	the	MyD88	TIR	domain	(Rana	et	al.,	2011).	However,	it	is	not	clear	whether	this	is	the	only	human	TLR	adaptor	protein	YpTdp	targets,	so	it	was	pertinent	for	us	to	investigate	whether	YpTIR	displayed	a	broader	binding	capabilities	to	human	TIR	domains.	GST	pull	down	analyses	showed	that	YpTIR	was	indeed	capable	of	binding	not	only	to	MyD88-TIR,	but	also	MAL,	TRIF-TIR,	and	possibly	TRAM,	indicating	that	YpTdp	may	act	on	multiple	TLR	signalling	pathways	(Fig.	4.4)	once	the	Y.	pestis	infects	a	host.	A	mutation	of	the	highly	conserved	proline	residue	in	position	173	of	YpTIR	to	alanine	resulted	in	the	loss	of	binding.	As	the	interaction	between	YpTIR	and	MyD88-TIR	is	known	and	previously	described	as	physiologically	relevant	(Rana	et	al.,	2011,	Spear	et	al.,	2012),	these	experiments	also	validate	the	methodology	used	for	experiments	presented	in	later	parts	of	this	chapter.		
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Figure	4.4	YpTIR	interacts	with	multiple	TLR	adaptor	TIR	domains.	Interactions	between	WT	(A)	or	P173H	mutant	(B)	His-tagged	YpTIR	and	GST-tagged	MyD88-TIR,	MAL,	TRIF-TIR,	and	TRAM	were	analysed	by	Western	blot.	Samples	were	probed	with	an	anti-His	primary	antibody.	Both	blots	shown	are	from	non-adjacent	parts	of	the	same	immunoblot.		
4.3.2	SARM-TIR	interacts	with	multiple	TLR	adaptors		 Based	on	previous	reports	(Carty	et	al.,	2006,	Ulrichts	et	al.,	2007),	we	were	expecting	the	TIR	domain	of	SARM	to	interact	with	the	TIR-domain	of	TRIF,	but	it	was	not	clear	whether	this	was	the	only	TLR	adaptor	protein	that	SARM	interacts	with.	GST	pull	down	analysis	was	performed	with	the	TIR	domains	from	all	other	four	human	TLR	adaptors,	and	interestingly,	a	positive	interaction	was	also	seen	with	MyD88-TIR	(Fig.	4.5).	Possible	weak	bands	in	the	lanes	corresponding	to	MAL	and	TRAM	were	sometimes	visible,	but	it	is	not	clear	if	these	were	the	results	of	TIR-TIR	interactions	or	not.	A	negative	control	consisting	of	free	GST	used	as	bait	was	included	in	the	assay,	confirming	that	SARM	was	not	interacting	with	the	GST-tag	of	the	bait	proteins,	or	the	glutathione	beads,	as	no	band	was	seen	in	this	lane.	This	result	is	an	indication	that	SARM	may	not	exclusively	target	the	TRIF-dependent	pathway,	as	inhibition	of	TLR	signalling	is	suspected	to	be	based	on	competitive	binding	to	the	sites	located	in	either	the	TIR	domain	of	a	receptor,	or	its	corresponding	adaptor,	and	a	broad	set	of	binding	partners	for	SARM	are	identified	here.	Although	it	is	difficult	to	make	a	quantitative	analysis	based	on	
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GST	pull	down	results,	a	slight	indication	of	stronger	binding	to	MyD88	and	TRIF	can	be	seen,	as	these	bands	are	considerably	thicker	than	the	ones	seen	in	other	lanes.	 As	mentioned	in	section	1.2.8,	the	BB-loop	regions	of	TIR	domain	proteins	have	repeatedly	been	identified	as	being	functionally	important.	Furthermore,	we	showed	in	section	2.3.2,	that	the	glycine	residue	in	position	601	in	the	SARM	amino	acid	sequence	is	one	of	the	most	conserved	residues	in	the	entire	TIR	domain.	This	prompted	us	to	query	whether	a	mutation	in	this	position	had	any	effect	on	binding	to	other	TIR	domain	proteins.	To	this	end,	we	performed	GST	pull	down	assays	using	a	SARM-TIR	(G601A)	mutant	protein.	It	was	interesting	to	see	that	using	identical	conditions	as	with	the	wild	type	protein,	SARM-TIR	(G601A)	displayed	no	binding	whatsoever	to	the	other	TLR	adaptor	TIR	domains	(Fig.	4.5).	This	result	shows	that	the	BB-loop	of	SARM	is	functionally	important	with	regards	to	forming	TIR-TIR	interactions,	and	provides	evidence	to	support	the	fact	that	interactions	may	be	formed	via	this	motif.	
	
Figure	4.5	SARM-TIR	interacts	with	multiple	TLR	adaptor	TIR	domains.	(Left)	Western	blot	analysis	of	purified	His-tagged	SARM-TIR	pulled	down	by	GST-tagged	MyD88-TIR,	MAL,	TRIF-TIR,	and	TRAM.	(Right)	Interactions	between	His-tagged	SARM-TIR	(G601A)	and	GST-tagged	MyD88-TIR,	MAL,	TRIF-TIR,	and	TRAM	were	analysed	by	Western	blot.	Samples	were	probed	with	an	anti-His	primary	antibody.	Both	blots	shown	are	from	non-adjacent	parts	of	the	same	immunoblot.	
	 133	
To	further	investigate	whether	the	SARM	BB-loop	is	the	actual	motif	that	mediates	binding	to	other	adaptor	TIR	domains,	a	peptide	based	on	this	region	(V591-K606)	was	expressed	as	a	GST-fusion	protein	and	used	in	a	pull	down	assay	with	MyD88-TIR.	As	this	peptide	is	tagged	with	GST,	it	needs	to	be	used	as	bait	in	the	assay,	unlike	the	setup	used	in	previous	assays.	We	used	a	GB1-tagged	MyD88	fusion	protein	with	a	C-terminal	His-tag	as	prey,	since	the	final	detection	is	performed	with	an	anti-His	antibody.	A	positive	interaction	was	observed	(Fig.	
4.6),	and	this	is	consistent	with	the	previous	results	demonstrating	that	mutating	the	G601	residue	in	the	SARM	sequence	results	in	a	complete	loss	of	binding.	
	
Figure	4.6	BB-loop	of	SARM	TIR	domain	interacts	with	MyD88-TIR.	Interactions	between	His-tagged	GB1-MyD88-TIR	and	GST-tagged	SARM-BB	with	or	without	the	G601A	mutation	were	analysed	by	Western	blot.	Samples	were	probed	with	an	anti-His	primary	antibody.		
4.3.3	BaTIR	interacts	with	multiple	human	TLR	adaptors		 The	TIR	domain	of	BaTdp,	a	previously	completely	uncharacterised	protein,	was	also	subjected	to	GST	pull	down	interaction	analyses	with	the	TIR	domains	from	the	four	human	TLR	adaptor	proteins	known	to	mediate	TLR	signalling.	Similarly	to	the	other	TIR	proteins	characterised	in	this	study,	a	clear	
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positive	interaction	was	seen	with	MyD88-TIR,	with	minor	possible	interactions	seen	with	MAL,	TRIF	and	TRAM	(Fig.	4.7).			
	
Figure	4.7	BaTIR	interacts	with	multiple	TLR	adaptor	TIR	domains.	Interactions	between	His-tagged	BaTIR	and	GST-tagged	MyD88-TIR,	MAL,	TRIF-TIR,	and	TRAM	were	analysed	by	Western	blot.	Samples	were	probed	with	an	anti-His	primary	antibody.			 This	result	may	be	an	indication	of	BaTdp	targeting	human	TLR	adaptor	proteins,	but	as	the	system	used	here	is	in	vitro,	employing	recombinantly	expressed	and	purified	proteins,	it	is	not	possible	to	draw	any	broad	conclusions	about	BaTdp	function.	However,	this	will	be	further	evaluated	in	chapter	6.		
4.3.4	Summary	of	pull	down	analyses		 From	the	pull	down	data	presented	here,	it	appears	that	the	TIR-TIR	interactions	formed	by	the	TIR	domains	of	SARM,	YpTdp	and	BaTdp	with	those	of	human	TLR	adaptor	proteins	are	not	particularly	specific	in	nature.	All	three	proteins	displayed	an	ability	to	interact	with	multiple	partners,	possibly	via	a	generic	mechanism.	The	indication	that	mutations	in	both	the	SARM	and	YpTdp	BB-loops	resulted	in	a	loss	of	binding	with	all	partner	proteins	supports	this	
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hypothesis.	A	summary	of	the	results	from	all	GST	pull	down	experiments	is	listed	in	Table	4.1.		
Table	4.1	Summary	of	GST	pull	down	experiments.	
Prey	 Bait	 Interaction	
His-SARM-TIR	 GST-MyD88-TIR	 Positive	
His-SARM-TIR	 GST-MAL	 Inconclusive	
His-SARM-TIR	 GST-TRIF-TIR	 Positive	
His-SARM-TIR	 GST-TRAM	 Inconclusive	
His-SARM-TIR	 GST	 Negative	
His-SARM-TIR	(G601A)	 GST-MyD88-TIR	 Negative	
His-SARM-TIR	(G601A)	 GST-MAL	 Negative	
His-SARM-TIR	(G601A)	 GST-TRIF-TIR	 Negative	
His-SARM-TIR	(G601A)	 GST-TRAM	 Negative	
His-SARM-TIR	(G601A	 GST	 Negative	
GB1-MyD88-TIR-His	 GST-SARM-BB	 Positive	
GB1-MyD88-TIR-His	 GST-SARM-BB	(G601A)	 Negative	
GB1-MyD88-TIR-His	 GST	 Negative	
GB1-YpTIR-His	 GST-MyD88-TIR	 Positive	
GB1-YpTIR-His	 GST-MAL	 Positive	
GB1-YpTIR-His	 GST-TRIF-TIR	 Positive	
GB1-YpTIR-His	 GST-TRAM	 Inconclusive	
GB1-YpTIR-His	 GST	 Negative	
GB1-YpTIR-His	(P173H)	 GST-MyD88-TIR	 Negative	
GB1-YpTIR-His	(P173H)	 GST-MAL	 Negative	
GB1-YpTIR-His	(P173H)	 GST-TRIF-TIR	 Negative	
GB1-YpTIR-His	(P173H)	 GST-TRAM	 Negative	
GB1-YpTIR-His	(P173H)	 GST	 Negative	
GB1-BaTIR-His	 GST-MyD88-TIR	 Positive	
GB1-BaTIR-His	 GST-MAL	 Positive	
GB1-BaTIR-His	 GST-TRIF-TIR	 Inconclusive	
GB1-BaTIR-His	 GST-TRAM	 Inconclusive	
GB1-BaTIR-His	 GST	 Negative		
4.3.5	NMR	analysis	of	MyD88-TIR		 An	attempt	was	made	to	further	characterise	the	interaction	between	SARM	and	MyD88	TIR	domains	by	NMR,	with	a	view	to	identifying	the	binding	site.	Initially,	the	SARM	TIR	domain	was	expressed	in	minimal	M9	media	containing	15NH4Cl	to	generate	15N-labelled	protein,	followed	by	purification	by	
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IMAC.	Spectra	were	recorded	at	280	K,	but	the	protein	displayed	poorly	dispersed	peaks,	indicating	large	amounts	of	misfolded	or	aggregated	protein	in	the	sample	mixture,	making	further	analysis	impossible.		As	the	SARM	TIR	domain	appeared	difficult	to	work	with,	the	MyD88	TIR	domain	was	instead	labelled	with	15N	for	NMR	analysis.	In	order	to	avoid	using	a	large	GST-tag,	the	protein	was	expressed	as	a	GB1-fusion	protein	instead,	and	purified	by	IMAC	and	SEC.	NMR	spectra	were	initially	recorded	at	280	K,	but	not	many	peaks	could	be	resolved	at	this	temperature.	Increasing	the	temperature	to	303	K	resulted	in	significantly	improved	quality	of	spectra,	with	well-dispersed	peaks	indicating	a	homogenous	sample	mixture	of	folded	protein.	Unlabelled	SARM	BB-loop	peptide	was	then	titrated	into	the	sample	mixture	for	up	to	4	molar	equivalents	of	GB1-MyD88-TIR	in	order	to	fully	saturate	binding.	As	shown	in	Figure	4.8,	only	minor	changes	in	chemical	shifts	could	be	observed,	making	it	difficult	to	determine	if	these	were	due	to	weak	protein-protein	interactions	or	subtle	changes	in	buffer	composition	when	titration	of	ligand	was	performed.				
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Figure	4.8	2D	(1H/15N)	HSQC	spectrum	of	GB1-MyD88-TIR.	Spectra	of	15N-labelled	GB1-MyD88-TIR	were	recorded	at	303°K	before	(green)	and	after	(red)	4	molar	equivalents	of	unlabelled	SARM	BB-loop	peptide	was	titrated	into	the	sample	mixture.			 The	assay	setup	was	also	reversed,	with	the	SARM	BB-loop	peptide	being	labelled	with	15N,	and	unlabelled	GB1-MyD8-TIR	being	titrated	into	the	solution.	As	expected	much	fewer	peaks	were	observed	in	the	spectrum	(Fig.	4.9),	given	that	the	peptide	comprises	fewer	amino	acids.	Consistent	with	the	previous	result,	only	minor	chemical	shift	changes	were	observed	when	unlabelled	GB1-MyD88-TIR	was	added,	making	it	difficult	to	draw	any	conclusions	from	this	analysis.	Without	any	peaks	singled	out	as	significantly	affected	by	titration	of	ligand,	assigning	residues	would	serve	little	purpose	and	was	therefore	not	performed.		
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Figure	4.9	2D	(1H/15N)	HSQC	spectrum	of	SARM	BB-loop	peptide.	Spectra	of	15N-labelled	SARM	BB-loop	peptide	were	recorded	at	303°K	before	(green)	and	after	(red)	the	addition	of	unlabelled	GB1-MyD88-TIR.		
4.3.6	SPR	analysis	shows	that	SARM	BB-loop	peptide	binds	to	the	
MyD88	TIR	domain		 In	a	further	attempt	to	characterise	the	suspected	interaction	between	MyD88-TIR	and	the	SARM	BB-loop	peptide,	SPR	was	utilised	to	show	protein-protein	interaction	in	real	time	mode.	SARM-BB	peptide	with	or	without	the	G601A	mutation	was	diluted	into	10	mM	sodium	acetate,	pH	4.0	and	approximately	500	RUs	of	peptides	were	immobilised	in	separate	EDC/NHS-activated	flow	cells	on	a	CM5	chip	using	a	10	µL/min	flow	rate	over	7	minutes.	Remaining	unoccupied	sites	were	then	blocked	with	ethanolamine-HCl,	pH	8.5	for	7	minutes.	A	reference	flow	cell	upstream	of	both	sample	flow	cells	was	also	prepared	by	injecting	blank	buffer	over	EDC/NHS	activated	surface,	followed	by	blocking	with	ethanolamine-HCl.	Purified	GB1-MyD88-TIR	was	then	diluted	into	25	mM	Tris-HCl,	145	mM	NaCl,	pH	7.4,	2.5	mM	CaCl2,	a	buffer	chosen	to	simulate	cellular	conditions,	and	injected	over	the	individual	flow	cells	at	30	µL/min	for	2	minutes.	A	weak	response	could	be	seen	in	the	flow	cell	immobilised	with	WT	
	 139	
SARM-BB	peptide,	while	no	significant	response	was	detected	in	the	flow	cell	immobilised	with	G601A	SARM-BB	peptide	(Fig.	4.10A-B).	We	also	decided	to	dilute	GB1-MyD88-TIR	into	a	buffer	comprised	of	25	mM	MES,	145	mM	NaCl,	pH	6.5,	2	mM	CaCl2	and	inject	the	protein	over	the	chip	surface.	This	buffer	was	chosen	as	infection-induced	inflammation	is	known	to	result	in	a	local	decrease	in	pH	(Coakley	et	al.,	2002)	and	mild	hypocalcemia	(Aderka	et	al.,	1987),	and	such	infection-inflammation	conditions	have	been	reported	to	increase	the	interaction	or	binding	affinity	of	immune-related	proteins	(Panda	et	al.,	2014,	Zhang	et	al.,	2009).	Injections	of	GB1-MyD88-TIR	in	this	buffer	resulted	in	noticeably	higher	response	levels	both	for	the	WT	and	mutant	peptide	(Fig.	
4.10C-D).	Furthermore,	injections	of	GB1-MyD88-TIR	over	the	SARM	G601A	mutant	peptide	exhibited	lower	responses	(panel	D).			
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Figure	4.10	SPR	analysis	of	GB1-MyD88-TIR	interaction	with	SARM-BB.	SPR	was	used	to	characterise	the	interaction	between	SARM-BB	peptide	and	GB1-MyD88-TIR	under	simulated	normal	(A-B)	or	infection-inflammation	(C-D)	conditions.	SARM-BB	peptide	was	immobilised	on	a	CM5	chip,	followed	by	injections	of	GB1-MyD88-TIR	protein	at	indicated	concentrations	for	2	minutes.	Sensorgrams	shown	are	representative	of	three	independent	experiments.	The	plot	was	generated	using	Graphpad	Prism	6.			 Attempts	were	made	to	fit	the	curves	using	a	1:1	Langmuir	model	in	order	to	calculate	the	affinity	of	interactions	observed,	but	the	results	were	inconsistent,	showing	KD	values	that	differed	by	more	than	a	factor	10	between	the	different	samples.	In	particular,	the	dissociation	phase	was	the	source	of	high	variability,	as	some	of	the	injected	samples	displayed	nearly	no	dissociation	at	all.					
	 141	
4.3.7	HDXMS	analysis	of	GB1-MyD88-TIR		 In	order	to	attempt	to	delineate	the	exact	binding	site	where	GB1-MyD88-TIR	binds	to	the	SARM-BB	peptide	HDXMS	analysis	was	performed.	GB1-MyD88-TIR	protein	was	diluted	into	20	volumes	of	deuterated	buffer	with	or	without	the	presence	of	a	molar	excess	of	SARM-BB	peptide,	followed	by	quenching	of	the	hydrogen/deuterium	exchange	at	various	time	points	by	adding	diluted	TFA	to	the	sample	mixture.	The	protein	was	immediately	digested	with	pepsin,	and	the	resulting	peptide	fragments	were	analysed	by	MS.	As	shown	in	Figure	4.11,	the	sequence	coverage	of	the	resulting	peptides	was	nearly	100%	of	the	protein.	Only	a	minor	part	of	the	fusion	protein,	corresponding	to	the	linker	region	between	GB1	and	MyD88-TIR	(VPRGS),	and	three	amino	acids	in	the	MyD88	αA	helix	(IQF)	were	not	covered.		
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Figure	4.11	Sequence	coverage	of	pepsin	digested	GB1-MyD88-TIR.	Pepsin	digestion	of	GB1-MyD88-TIR	following	incubation	in	deuterated	buffer	resulted	in	83	individual	peptides	being	detected	by	mass	spectrometry.	96%	of	the	full	fusion	protein	sequence	(195	of	203	residues)	was	covered.	Peptide	coverage	map	was	generated	using	MS	Tools	(Kavan	and	Man,	2011).		 Comparison	of	deuterium	uptake	for	each	individual	peptide	fragment	at	the	five	different	time	points	where	the	hydrogen/deuterium	exchange	was	quenched	(0.5,	1,	2,	5	and	10	minutes)	revealed	relatively	small	differences	between	the	GB1-MyD88-TIR	incubated	with	or	without	SARM-BB	peptide.	A	butterfly	plot	was	used	to	visualise	the	changes,	where	each	peptide	fragment	is	distributed	over	the	X-axis	in	the	approximate	position	it	occurs	in	the	amino	acid	sequence,	and	the	mass	change	is	plotted	on	the	Y-axis	(Fig.	4.12).		
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Figure	4.12	Butterfly	plot	of	HDXMS	result.	Differences	in	GB1-MyD88-TIR	deuterium	uptake	when	SARM-BB	peptide	was	present	in	the	sample	mixture	was	visualised	in	a	butterfly	plot.	X-axis	indicates	approximate	position	the	peptide	occurs	in	the	GB1-MyD88-TIR	protein	sequence.	Each	line	represents	one	time	point.	The	plot	was	generated	using	Graphpad	Prism	6.		 No	specific	region	showed	consistent	changes	in	deuteration	above	1	Da,	although	a	region	around	peptides	number	50-80	displayed	some	minor	differences.	Many	of	these	were	long	peptides	corresponding	to	partially	cleaved	fragments	with	a	high	degree	of	variation	between	individual	samples.	To	further	investigate,	deuterium	uptake	plots	were	generated	for	certain	peptides	corresponding	to	exposed	motifs	in	the	MyD88-TIR	structure,	and	which	displayed	little	sample	to	sample	variation	(Fig.	4.13).		
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Figure	4.13	Deuterium	uptake	in	exposed	motifs	of	GB1-MyD88-TIR.	Kinetic	traces	of	deuterium	uptake	in	peptides	corresponding	to	solvent	accessible	motifs	in	the	MyD88	TIR	domain	show	that	the	presence	of	SARM-BB	loop	peptide	resulted	in	a	significantly	slower	uptake	in	the	αC	helix,	but	no	significant	differences	in	other	exposed	motifs.	Sequences	and	approximate	structural	motifs	are	indicated	above	each	plot.	Y-axes	are	adjusted	to	display	maximum	theoretical	deuteration	for	each	peptide.	Diagrams	were	generated	using	Graphpad	Prism	6.			 Nearly	all	peptide	fragments	display	identical	uptake	rates	when	comparing	the	GB1-MyD88-TIR	protein	incubated	with	or	without	SARM-BB.	Only	one	fragment	(YLQSKECDF,	corresponding	to	the	αC	helix)	displayed	a	significantly	lower	deuterium	uptake	when	the	GB1-MyD88-TIR	fusion	protein	
	 145	
was	incubated	together	with	the	SARM-BB	peptide.	This	could	be	indicative	of	the	peptide	binding	to	this	motif,	however	it	is	important	to	note	that	the	difference	in	mass	was	very	small.	Overall,	the	extent	of	deuteration	was	consistently	low	for	all	protein	motifs,	at	most	approaching	50%	after	10	minutes.	This	can	be	compared	with	a	previous	HDXMS	study	of	the	TcpB	TIR	domain	protein,	where	many	exposed	motifs	displayed	nearly	100%	deuteration	after	just	10	seconds	of	incubation	(Snyder	et	al.,	2014).			
4.4	Discussion		 Although	the	data	presented	in	this	chapter	have	not	been	completely	consistent,	much	novel	information	about	SARM,	YpTdp	and	BaTdp	have	still	been	generated.	Using	GST	pull	down	methodology,	the	SARM	TIR-domain	was	found	to	interact	with	multiple	human	TLR	adaptor	proteins,	including	the	MyD88	TIR	domain.	This	result	suggests	that	SARM	may	form	a	protein-protein	complex	with	MyD88,	possibly	disrupting	the	ability	of	MyD88	to	bind	with	TLRs	or	MAL.	We	were	also	able	to	identify	a	single	amino	acid	residue	in	the	predicted	SARM	BB-loop	motif,	G601,	where	an	alanine	substitution	resulted	in	a	complete	lack	of	binding.	This	is	an	indication	of	this	motif	being	functionally	important,	which	we	will	try	to	further	investigate	in	the	following	chapter.		 While	pull	down	methodology	is	not	considered	a	quantitative	technique,	the	relative	intensity	of	bands	displayed	during	Western	blot	analysis	can	approximately	be	correlated	to	the	strength	of	the	interaction.	The	data	presented	here	could	have	been	improved	by	consistently	including	a	positive	control	sample	consisting	of	proteins	forming	a	known	TIR-TIR	interaction,	such	as	that	between	MyD88	and	YpTIR	or	MAL,	as	well	as	comparing	the	amount	of	
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pulled	down	prey	protein	to	the	amount	of	input.	If	this	had	been	done,	the	relative	strength	of	interactions	seen	may	have	been	approximated.	In	addition,	immunoblots	should	also	have	been	stained	with	an	anti-GST	antibody	to	fully	rule	out	the	possibility	of	inconsistent	binding	of	bait	proteins.				 As	it	was	difficult	to	obtain	clean	data	using	the	full	SARM	TIR	domain	protein,	we	designed	a	peptide	based	around	the	SARM	BB-loop	motif.	This	short	peptide	was	found	to	interact	with	the	MyD88	TIR	domain	using	GST	pull	down,	and	SPR	analysis	indicated	that	the	interaction	is	a	high	affinity	one.	However,	during	NMR	analysis,	we	did	not	observe	any	significant	interaction	with	MyD88-TIR.	Because	of	its	high	sensitivity,	NMR	is	typically	a	much	better	suited	technique	for	characterising	weak	protein-protein	interactions	than	GST	pull	down	(Vaynberg	and	Qin,	2006),	so	it	was	surprising	that	we	did	not	observe	an	interaction	with	this	method.	However,	the	interaction	between	MyD88-TIR	and	SARM-BB	peptide,	observed	during	pull	down	experiments,	does	not	appear	to	be	a	false	positive	result	as	we	can	also	observe	it	by	SPR.		While	we	detect	specific	an	interaction	between	MyD88-TIR	and	SARM-BB	peptide	using	SPR,	no	in-depth	analysis	of	the	kinetic	curves	generated	was	performed	given	that	nearly	no	dissociation	was	seen.	While	this	type	of	curve	may	be	expected	for	a	very	high	affinity	interaction,	it	is	unlikely	that	it	accurately	represents	the	interaction	between	the	ligand	and	analyte	in	this	case.	It	is	not	clear	why	we	don’t	see	any	significant	dissociation	after	the	injections	are	complete,	but	a	possible	explanation	could	be	that	the	analyte	precipitates	on	the	chip	surface.	It	may	also	be	an	artefact	of	rebinding	of	GB1-MyD88-TIR	associating	with	the	reference	cell,	followed	by	associating	with	the	sample	cell	during	the	analyte	dissociation	phase.	By	using	HDXMS,	we	were	able	to	identify	
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a	possible	site	on	the	MyD88	TIR	domain	where	the	SARM-BB	peptide	binds.	However,	the	data	was	not	very	convincing	as	the	difference	in	deuterium	uptake	was	very	small,	but	this	could	also	be	indicative	of	a	weak	interaction	during	normal	physiological	conditions.	Ideally,	this	analysis	should	have	been	repeated	using	simulated	infection-inflammation	conditions.	While	the	buffer	conditions	used	during	pull	down	and	NMR	analyses	were	chosen	to	simulate	normal	physiological	conditions,	SPR	results	indicated	that	interactions	might	be	stronger	under	slightly	acidic	pH	and	mild	hypocalcemia.	It	would	be	interesting	to	have	repeated	analyses	under	these	conditions	to	see	if	any	difference	could	be	seen.	An	even	better	approach	that	bypasses	the	need	for	designing	suitable	buffers	would	be	to	monitor	interaction	in	a	cellular	environment.	Co-immunoprecipitation	follows	the	same	overall	principles	as	pull	down	analysis	and	would	be	a	suitable	choice	for	doing	this.		 Regarding	YpTdp,	we	were	able	to	demonstrate	that	the	TIR	domain	of	the	protein	not	only	associates	with	human	MyD88-TIR,	but	also	other	TLR	adaptor	proteins.	The	P173H	mutation,	which	was	previously	shown	to	result	in	an	inability	to	associate	with	MyD88-TIR,	was	also	shown	here	to	result	in	a	lack	of	binding	to	the	other	TLR	adaptors.	This	could	be	a	sign	of	the	protein	using	a	generic	mechanism	based	on	common	structural	features	to	form	TIR-TIR	complexes.	YpTdp	expression	in	mammalian	cells	has	previously	been	demonstrated	to	result	in	a	mild	inhibition	of	TLR4-mediated	immune	activation	(Spear	et	al.,	2012),	and	the	results	presented	here	provides	further	clues	to	possible	mechanisms	used	by	the	protein	to	subvert	innate	immune	activation.		 BaTdp	has	not	previously	been	studied,	but	the	data	presented	here	indicates	that	the	protein	binds	to	multiple	human	TLR	adaptor	proteins,	
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possibly	an	indication	of	the	protein	playing	a	role	in	modulating	host	TLR	signalling	following	infection.	This	will	be	further	investigated	in	chapter	6.		 The	overall	purpose	of	the	experiments	presented	in	this	chapter	was	to	obtain	further	insight	into	the	mechanisms	used	by	SARM,	YpTdp	and	BaTdp	to	form	TIR-TIR	interactions	with	human	TLR	adaptor	proteins.	SARM-TIR	was	found	to	associate	not	only	with	TRIF-TIR,	but	also	MyD88-TIR,	and	association	was	found	to	be	dependent	on	the	G601	residue.	In	the	following	chapter	we	will	investigate	whether	SARM	is	able	to	inhibit	MyD88-dependent	immune	signalling,	and	whether	the	G601	residue	is	functionally	important	or	not.		 	
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Chapter	5		
The	cellular	functions	of	SARM		
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5.1	Introduction		 In	the	previous	chapter	various	interaction	assays	were	used	to	show	that	the	TIR	domain	of	SARM	is	able	to	interact	with	several	cytoplasmic	TLR	adaptor	proteins,	including	TRIF	and	MyD88.	A	mutation	in	the	BB-loop	located	within	the	SARM	TIR	domain	resulted	in	a	fully	reduced	binding	capability.	Furthermore,	a	short	peptide	based	on	the	SARM	BB-loop	motif	was	found	to	interact	with	the	TIR	domain	of	MyD88,	suggesting	that	the	SARM-MyD88	interaction	is	mediated	via	the	BB-loop	region.		 In	this	chapter,	an	assessment	of	the	effect	SARM	expression	has	on	cell	based	TLR-mediated	activation	of	innate	immunity,	specifically	the	activation	of	pro-inflammatory	cytokines,	will	be	presented.	We	investigated	whether	SARM	exclusively	targets	the	TRIF-dependent	pathway,	and/or	also	the	MyD88-dependent	pathway.	We	also	explored	the	effects	of	the	G601A	mutation,	in	the	BB-loop	region	of	the	TIR	domain,	on	cell	based	SARM	function.		 As	mentioned	in	chapter	1,	SARM	was	initially	reported	to	only	affect	TRIF-mediated	TLR	signalling	(Carty	et	al.,	2006),	although	studies	published	since	then	have	indicated	that	the	MyD88	dependent	pathway	may	also	be	targeted	(Peng	et	al.,	2010,	Yuan	et	al.,	2010).	The	conflicting	results	may	be	due	to	SARM	acting	on	multiple	targets,	or	differences	in	experimental	design	between	the	studies.	The	findings	presented	here	support	SARM	having	a	role	in	both	MyD88	and	TRIF	dependent	TLR	signalling.					
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5.2	Materials	and	methods	
5.2.1	General	reagents	and	antibodies		 Monoclonal	mouse	antibody	to	V5	(α-V5),	polyclonal	donkey	α-mouse	IgG	Alexa	Fluor	546	conjugate,	polyclonal	goat	α-rabbit	IgG	Alexa	Fluor	488	conjugate,	polyclonal	goat	α-mouse	IgG	Alexa	Fluor	488	conjugate,	and	polyclonal	goat	α-rabbit	IgG	Alexa	Fluor	568	conjugate	were	from	Invitrogen.	Monoclonal	mouse	α-FLAG	M2	and	polyclonal	rabbit	α-actin	were	from	Sigma.	Monoclonal	mouse	α-Glyceraldehyde	3-phosphate	dehydrogenase	(GAPDH)	was	from	Santa	Cruz	Biotechnology.	Monoclonal	rabbit	α-SARM	was	from	Cell	Signaling	Technology.	Polyclonal	rabbit	α-GFP	was	from	Abcam.	Monoclonal	mouse	α-Cytochrome	C	was	from	BD	Biosciences.	Polyclonal	rabbit	α-TLR4	was	from	Zymed.	Monoclonal	mouse	α-HA	was	from	Roche.	Polyclonal	goat	α-mouse	IgG	HRP	conjugate,	polyclonal	goat	α-rabbit	IgG	HRP	conjugate,	and	polyclonal	rabbit	α-goat	IgG	HRP	conjugate	were	from	Dako.	E.	coli	055:B5	LPS	and	LTA	were	from	Sigma.		
5.2.2	Generation	of	mammalian	expression	constructs		 Mammalian	expression	plasmids	were	generated	using	similar	methodology	as	described	in	section	3.2.1	with	the	primers	listed	in	Table	5.1.	Genomic	DNA	from	U937	cells	was	used	as	template	for	PCR.	pCDNA	plasmids	coding	for	untagged	SARM,	and	GFP-tagged	SARM	and	SARM-TIR	were	from	Dr.	Laishram	Pradeepkumar	Singh,	National	University	of	Singapore.	Site-directed	mutagenesis	was	performed	as	described	in	section	3.2.2.	The	final	plasmids	to	be	used	in	cell-based	assays	were	purified	using	EndoFree	plasmid	maxi	kits	
	 152	
(Qiagen)	to	ensure	that	the	DNA	was	not	contaminated	with	endotoxin	from	the	
E.	coli	host.		
Table	5.1	Primers	used	for	MyD88	plasmid	cloning.	
Construct	 Residues	 Nucleotide	sequence	(5’-3’)	 Vector	
GFP-MyD88	 1-296	 GATCAAGCTTCGATGCGACCCGAC	
GATCGGTACCTCAGGGCAGGGACAA	
pEGFP-C1	
MyD88-FLAG	 1-296	 GATCAAGCTTATGCGACCCGACCG	
GATCGGTACCTCAGGGCAGGGACAA	
pXJ40-FLAG	
Underlined	sequences	AAGCTT	and	GGTACC	correspond	to	restriction	sites	HindIII	and	KpnI	respectively.		
5.2.3	Mammalian	cell	cultures		 Cells	used	in	this	study	were	Human	embryonic	kidney	293	cells	transformed	with	simian	virus	40	(SV40)	large	T	antigen	(HEK293T),	HEK293	cells	stably	transfected	with	plasmids	encoding	TLR4,	MD2	and	CD14	(HEK-TLR4),	HEK293	cells	stably	transfected	with	plasmid	encoding	for	hemagglutinin-tagged	TLR2	(HEK-TLR2),	NIH/3T3,	and	U937.	HEK	and	NIH/3T3	cells	were	maintained	in	Dulbecco’s	Modified	Eagle	Medium	(DMEM)	(Gibco)	supplemented	with	10%	(v/v)	fetal	bovine	serum	(FBS)	(Invitrogen)	at	37°C,	5%	CO2,	under	humidified	environment.	HEK-TLR4	cultures	were	also	supplemented	with	10	µg/mL	blasticidin	and	50	µg/mL	hygromycin	B,	while	HEK-TLR2	cell	cultures	were	supplemented	with	only	blasticidin.	U937	cells	were	grown	in	Roswell	Park	Memorial	Institute	(RPMI)	1640	medium	(Gibco)	supplemented	with	10%	(v/v)	FBS	at	37°C,	5%	CO2,	under	humidified	environment	using	100	U/mL	penicillin	and	100	µg/mL	streptomycin	as	antibiotic	selection.	Cells	were	typically	grown	in	T25	culture	flasks	until	they	reached	70-90%	confluency,	after	
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which	they	were	passaged	using	a	1:10	split.	HEK293T	and	NIH/3T3	cells	were	dissociated	from	the	surface	using	TrypLE	Express	trypsin	replacement	enzyme	(Gibco),	while	HEK-TLR4	and	HK-TLR2	cells	were	dissociated	mechanically	using	a	cell	scraper	to	ensure	the	expressed	receptors	were	not	compromised	by	trypsinisation.	U937	cells	are	grown	in	suspension	and	therefore	do	not	require	a	dissociation	step	prior	to	subculturing.	All	experiments	were	performed	with	cells	at	a	passage	number	between	5-20.	Prior	to	use	in	assay,	U937	cells	were	differentiated	into	macrophages	by	stimulation	with	30	ng/mL	phorbol	myristate	acetate	(PMA)	(Sigma)	supplemented	to	the	growth	medium	for	24	hours,	followed	by	recovery	in	regular	culture	medium	for	24	hours	prior	to	using	the	cells	for	experiments.		
5.2.4	Freezing	of	mammalian	cells		 Stocks	of	mammalian	cells	were	regularly	frozen	by	first	collecting	and	harvesting	the	cells	by	centrifugation	at	100	x	g	for	5	minutes.	Cells	were	then	resuspended	in	growth	medium	supplemented	with	5%	dimethyl	sulfoxide	(DMSO)	at	a	concentration	of	1-3	x	106	cells/mL	and	aliquoted	1	mL	into	cryogenic	vials	(Nunc).	To	ensure	a	slow	freezing	process,	necessary	due	to	the	risk	of	rapidly	forming	ice	crystals	damaging	the	cells,	vials	were	placed	in	a	sealed	styrofoam	box	and	placed	at	-80°C	overnight.	The	following	day,	the	vials	were	placed	in	liquid	nitrogen	where	they	were	stored	permanently.					
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5.2.5	Thawing	of	mammalian	cells		 Thawing	of	frozen	cells	was	done	by	removing	one	cryogenic	vial	from	the	liquid	nitrogen	storage	and	immediately	placing	it	in	a	37°C	water	bath	with	the	cap	remaining	over	the	water	surface	and	gently	moving	the	vial	in	circles.	When	only	a	small	bit	of	ice	was	remaining	in	the	vial,	the	cells	were	transferred	to	a	50	mL	Falcon	tube	and	20	mL	antibiotic-free	growth	medium	was	added	dropwise.	After	gentle	mixing	by	inversion,	the	cells	were	collected	by	centrifugation	at	100	x	g	for	10	min.	The	cells	were	then	resuspended	in	20	mL	fresh	culture	medium	without	antibiotics	and	cultured	in	a	T75	culture	vessel.	After	two	passages,	selective	antibiotics	were	added,	after	which	the	cells	were	cultured	as	described	in	section	5.2.3.		
5.2.6	Transfection	of	mammalian	cells		 Four	different	kits	for	transfection	of	mammalian	cells	were	used:	Lipofectamine	2000	(Life	technologies),	Lipofectamine	3000	(Life	technologies),	TurboFect	transfection	reagent	(Thermo	Scientific),	and	X-tremeGENE	HP	DNA	transfection	reagent	(Roche).	All	reagents	were	used	according	to	the	manufacturer’s	instructions.		
5.2.7	Enumeration	of	cells		 Cell	counting	was	either	done	manually	with	an	improved	Neubauer	hemocytometer	chamber	using	a	Diaphot-TMD	inverted	microscope	(Nikon),	or	automatically	using	a	Countess	II	FL	automated	cell	counter	(Life	technologies).	In	both	cases,	cells	were	first	stained	with	Trypan	blue	(Gibco)	in	order	to	ensure	
	 155	
that	only	viable	cells	were	counted.	For	cell	counting	with	a	hemocytometer,	four	boxes	were	counted	and	an	average	value	was	used.		
5.2.8	Trypan	blue	exclusion	test	of	cell	viability		 Cells	were	routinely	tested	for	overall	viability	by	mixing	a	homogenous	cell	suspension	with	an	equal	volume	of	0.4%	Trypan	blue	solution	(Gibco)	and	viewed	under	a	microscope.	Dead	cells	appeared	blue	while	viable	cells	remained	clear	and	refractile,	as	the	dye	is	unable	to	penetrate	the	membrane	of	healthy	cells.	Experiments	were	only	performed	with	cell	cultures	where	the	overall	viability	was	at	least	95%.		
5.2.9	Preparation	of	cell	lysates		 Mammalian	cells	grown	in	6-well	plates	were	washed	twice	in	ice	cold	PBS,	before	being	resuspended	in	300	µL	cold	lysis	buffer	(50	mM	Tris,	1	mM	EDTA,	150	mM	NaCl,	0.5%	Triton	X-100,	pH	7.4)	and	incubated	under	gentle	agitation	at	4°C	for	30	min.	Cell	debris	was	removed	by	centrifugation	at	12,000	x	g	for	20	min	at	4°C,	and	the	supernatant	was	collected.	An	equal	amount	of	supernatant	was	mixed	with	2X	SDS-PAGE	sample	buffer	and	the	mixture	was	boiled	at	95°C	for	5	min.	The	samples	were	then	resolved	on	a	12%	SDS-PAGE	gel	and	analysed	by	Western	blot.		
5.2.10	Immunofluorescence	staining		 Cells	grown	on	coverslips	in	12-well	plates	were	washed	twice	in	ice	cold	PBS	and	fixed	with	500	µL	4%	paraformaldehyde	(PFA)	in	PBS	for	15-20	min	at	
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room	temperature.	The	cells	were	then	washed	three	times	with	PBS	and	blocked	with	500	µL	blocking	buffer	(2%	BSA,	0.1%	Triton	X-100	in	PBS)	for	30	min.	Cells	were	then	stained	with	200	µL	of	the	indicated	primary	antibody	diluted	1:500	in	blocking	buffer	either	for	2	hours	at	room	temperature	or	overnight	at	4°C.	After	washing	three	times	with	PBST,	200	µL	of	secondary	antibody	diluted	1:500	in	blocking	buffer	was	added	and	the	cells	were	incubated	at	room	temperature	for	2	hours.	The	cells	were	finally	washed	three	times	with	PBST	and	once	with	PBS,	after	which	they	were	mounted	on	glass	slides	with	ProLong	Gold	Antifade	mounting	medium	containing	DAPI	(Life	Technologies)	and	cured	in	the	dark	at	room	temperature	overnight.	The	following	day,	slides	were	sealed	with	clear	nail	polish	(Maybelline)	and	stored	at	4°C	until	analysed	by	microscopy.		
5.2.11	Confocal	microscopy		 To	stain	for	mitochondria,	cells	seeded	on	coverslips	in	12-well	plates	were	incubated	with	30	nM	of	either	deep	red	or	orange	mitotracker	(Invitrogen)	at	37°C	for	30	min.	After	being	washed	twice	in	PBS,	cells	were	stained	with	antibodies	as	indicated	in	section	5.2.10.	Cells	were	then	viewed	under	a	LSM	510	META	confocal	microscopy	using	an	EC	Plan-Neofluar	100X/1.3	oil	immersion	objective	(Carl	Zeiss).	Experiments	were	performed	at	the	Centre	for	BioImaging	Sciences	(CBIS),	National	University	of	Singapore.					
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5.2.12	PAMP	stimulation	assays		 HEK-TLR2	or	HEK-TLR4	cells	(Invivogen),	which	stably	express	TLR2	and	TLR4,	respectively,	were	seeded	in	24-well	plates	at	6	x	104	cells/well	in	1	mL	growth	medium	for	24	hours	before	transfection.	The	amount	of	plasmid	used	for	transfection	was	normalised	to	1	µg/mL	growth	medium	with	empty	pCDNA	vector.	24	hours	after	transfection,	the	growth	medium	was	replaced	with	medium	containing	100	ng/mL	LPS	for	HEK-TLR4	cells,	or	1000	ng/mL	LTA	for	HEK-TLR2	cells.	After	24	hours	of	PAMP	stimulation,	growth	media	were	collected	and	stored	at	-80°C	until	further	analysed	for	secreted	cytokine	content	by	enzyme-linked	immunosorbent	assay	(ELISA).		
5.2.13	ELISA		 ELISA	was	used	to	measure	the	amounts	of	TNF-α,	IL-8,	and	IL-6	present	in	culture	supernatants.	Antibodies	and	standard	proteins	from	OptEIA	human	cytokine	ELISA	kits	(BD	BioSciences)	were	used	for	analysis.	Capture	antibodies	were	diluted	1:250	in	100	mM	sodium	carbonate	buffer,	pH	9.5,	and	100	µL	was	loaded	into	each	well	of	a	96-well	MaxiSorp	Immuno-plate	(Nunc).	The	plates	were	then	sealed	with	parafilm	and	incubated	at	4°C	overnight	in	order	to	coat	the	wells	with	the	capture	antibodies.	The	following	day,	wells	were	washed	three	times	with	300	µL	PBST	and	blocked	with	200	µL	1%	BSA	in	PBS	for	one	hour	at	room	temperature.	After	three	wash	cycles	with	PBST,	100	µL	of	samples	and	standard	proteins	diluted	appropriately	in	blocking	buffer	were	added	to	each	well,	followed	by	incubation	at	room	temperature	for	two	hours.	Wells	were	then	washed	five	times	in	PBST,	and	100	µL	of	biotin-conjugated	detection	
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antibodies	diluted	1:250	in	blocking	buffer	together	with	streptavidin-labelled	HRP	(also	diluted	1:250)	were	added	to	each	well.	Plates	were	incubated	at	room	temperature	for	one	hour,	followed	by	7	wash	cycles	in	PBST.	To	initiate	the	detection	process,	1	mg	of	3,3′,5,5′-Tetramethylbenzidine	(TMB)	(Sigma)	dissolved	in	1	mL	DMSO	was	diluted	to	10	mL	in	50	mM	phosphate-citrate	buffer,	pH	5.0,	and	2	µL	of	30%	H2O2	was	added	to	the	mixture.	100	µL	of	TMB	solution	was	added	to	each	well	and	the	plate	was	incubated	in	the	dark	at	room	temperature	for	approximately	one	hour.	25	µL	of	2	M	H2SO4	was	then	added	to	each	well	to	stop	the	TMB	reaction,	and	cytokine	levels	were	finally	measured	by	reading	the	absorbance	of	each	well	at	450	nm.		
5.2.14	MTT	cell	viability	assay		 Cell	viability	was	estimated	with	the	(4,5-dimethylthylthiazol-2-yl)-2,5-diphenyltetrazolium	bromide	(MTT)	method.	Cells	were	seeded	in	a	96-well	plate	at	5000	cells/well	in	100	µL	growth	medium	per	well	and	grown	at	37°C,	5%	CO2,	in	a	humidified	environment.	24	hours	after	seeding,	cells	were	transfected	with	expression	vectors	at	amounts	up	to	1	µg/mL	growth	medium,	followed	by	further	incubation	for	up	to	48	hours.	The	total	amount	of	plasmid	was	normalised	to	1	µg/mL	growth	medium	using	empty	pCDNA-vector	during	transfection.	To	quantify	cell	viability,	MTT	tetrazolium	salt	(Sigma)	was	dissolved	in	PBS	at	5	mg/mL,	and	20	µL	was	added	to	each	well	followed	by	incubation	at	37°C	for	4	hours.	The	dark	formazan	crystals	that	were	formed	during	this	period	of	time	could	then	be	solubilised	at	37°C	overnight	by	adding	100	µL	10%	SDS	in	10	mM	HCl	to	each	well.	The	following	day,	the	metabolic	activity	of	viable	cells	was	estimated	by	measuring	the	absorbance	at	590	nm	
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using	a	Synergy	Mx	microplate	reader	(BioTek).	The	appropriate	amount	of	cells	to	be	seeded	was	originally	estimated	by	seeding	between	100	to	100,000	cells/well,	using	1:2	serial	dilutions,	and	performing	the	full	analysis	using	only	the	empty	vector	control	for	transfection.	For	following	experiments,	a	cell	seeding	density	that	resulted	in	an	absolute	absorbance	reading	of	0.75-1.25	was	used.	
	
5.2.15	Subcellular	fractionation		 To	isolate	mitochondria	from	homogenised	cells,	a	mitochondria	isolation	kit	(Pierce)	was	used.	Cells	grown	in	6-well	plates	and	transfected	with	indicated	plasmids	were	washed	twice	with	ice	cold	PBS	and	harvested	with	a	cell	scraper.	The	cells	were	collected	in	an	Eppendorf	tube	and	pelleted	by	centrifugation	at	850	x	g	2	min	at	4°C.	Cells	were	resuspended	by	adding	800	µL	reagent	A	(suspension	buffer)	to	each	tube,	followed	by	vortex-mixing	at	medium	speed	for	5	seconds.	Tubes	were	then	incubated	on	ice	for	2	min,	after	which	10	µL	reagent	B	(lysis	reagent)	was	added.	Mixing	was	done	by	vortexing	at	high	speed	for	5	seconds	every	minute	until	5	minutes	had	passed,	with	the	tubes	being	chilled	on	ice	between	each	mixing	step.	800	µL	reagent	C	(neutralisation	reagent)	was	then	added	and	the	tubes	were	mixed	by	inversion.	Cell	debris	was	removed	by	centrifugation	at	700	x	g	10	min	at	4°C.	The	supernatants	were	transferred	to	new	tubes	and	mitochondria	were	separated	from	the	cytosol	by	centrifugation	at	12,000	x	g	5	min	at	4°C.	The	mitochondria-containing	pellets	were	washed	once	in	500	µL	reagent	C,	after	which	the	pellets	were	dissolved	in	2X	SDS-PAGE	
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sample	buffer	by	boiling	at	95°C.	Samples	were	analysed	by	SDS-PAGE	and	Western	blot	analysis	using	the	antibodies	indicated.		
5.2.16	Western	blot		 Western	blot	analysis	was	performed	as	described	in	section	3.2.16	with	the	difference	that	visualisation	and	detection	of	protein	bands	was	performed	using	enhanced	chemiluminescent	(ECL)	HRP	substrate	and	an	ImageQuant	LAS	4000	mini	system	(GE	Healthcare).	The	ECL	reagents	used	were	either	SuperSignal	West	Pico	Chemiluminescent	Substrate	(Thermo	Scientific)	or	WesternBright	ECL	(Advansta).		
5.2.17	Detection	of	apoptosis	by	Annexin	V	staining		 Early	and	late	stage	apoptosis	was	detected	using	an	Annexin	V	apoptosis	detection	kit	FITC	(eBioscience).	Cells	were	grown	in	6-well	plates	and	transfected	with	2	µg	of	the	indicated	plasmid	using	Turbofect	transfection	reagent.	At	24	and	48	hours	post	transfection,	cells	were	harvested	and	washed	twice	in	ice	cold	PBS,	and	resuspended	in	1X	binding	buffer	at	a	concentration	of	approximately	1	x	106	cells/mL.	100	µL	cell	suspension	was	then	mixed	gently	with	5	µL	FITC	conjugated	Annexin	V	reagent	and	incubated	for	15	min	at	RT	in	the	dark.	After	one	wash	with	binding	buffer,	cells	were	resuspended	in	500	µL	binding	buffer	and	5	µL	7-Aminoactinomycin	(7-AAD)	was	added	to	the	mixture.	Cells	were	analysed	by	Fluorescence-activated	cell	sorting	(FACS)	within	4	hours,	and	stored	on	ice	in	the	dark	until	then.	As	a	positive	control,	actinomycin	D	(ActD)	from	Streptomyces	sp.	(Sigma)	was	added	to	cell	cultures	at	a	
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concentration	of	1	µg/mL	for	12	hours	to	induce	cellular	apoptosis,	followed	by	staining	with	Annexin	V	and	7-AAD.		
5.2.18	FACS	analysis		 Early	and	late	stage	apoptotic	cells	were	quantified	by	FACS	using	a	LSR	Fortessa	flow	cytometry	analyser	(BD	Biosciences)	at	low	flow	rate	for	15,000	events.	Data	were	analysed	using	Summit	4.3	software	(Beckman	Coulter).	Experiments	were	performed	at	the	flow	cytometry	laboratory	unit	at	Yong	Loo	Lin	School	of	Medicine,	National	University	of	Singapore.		
5.2.19	Detection	of	cellular	uptake	of	Antennapedia-tagged	
SARM	peptide		 SARM	BB-loop	(VFIDVEKLEAGKFED)	peptide	N-terminally	fused	with	the	
Antennapedia	homeodomain	(RQIKIWFQNRRMKWKK)	and	C-terminally	conjugated	with	K-rhodamine	was	synthesised	by	Genemed	Synthesis	Inc.,	USA.	The	lyophilised	peptide	was	of	>95%	purity,	estimated	by	HPLC,	and	was	reconstituted	in	PBS	and	stored	at	-80°C	until	used.	HEK293T	cells	grown	on	coverslips	in	12-well	plates	were	incubated	with	10	µM	peptide	for	the	indicated	time	points,	after	which	cells	were	washed	twice	in	ice	cold	PBS	and	fixed	with	4%	PFA	for	15	min	at	RT.	Following	an	additional	three	washes	with	PBS,	cells	were	mounted	on	microscopy	slides	in	DAPI	containing	mounting	medium	and	cured	overnight	at	RT	in	the	dark.	The	following	day	cells	were	viewed	under	fluorescence	microscope	to	evaluate	the	amount	of	rhodamine	conjugated	peptide	available	in	the	cytoplasm	at	each	time	point.	
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5.2.20	Statistical	significance		 All	experiments	were	performed	using	at	least	three	biological	replicates	and	three	technical	replicates,	unless	otherwise	stated.	Data	are	presented	as	means	±	standard	deviation	(SD).	Differences	were	analysed	by	two-tailed	student’s	t-test	in	Graphpad	Prism	6,	and	p	values	<	0.05	were	considered	significant.		
5.3	Results	
5.3.1	Only	full	length	SARM	is	localised	to	the	mitochondria			 Although	all	in	vitro	interaction	assays	presented	in	chapter	4	were	conducted	using	the	isolated	SARM	TIR	domain,	multiple	studies	have	demonstrated	that	this	domain	alone	is	insufficient	for	downregulating	innate	immunity	(Belinda	et	al.,	2008,	Carty	et	al.,	2006).	A	study	by	Panneerselvam	and	colleagues	also	demonstrated	that	an	intact	N-terminus	is	required	for	mitochondrial	localisation	of	SARM	(Panneerselvam	et	al.,	2012a).	In	order	to	confirm	that	the	isolated	SARM	TIR	domain	would	not	localise	to	mitochondria,	we	transfected	HEK293T	cells	grown	on	coverslips	in	12-well	plates	with	1	µg	of	constructs	coding	for	GFP-tagged	full	length	SARM	or	TIR	domain	only.	The	cells	were	then	stained	with	mitotracker	dye	24	hours	post-transfection,	followed	by	visual	inspection	by	fluorescence	microscopy.	As	shown	in	Figure	5.1,	a	clear	localisation	to	the	mitochondria	was	seen	with	full	length	SARM,	while	TIR	only	appeared	to	be	ubiquitously	distributed	throughout	the	cell.		
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Figure	5.1	SARM	cellular	localisation.	HEK293T	cells	were	transfected	with	plasmids	encoding	GFP-tagged	SARM	(A)	or	GFP-tagged	SARM-TIR	(B).	24	hours	post	transfection,	cells	were	treated	with	mitotracker	dye	to	stain	mitochondria,	fixed	and	viewed	under	microscope.	All	scale	bars,	10	µm.	Original	magnification	X100.		 		 Mitochondria	were	also	isolated	from	cytosol	using	differential	centrifugation,	and	proteins	from	both	fractions	were	denatured	and	resolved	by	SDS-PAGE,	followed	by	analysis	by	Western	blot	(Fig.	5.2).	As	indicated	by	the	microscopy	study,	full	length	SARM	was	exclusively	present	in	the	mitochondrial	fraction	confirming	earlier	results	(Panneerselvam	et	al.,	2012a),	while	SARM-TIR	was	also	seen	in	the	cytosolic	fraction.	The	cytosolic	marker,	GAPDH,	was	also	seen	in	the	mitochondrial	fractions,	indicative	of	insufficient	washing	of	the	mitochondrial	pellet	at	the	last	stage	of	separation.	However,	none	of	the	mitochondrial	marker	cytochrome	C	could	be	seen	in	the	cytosolic	fraction.			
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Figure	5.2	Full	length	SARM	localises	to	mitochondria.	Mitochondrial	(mito)	and	cytosolic	(cyto)	fractions	of	lysed	HEK293T	cells	expressing	GFP-tagged	SARM	(A)	or	GFP-tagged	SARM-TIR	(B)	were	isolated	by	differential	centrifugation.	Protein	content	of	each	fraction	was	resolved	by	SDS-PAGE	and	analysed	by	Western	blot.	Membranes	were	probed	with	anti-GFP	to	indicate	SARM	expression,	anti-GAPDH,	a	cytosolic	marker,	and	anti-cytochrome	C,	a	mitochondrial	marker.	Results	are	representative	of	at	least	two	independent	experiments.		
5.3.2	MyD88	is	localised	to	the	mitochondria		 The	exact	cellular	localisation	of	MyD88	has	not	previously	been	described.	Nishiya	and	colleagues	reported	that	MyD88	appeared	in	condensed	form	in	the	cytoplasm	following	expression	in	HEK293T	cells,	but	were	unable	to	resolve	which	organelle(s)	the	protein	resided	in	(Nishiya	et	al.,	2007).	In	their	experiments,	they	performed	staining	of	endoplasmic	reticulum	(ER),	Golgi	apparatus,	endosomes,	and	lysosomes,	but	could	not	see	any	significant	overlap	with	overexpressed	MyD88	during	microscopy	studies.	However,	no	mitochondrial	staining	was	performed.		 We	wanted	to	see	if	MyD88,	just	like	SARM,	would	localise	to	the	mitochondria	when	expressed	in	HEK293T	cells	and	used	a	GFP-tagged	construct	for	direct	detection	by	fluorescence	microscopy	(Fig.	5.3).	Co-expression	with	V5-tagged	SARM	was	also	performed,	in	order	to	see	if	any	co-localisation	of	the	two	proteins	could	be	seen.	SARM-V5	was	stained	with	α-V5	antibody,	followed	by	fluorescence	staining	with	α-mouse	IgG	Alexa	Fluor	546	
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conjugate.	Similarly	to	previous	studies,	MyD88	appeared	as	condensed	spots	in	the	cytoplasm,	and	the	majority	of	these	appeared	to	localise	to	the	mitochondria.	No	difference	was	seen	when	MyD88	was	co-expressed	with	SARM.	Protein	expression	was	also	performed	in	NIH/3T3	cells	to	see	if	the	localisation	was	easier	to	determine,	but	the	results	were	similar	as	with	HEK293T	cells	(data	not	shown).		
	
Figure	5.3	MyD88	cellular	localisation.	HEK293T	cells	were	transfected	with	plasmids	encoding	GFP-tagged	MyD88	(Top)	or	both	V5-tagged	SARM	and	GFP-tagged	MyD88	(Bottom).	24	hours	post	transfection,	cells	were	treated	with	mitotracker	dye	to	stain	mitochondria,	stained	with	α-V5	antibody	followed	by	secondary	staining	with	Alexa	Fluor	546	conjugated	antibody,	fixed	and	viewed	under	microscope.	All	scale	bars,	10	µm.	Original	magnification	X100.			 Subcellular	fractionation	was	performed	to	see	if	MyD88	could	be	found	in	the	cytosolic	fraction	or	not,	but	the	protein	was	exclusively	seen	in	the	mitochondrial	fraction	(Fig.	5.4),	indicating	that	MyD88	had	localised	to	the	mitochondria	after	expression	in	the	cell.	This	also	means	that	any	cellular	co-localisation	with	SARM	seen	cannot	be	attributed	to	an	interaction	between	the	two	proteins,	as	they	both	appear	to	target	the	same	organelle.			
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Figure	5.4	MyD88	localises	to	mitochondria.	Mitochondrial	(mito)	and	cytosolic	(cyto)	fractions	of	lysed	HEK293T	cells	expressing	either	GFP-tagged	MyD88	alone	(A)	or	V5-tagged	SARM	and	GFP-tagged	MyD88	(B)	were	isolated	by	differential	centrifugation.	Protein	content	of	each	fraction	was	resolved	by	SDS-PAGE	and	analysed	by	Western	blot.	Membranes	were	probed	with	anti-GFP	to	indicate	SARM	expression,	anti-GAPDH,	a	cytosolic	marker,	and	anti-cytochrome	C,	a	mitochondrial	marker.	Results	are	representative	of	at	least	two	independent	experiments.		
5.3.3	SARM	overexpression	suppresses	TLR4-mediated	cytokine	
secretion		 Before	any	SARM	expression	studies	were	conducted	in	HEK-TLR4	cells,	we	wanted	to	ensure	that	the	cells	were	expressing	TLR4	as	expected	and	were	LPS-responsive.	Cells	grown	on	coverslips	in	12-well	plates	were	fixed	in	4%	PFA	and	stained	with	α-TLR4	antibody,	followed	by	secondary	staining	with	an	Alexa	Fluor	488	conjugated	antibody.	After	being	mounted	in	DAPI-containing	mounting	medium,	cells	were	viewed	under	fluorescence	microscope.	As	shown	in	Figure	5.5,	TLR4	was	seen	to	be	expressed	on	the	cellular	membrane	as	expected,	indicating	proper	cellular	localisation	of	the	receptor.				
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Figure	5.5	HEK293	cells	expressing	TLR4.	HEK-TLR4	cells	grown	on	coverslips	were	stained	with	α-TLR4	antibody	followed	by	secondary	staining	with	Alexa	Fluor	488	conjugated	antibody,	fixed	and	viewed	under	microscope.	All	scale	bars,	10	µm.	Original	magnification	X100.		 TLR	activation	triggers	a	chain	of	signalling	events	that	ultimately	results	in	the	release	of	inflammatory	cytokines,	which	is	what	we	used	to	quantify	immune	activation.	Cells	grown	in	24-well	plates	were	stimulated	with	LPS	at	various	concentrations	to	confirm	that	the	TLR4	recognised	the	PAMP,	as	well	as	finding	a	suitable	dose	for	conducting	further	experiments.	Cells	were	stimulated	for	24	hours,	after	which	culture	supernatants	were	probed	for	IL-8	content	by	ELISA.	As	shown	in	Figure	5.6,	a	clear	immune	response	could	be	seen	in	all	treated	cells,	with	a	maximum	response	being	approached	at	a	dose	of	100	ng/mL	LPS,	which	is	also	the	dose	recommended	by	the	manufacturer	for	a	standard	experiment.				
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Figure	5.6	HEK-TLR4	cells	are	LPS	responsive.	HEK-TLR4	cells	were	stimulated	with	increasing	concentrations	of	LPS	for	24	hours.	Cell	supernatants	were	collected	and	analysed	for	IL-8	content	by	ELISA.	Data	represent	means	±	SD	of	three	independent	experiments.			 To	test	if	SARM	expression	was	able	to	suppress	LPS-mediated	immune	signalling	in	HEK-TLR4	cells,	the	cells	were	seeded	in	24-well	plates	and	transfected	with	different	amounts	of	pCDNA-SARM	vector.	24	hours	post-transfection,	cells	were	stimulated	with	100	ng/mL	LPS	for	an	additional	24	hours,	and	ELISA	was	used	to	measure	IL-8,	TNFα,	and	IL-6	content	in	culture	supernatants	(Fig.	5.7).	SARM	expression	was	associated	with	significantly	reduced	secretion	of	inflammatory	cytokines	IL-8	and	TNFα,	although	IL-6	levels	were	below	the	detection	limit	in	all	samples	(<4.7	pg/mL).	These	results	are	consistent	with	previously	published	studies	(Belinda	et	al.,	2008,	Carty	et	al.,	2006,	Peng	et	al.,	2010,	Yuan	et	al.,	2010),	all	showing	that	SARM	suppresses	TLR	signalling	in	a	dose-dependent	manner.	However,	as	TLR4	acts	on	both	the	MyD88-	and	TRIF-dependent	pathways,	it	is	not	possible	to	delineate	which	pathway	SARM	is	acting	on	in	these	experiments.		
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Figure	5.7	SARM	expression	supresses	LPS-mediated	TNFα	and	IL-8	secretion	in	
HEK-TLR4	cells.	HEK-TLR4	cells	were	transfected	with	increasing	amounts	of	pCDNA-SARM	plasmid.	24	hours	post	transfection,	cells	were	stimulated	with	100	ng/mL	LPS	for	an	additional	24	hours.	Cell	supernatants	were	collected	and	analysed	for	IL-8	(A)	and	TNFα	(B)	content.	Data	represent	means	±	SD	of	at	least	three	independent	experiments.	*,	p	<	0.05;	**,	p	<	0.01	compared	with	empty	vector	plus	LPS.				 In	chapter	4,	the	G601A	mutation	in	SARM	was	shown	to	prevent	the	protein	from	interacting	with	TIR	domains	of	other	TLR	adaptor	proteins.	To	evaluate	if	this	mutation	has	any	effect	on	the	protein’s	immunomodulation,	HEK-TLR4	cells	were	transfected	with	increasing	amounts	of	pCDNA-SARM	(G601A)	mutant	vector	and	stimulated	with	100	ng/mL	LPS	for	24	hours.	Interestingly,	expression	of	mutant	SARM	did	not	influence	secretion	of	IL-8	or	TNFα	in	any	direction	(Fig.	5.8),	suggesting	that	an	intact	BB-loop	region	of	SARM	TIR	domain	is	critical	for	immune	suppressive	function.		
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Figure	5.8	SARM	(G601A)	expression	has	no	effect	on	LPS-mediated	TNFα	and	IL-8	
secretion	in	HEK-TLR4	cells.	HEK-TLR4	cells	were	transfected	with	increasing	amounts	of	pCDNA-SARM	(G601A)	mutant	plasmid.	24	hours	post	transfection,	cells	were	stimulated	with	100	ng/mL	LPS	for	an	additional	24	hours.	Cell	supernatants	were	collected	and	analysed	for	IL-8	(A)	and	TNFα	(B)	content.	Data	represent	means	±	SD	of	at	least	three	independent	experiments.			 To	investigate	whether	SARM	was	only	acting	on	TRIF	mediated	signalling,	or	also	MyD88	signalling,	it	was	necessary	to	design	an	experiment	that	selectively	activates	the	MyD88	dependent	pathway.	The	most	direct	way	to	do	this	was	to	simply	induce	an	immune	response	in	the	cell	by	overexpressing	MyD88.	To	ensure	that	this	resulted	in	detectable	secretion	of	IL-8,	HEK-TLR4	cells	were	transfected	with	increasing	amounts	of	MyD88	coding	vector	and	incubated	for	24	or	48	hours,	followed	by	ELISA	analysis	of	culture	supernatants	(Fig.	5.9).	A	clear	increase	of	IL-8	secretion	could	be	seen	in	a	dose-dependent	manner	following	MyD88	expression,	indicating	that	this	assay	could	be	used	to	probe	any	effect	SARM	expression	would	have	on	immune	signalling	via	MyD88.		
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Figure	5.9	MyD88	expression	can	induce	an	innate	immune	response	in	HEK-TLR4	
cells.	HEK-TLR4	cells	were	transfected	with	increasing	amounts	of	pX40-MyD88	vector.	24	(A)	or	48	(B)	hours	post	transfection,	cell	supernatants	were	collected	and	analysed	for	IL-8	content	by	ELISA.	Data	represent	means	±	SD	of	three	independent	experiments.		 HEK-TLR4	cells	were	co-transfected	with	100	ng	MyD88-	and	increasing	amounts	of	SARM-plasmids,	and	incubated	for	48	hours	to	evaluate	if	SARM	expression	could	suppress	secretion	of	inflammatory	cytokines,	IL-8	and	TNFα,	as	well	as	if	any	immunosuppressive	effect	was	retained	in	the	G601A	mutant	SARM	protein.	As	shown	in	Figure	5.10,	SARM	expression	was	associated	with	significantly	reduced	levels	of	IL-8	found	in	cell	supernatants,	while	expression	of	SARM	(G601A)	did	not	seem	to	reduce	cytokine	expression	at	all.			
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Figure	5.10	MyD88	expression	can	induce	an	innate	immune	response	in	HEK-
TLR4	cells.	HEK-TLR4	cells	were	co-transfected	with	100	ng	pX40-MyD88	plasmid	and	increasing	amounts	of	pCDNA-SARM	(A)	or	pCDNA-SARM	(G601A)	(B)	plasmid.	48	hours	post	transfection,	cell	supernatants	were	collected	and	analysed	for	IL-8	content.	Data	represent	means	±	SD	of	at	least	three	independent	experiments.	**,	p	<	0.01	compared	with	MyD88	vector	transfection	alone.		These	results	strongly	suggest	that	SARM	targets	MyD88-dependent	immune	signalling,	although	a	possible	explanation	could	still	be	that	MyD88	expression	is	first	inducing	expression	of	multiple	inflammatory	cytokines,	some	of	which	may	induce	a	feedback	loop	that	engages	TRIF-dependent	signalling,	after	which	SARM	expression	in	turn	downregulates	TRIF-signalling.	As	the	experiments	are	performed	in	a	model	cell	line	that	is	not	natively	immunocompetent,	this	does	not	seem	likely,	but	cannot	be	ruled	out	as	an	explanation	for	the	observed	results	at	this	stage.	In	order	to	fully	conclude	that	SARM	affects	the	release	of	inflammatory	cytokines	following	MyD88-signalling,	experiments	in	a	cell	line	that	exclusively	utilises	MyD88-dependent	signalling	should	be	used.	HEK293	cells	stably	transfected	with	several	different	TLRs	are	available	commercially,	and	since	multiple	TLRs	are	known	to	only	signal	via	this	pathway,	there	are	many	possible	choices	for	selecting	a	model	cell	line	for	this	
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purpose.	One	example	is	the	HEK-TLR2	cells,	which	can	be	specifically	stimulated	with	LTA	to	induce	an	immune	response.		
5.3.4	SARM	overexpression	suppresses	TLR2-mediated	cytokine	
secretion			 The	TLR2	receptor	expressed	in	HEK-TLR2	cells	is	tagged	with	hemagglutinin	(HA)	for	the	purpose	of	simple	detection,	and	before	any	functional	experiments	were	conducted	in	this	cell	line,	cells	were	stained	with	an	α-HA	antibody,	followed	by	secondary	staining	with	α-mouse	IgG	Alexa	Fluor	488	conjugate.	Cells	were	viewed	under	fluorescence	microscope,	and	as	shown	in	Figure	5.11,	TLR2	was	localised	to	the	cell	membrane	as	expected.		
	
Figure	5.11	HEK293	cells	expressing	TLR2.	HEK-TLR2	cells	expressing	HA-tagged	TLR2	were	grown	on	coverslips	and	stained	with	α-HA	antibody	followed	by	secondary	staining	with	Alexa	Fluor	488	conjugated	antibody,	fixed	and	viewed	under	microscope.	All	scale	bars,	10	µm.	Original	magnification	X100.			 HEK-TLR2	cells	grown	in	24-well	plates	were	then	stimulated	with	increasing	concentrations	of	LTA	for	24	hours,	followed	by	probing	the	cell	supernatants	for	IL-8	content	by	ELISA	(Fig.	5.12).	Treatment	with	LTA	was	found	to	induce	IL-8	activation,	although	the	response	was	lower	than	that			measured	for	HEK-TLR4	cells	treated	with	LPS.		
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Figure	5.12	HEK-TLR2	cells	are	LTA	responsive.	HEK-TLR2	cells	were	stimulated	with	increasing	concentrations	of	LTA	for	24	hours.	Cell	supernatants	were	collected	and	analysed	for	IL-8	content	by	ELISA.	Data	represent	means	±	SD	of	three	independent	experiments.			 To	test	if	SARM	expression	could	selectively	suppress	MyD88	mediated	immune	signalling,	and	if	any	observed	effect	was	dependent	on	an	intact	BB-loop	motif,	HEK-TLR2	cells	were	transfected	with	various	amounts	of	pCDNA-SARM	or	pCDNA-SARM	(G601A)	plasmids.	At	24	hours	post-transfection,	cells	were	stimulated	with	1000	ng/mL	LTA	to	induce	TLR2	activation,	and	cell	supernatants	were	collected	and	analysed	by	ELISA	for	IL-8	content	(Fig.	5.13).	TNFα	content	was	also	investigated,	but	the	levels	in	all	samples	were	below	the	detection	limit	(data	not	shown).			
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Figure	5.13	SARM	expression	supresses	LTA-mediated	IL-8	secretion	in	HEK-TLR2	
cells.	HEK-TLR2	cells	were	transfected	with	increasing	amounts	of	pCDNA-SARM	(A)	or	pCDNA-SARM	(G601A)	(B)	plasmid.	24	hours	post	transfection,	cells	were	stimulated	with	1000	ng/mL	LTA	for	an	additional	24	hours.	Cell	supernatants	were	collected	and	analysed	for	IL-8	content.	Data	represent	means	±	SD	of	at	least	three	independent	experiments.	*,	p	<	0.05	compared	with	empty	vector	plus	LTA.			
5.3.5	Cell	viability	assay		 Although	a	decrease	in	the	absolute	amounts	of	inflammatory	cytokines	detected	in	the	cell	culture	media	is	certainly	a	strong	indicator	of	an	anti-inflammatory	effect,	a	problem	with	this	type	of	assay	is	that	it	is	not	normalised	to	the	absolute	number	of	healthy	cells.	If	SARM	expression	also	results	in	a	significant	decrease	of	viable	cells,	similar	results	would	be	observed	as	shown	above.	In	order	to	rule	out	this	possibility,	MTT	cell	viability	assays	were	conducted.	This	assay	utilises	the	ability	of	healthy	and	metabolically	active	cells	to	reduce	MTT	tetrazolium	salt	into	dark	insoluble	formazan	crystals.	The	amount	of	crystals	formed	is	correlated	to	the	number	of	viable	cells	present	in	the	well,	and	after	the	crystals	are	dissolved,	quantitation	by	spectrophotometric	measurement	can	be	performed.	As	shown	in	Figure	5.14,	overexpression	of	both	SARM	and	the	SARM	(G601A)	mutant	resulted	in	a	slight	reduction	of	overall	cell	viability,	but	there	was	no	difference	between	the	two	different	
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proteins.	This	demonstrates	that	the	differences	in	secreted	levels	of	inflammatory	cytokines	detected	in	the	response	to	LPS	and	LTA	are	not	due	to	reduced	viability	of	cells	transfected	with	plasmid	coding	for	WT	SARM.	In	addition,	no	dose	dependent	effect	from	the	amount	of	plasmid	transfected	were	observed.		
	
Figure	5.14	MTT	cell	viability	assay	of	HEK293T	cells	expressing	SARM	or	SARM	
(G601A).	HEK-TLR4	cells	were	transfected	with	increasing	amounts	of	pCDNA-SARM	(A)	or	pCDNA-SARM	(G601A)	(B)	plasmid	and	incubated	for	24	hours.	Cells	were	treated	with	MTT	dye	for	4	hours	and	formazan	crystals	were	solubilised	overnight.	Overall	cell	viability	was	quantified	by	measuring	the	absorbance	at	590	nm.	Data	represent	means	±	SD	of	three	independent	experiments.		
5.3.6	SARM	overexpression	induces	apoptosis	in	HEK293T	cells		 SARM	expression	has	previously	been	shown	to	play	a	role	in	programmed	cell	death	(Gerdts	et	al.,	2015,	Gerdts	et	al.,	2013,	Osterloh	et	al.,	2012,	Panneerselvam	et	al.,	2012a,	Panneerselvam	et	al.,	2012b),	so	we	wanted	to	investigate	whether	the	G601A	mutation	in	the	SARM	TIR	domain	BB-loop	had	any	effect	on	the	protein’s	pro-apoptotic	functionality.	HEK293T	cells	were	used	as	a	model	cell	line	for	these	experiments,	which	is	the	same	cell	line	used	by	Panneerselvam	and	colleagues	in	their	studies	from	2012.	
	 177	
	 Early	stage	apoptosis	was	measured	by	staining	cells	with	Annexin	V.	This	is	a	phospholipid-binding	protein	that	preferentially	binds	to	phosphatidylserine	(PS)	(Andree	et	al.,	1990,	Tait	et	al.,	1989),	which	during	the	early	stages	of	apoptosis	translocate	to	the	extracellular	membrane	(Fadok	et	al.,	1992).	This	change	is	performed	in	order	to	expose	a	motif	recognised	by	macrophages,	thus	making	the	cell	a	target	for	phagocytosis,	and	can	be	monitored	by	flow	cytometry	(Koopman	et	al.,	1994,	Vermes	et	al.,	1995).	To	differentiate	these	cells	from	those	in	the	later	stages	of	apoptosis,	cells	were	also	stained	with	7-AAD,	a	general	purpose	viability	dye	that	binds	to	DNA	(Modest	and	Sengupta,	1974)	and	is	unable	to	penetrate	the	cellular	membrane	during	early	stage	apoptosis,	but	gets	through	as	the	integrity	of	the	membrane	is	lost	during	the	later	stages	(Schmid	et	al.,	1992).	For	a	positive	control,	cells	were	treated	for	12	hours	with	1	µg/mL	actinomycin	D,	a	well-known	inducer	of	apoptosis	in	multiple	cell	lines	(Kleeff	et	al.,	2000,	Leist	et	al.,	1994,	Martin	et	al.,	1990).		 HEK293T	cells	grown	in	6-well	plates	were	transfected	with	2	µg	pCDNA-SARM	or	pCDNA-SARM	(G601A)	for	up	to	48	hours,	followed	by	staining	with	Annexin	V	and	7-AAD.	Cells	that	were	either	non-transfected	or	transfected	with	empty	pCDNA	vector	were	used	as	negative	controls.	Consistent	with	previous	studies,	SARM	expression	was	associated	with	an	increase	of	both	early	and	late	stage	apoptotic	cells	(Fig.	5.15),	compared	with	cells	transfected	with	an	empty	vector	control.	The	G601A	mutation	had	no	significant	effect	on	SARM’s	pro-apoptotic	potential,	indicating	that	the	SARM	TIR-domain	BB-loop	motif	may	not	be	critical	for	inducing	apoptosis.			
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Figure	5.15	SARM	expression	induces	apoptosis	in	HEK293T	cells.	HEK293T	cells	were	transfected	with	indicated	plasmid	and	incubated	for	up	to	48	hours,	stained	with	Annexin	V	and	7-AAD,	followed	by	analysis	by	FACS.	(A)	Dot	plots	indicate	a	larger	proportion	of	both	early	and	late	stage	apoptotic	cells	48	hours	post	transfection	when	transfected	with	pCDNA-SARM	and	pCDNA-SARM	(G601A),	compared	with	empty	pCDNA	plasmid.	Plots	are	representative	of	three	independent	experiments.	(B)	Statistical	analysis	of	three	independent	experiments.	Quadrants	plotted	are	indicated	above	diagrams.	Data	represent	means	±	SD.	*,	p	<	0.05;	**,	p	<	0.01	compared	with	transfection	with	empty	vector.	NT,	non-transfected;	EV,	empty	vector.		
5.3.7	Differentiated	U937	cells	are	difficult	to	transfect	when	
using	standard	transfection	reagents		 Although	model	cell	lines	such	as	HEK293	are	excellent	to	use	for	performing	experiments	in	a	simplified	cellular	environment,	results	would	be	
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even	more	convincing	if	generated	in	a	fully	immunocompetent	cell	line.	U937	cells	are	known	to	differentiate	into	macrophage-like	cells	as	a	response	to	stimulation	with	PMA	(Gidlund	et	al.,	1981),	making	them	an	attractive	system	for	performing	immune	related	experiments.	It	is	also	known	that	U937	cells	respond	to	stimulation	by	LPS	(Aderka	et	al.,	1989)	and	other	PAMPs	(Nakagawa	et	al.,	2002)	by	increased	secretion	of	proinflammatory	cytokines.	However,	it	is	also	well	known	that	these	cells	are	associated	with	low	transfection	efficiencies	using	standard	transfection	techniques	(Martinet	et	al.,	2003,	Tietz	and	Berghoff,	2012),	making	overexpression	studies	technically	challenging.		To	test	if	SARM	plasmid	transfection	was	feasible	in	this	cell	line,	differentiated	U937	cells	were	grown	on	coverslips	in	12-well	plates	and	transfected	with	1	µg	pEGFP-SARM	plasmid	for	24	hours,	followed	by	either	analysis	by	fluorescence	microscopy	(Fig.	5.16)	or	Western	blot	analysis	of	cell	lysates	(Fig.	5.17).	None	of	the	four	transfection	reagents	used	(Lipofectamine	2000,	Lipofectamine	3000,	TurboFect	transfection	reagent,	and	X-tremeGENE	HP	DNA	transfection	reagent)	yielded	any	useful	levels	of	protein	expression.	No	protein	expression	could	be	detected	by	Western	blot,	and	only	sporadic	cells	(<1%)	expressing	GFP-SARM	could	be	seen	under	fluorescence	microscope.	Optimisation	of	transfection	parameters	such	as	amounts	of	transfection	reagent,	amounts	of	plasmid	used,	and	transfection	time	were	attempted,	but	no	significant	improvements	could	be	seen.	As	SARM	protein	expression	could	not	be	induced,	no	overexpression	experiments	were	conducted	in	this	cell	line.		
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Figure	5.16	Fluorescence	microscopy	analysis	of	U937	cells	transfected	with	GFP-
SARM	plasmid.	U937	cells	differentiated	with	30	ng/mL	PMA	for	24	hours	were	transfected	with	plasmid	encoding	for	GFP-tagged	SARM	(green)	using	Turbofect	(A),	Lipofectamine	2000	(B),	Lipofectamine	3000	(C),	or	X-tremeGENE	HP	(D).	24	hours	post	transfection,	cells	were	fixed	and	viewed	under	microscope.	All	scale	bars,	100	µm.	Original	magnification	X10.	
	
Figure	5.17	Western	blot	analysis	of	U937	cells	transfected	with	GFP-SARM	
plasmid.	U937	cells	differentiated	with	30	ng/mL	PMA	for	24	hours	were	transfected	with	plasmid	encoding	for	GFP-tagged	SARM	using	indicated	transfection	reagents.	24	hours	post	transfection,	cells	were	lysed	and	protein	content	was	analysed	by	Western	blot	using	an	α-GFP	primary	antibody	or	α-actin	antibody	for	loading	control.			
	 181	
5.3.8	Cellular	uptake	of	ANTP-tagged	peptide	derived	from	
SARM	BB-loop	sequence		 During	the	interaction	studies	presented	in	chapter	4,	a	peptide	based	on	the	BB-loop	motif	in	the	SARM	TIR	domain	was	able	to	interact	with	MyD88-TIR.	We	wanted	to	test	whether	this	small	peptide	had	any	immune	suppressive	effect	on	mammalian	cells,	but	as	cellular	expression	of	small	peptides	is	typically	difficult	to	induce,	a	delivery	system	was	needed	to	transport	the	peptide	across	the	cell	membrane.		 A	peptide	based	on	the	SARM	BB-loop	sequence	fused	with	the	cell	penetrating	sequence	from	the	Antennapedia	homeodomain	(ANTP)	was	generated,	C-terminally	tagged	with	rhodamine	for	ease	of	detection.	A	study	by	Jones	and	colleagues	have	indicated	that	unlabelled	ANTP	peptide	has	a	lower	cytotoxic	effect	on	host	cells	than	other	common	cell	penetrating	peptides,	such	as	TAT,	transportan	and	polyarginine	(Jones	et	al.,	2005),	although	labelling	with	rhodamine	was	also	associated	with	a	noticeable	decrease	in	cell	viability.	To	determine	an	acceptable	concentration	of	ANTP-SARM-BB	to	use	in	cell	based	assays,	HEK293T	cells	were	exposed	to	the	peptide	at	increasing	concentrations	for	24	hours,	followed	by	measuring	the	overall	cell	viability	by	MTT	assay.	As	shown	in	Figure	5.18,	a	dose	dependent	cytotoxic	effect	was	seen,	but	the	overall	viability	remained	high	for	cells	treated	with	10	µM	peptide	or	less.	These	results	are	consistent	with	those	obtained	by	Jones	and	colleagues,	where	EC50	of	a	rhodamine	labelled	ANTP	peptide	was	estimated	to	be	around	10-20	µM	when	HeLa,	CHO	and	A549	were	treated	for	30	minutes	(Jones	et	al.,	2005).		
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Figure	5.18	MTT	assay	of	HEK293T	cells	stimulated	with	ANTP-SARM-BB.	HEK293T	cells	were	exposed	to	ANTP-SARM-BB	peptide	at	indicated	concentrations	for	24	hours,	followed	by	cell	viability	estimation	by	MTT	assay.	Data	represent	means	±	SD	of	three	independent	experiments.			 To	determine	how	fast	the	ANTP-SARM-BB	peptide	crosses	the	HEK293T	cell	membrane,	cells	were	exposed	to	the	peptide	for	0.5,	1,	2	and	4	hours,	followed	by	analysis	by	fluorescence	microscope.	As	shown	in	Figure	5.19,	the	rhodamine-labelled	peptide	could	be	seen	in	the	cytosol	after	just	30	minutes,	indicating	that	the	transport	over	the	membrane	was	very	fast	and	not	likely	to	be	a	limiting	factor	for	further	analyses.		
	 183	
	
Figure	5.19	ANTP-SARM-BB	crosses	the	HEK293T	cell	membrane.	HEK293T	cells	were	treated	with	10	µM	of	rhodamine-labelled	ANTP-SARM-BB	peptide	for	indicated	durations,	followed	by	fixing	of	cells	and	analysis	by	fluorescence	microscopy.	All	scale	bars,	10	µm.	Original	magnification	X100.			 Cells	expressing	GFP-tagged	MyD88	were	also	treated	with	the	SARM	BB-loop	peptide	in	order	to	evaluate	whether	the	peptide	targets	MyD88	in	the	cell.	Previous	results	presented	in	chapter	4	indicated	that	the	SARM	BB-loop	peptide	interacts	with	the	MyD88	TIR	in	vitro.	As	shown	in	Figure	5.20,	we	could	observe	an	overlap	between	the	rhodamine	labelled	ANTP-SARM-BB	and	GFP-tagged	MyD88	after	overnight	incubation,	indicating	that	the	SARM	BB-loop	targets	MyD88	in	a	cellular	environment.	
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Figure	5.20	ANTP-SARM-BB	co-localises	with	GFP-MyD88.	HEK293T	cells	were	transfected	with	plasmid	encoding	for	GFP-tagged	MyD88.	24	hours	post	transfection,	cells	were	treated	with	10	µM	rhodamine	tagged	ANTP-SARM-BB	peptide	for	30	minutes.	Cells	were	fixed	and	viewed	under	fluorescence	microscope.	All	scale	bars,	10	µm.	Original	magnification	X100.		
5.3.9	SARM	BB-loop	peptide	has	a	mild	inhibitory	effect	on	LPS	
mediated	cytokine	activation	in	HEK-TLR4	cells		 Finally,	we	sought	to	determine	whether	the	SARM	BB-loop	peptide	would	be	able	to	suppress	TLR-mediated	immune	activation.	HEK	cells	expressing	either	TLR2	or	TLR4	were	treated	with	increasing	concentrations	of	ANTP-SARM-BB	peptide	for	30	min,	after	which	the	cells	were	washed	in	PBS	and	incubated	with	culture	media	supplemented	with	either	100	ng/mL	LPS	or	1000	ng/mL	LTA.	The	following	day,	cell	supernatants	were	collected	and	analysed	for	IL-8	content	by	ELISA	(Fig.	5.21).	HEK-TLR4	cells	showed	a	slight	but	significant	decrease	in	IL-8	secretion	when	treated	with	5	µM	or	more	ANTP-SARM-BB.	It	is	possible	that	the	concentrations	used	were	not	high	enough	to	induce	a	potent	immune-suppressive	effect.	HEK-TLR2	cells	also	displayed	slightly	reduced	IL-8	levels	after	peptide	treatment,	but	the	differences	were	not	statistically	significant.	
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Figure	5.21	ANTP-SARM-BB	stimulation	of	HEK-TLR4	cells	reduces	LPS-mediated	
IL-8	activation.	HEK-TLR4	(A)	or	HEK-TLR2	(B)	cells	were	treated	with	increasing	concentrations	of	ANTP-SARM-BB	peptide	for	30	minutes,	followed	by	stimulation	with	either	100	ng/mL	LPS	or	1000	ng/mL	LTA	for	an	additional	24	hours.	Cell	supernatants	were	collected	and	analysed	for	IL8-content.	Data	represent	means	±	SD	of	at	least	three	independent	experiments.	*,	p	<	0.05	compared	with	cells	only	treated	with	corresponding	PAMP.			
5.4	Discussion		 The	main	purpose	of	the	experiments	presented	in	this	chapter	was	to	evaluate	whether	SARM	was	acting	exclusively	on	the	TRIF	dependent	TLR	signalling	pathway,	and	if	the	G601A	mutation	in	the	SARM	BB-loop	would	lead	to	a	reduction	of	immunosuppressive	effect.		Instead	of	quantitating	gene	expression	by	measuring	cellular	mRNA	levels,	we	have	used	the	actual	cumulative	secretion	of	certain	key	inflammatory	cytokines	for	evaluating	the	anti-inflammatory	effects	of	SARM.	The	benefit	of	doing	this	is	that	it	is	well	known	that	mRNA	levels	do	not	always	correlate	well	with	actual	gene	expression	(Vogel	and	Marcotte,	2012).	The	downside	of	this	approach	is	that	we	do	not	obtain	any	mechanistic	information	on	the	exact	genes	that	are	up-	or	downregulated	in	response	to	SARM	expression.	IL-8	was	the	main	cytokine	measured	in	this	study,	as	it	is	a	key	inflammatory	cytokine	expressed	in	a	wide	range	of	tissues	(Bickel,	1993)	and	has	been	suggested	as	a	
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biomarker	for	multiple	inflammatory	diseases	such	as	osteomyelitis	(Gratz	et	al.,	2001a),	IBD	(Gratz	et	al.,	2001b),	chorioamnionitis	(Shimoya	et	al.,	1992),	pyelonephritis	(Sheu	et	al.,	2006)	and	nosocomial	bacterial	infection	(Franz	et	al.,	1999).		The	results	presented	here	consistently	showed	that	MyD88-dependent	TLR	signalling	was	downregulated	by	SARM,	as	SARM	over-expression	was	able	to	reduce	both	TLR2-	and	TLR4-mediated	activation	of	IL-8.	The	G601A	mutation	in	the	SARM	BB-loop	resulted	in	a	completely	abolished	ability	to	suppress	both	TLR2-	and	TLR4-induced	immune	activation.	As	discussed	in	chapter	1,	this	motif	has	previously	been	described	as	functionally	important	in	multiple	TIR	domain	proteins.	A	small	peptide	derived	from	this	motif	was	also	able	to	slightly	suppress	LPS	induced	IL-8	activation	in	HEK-TLR4	cells.	However,	the	reduction	was	only	minor	and	it	is	difficult	to	attribute	this	to	an	immunosuppressive	effect,	as	the	peptide	was	also	found	to	have	a	mild	cytotoxic	effect	on	the	host	cell.	In	future,	this	assay	may	need	to	be	performed	in	an	immune	responsive	cell.	 While	TLR-mediated	immune	activation	resulted	in	robust	IL-8	production	in	the	results	presented	here,	we	were	surprised	to	see	that	the	amounts	of	TNFα	released	from	cells	consistently	appeared	to	be	very	low.	We	do	not	know	the	precise	reason	for	this,	but	the	issue	was	present	with	all	cell	lines	used	in	this	study.	Given	that	IL-8	could	be	detected	in	the	cell	supernatants	without	difficulty,	immune	activation	was	clearly	successful.	It	should	be	noted	that	production	of	IL-8	and	TNFα	follows	different	signal	transduction	pathways	(Foreback	et	al.,	1998,	Patrone	et	al.,	2006),	which	hypothetically	could	explain	the	uneven	response.	However,	a	more	likely	explanation	is	that	the	low	TNFα	
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levels	detected	were	due	to	problems	with	the	specific	assay	conditions	or	sample	handling.	It	is	known	that	cytokines	are	not	very	stable	in	solution	(Flower	et	al.,	2000,	Friebe	and	Volk,	2008),	and	degradation	of	TNFα	between	cellular	secretion	and	analysis	by	ELISA	is	a	possibility.	During	cytokine	quantitation	by	ELISA,	the	standard	curves	used	were	based	on	measurements	using	recombinant	protein,	so	differences	in	antibody	affinity	against	recombinant	and	natural	TNFα	could	also	hypothetically	have	played	a	role.		As	both	cytokine	secretion	and	cell	viability	were	analysed	here,	the	argument	for	normalising	the	amounts	of	cytokines	against	the	number	of	viable	cells	could	be	made.	A	problem	with	this	adjustment	would	be	that	only	endpoint	measurements	of	supernatant	cytokine	levels	and	cell	viability	were	made,	usually	after	24	hours	of	incubation.	While	it	is	known	that	TLR	PAMP	stimulation	typically	results	in	a	fast	activation	and	release	of	cytokines	(Reimer	et	al.,	2008),	the	exact	dynamics	of	SARM-induced	apoptosis	is	not	known.	Regardless,	data	presented	here	could	have	been	improved	with	the	addition	of	more	detailed	time-course	measurements	of	both	cytokine	activation	and	cellular	apoptosis.		 	
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Chapter	6		
The	cellular	functions	of	BaTdp	
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6.1	Introduction	In	chapter	4,	GST	pull-down	assay	was	used	to	demonstrate	that	the	TIR	domain	of	BaTdp	was	able	to	interact	with	the	TIR	domains	of	multiple	human	TLR	adaptor	proteins,	including	MyD88.	In	this	chapter,	cell-based	assays	were	used	to	investigate	whether	BaTdp	would	target	MyD88	when	overexpressed	in	human	cells,	and	whether	BaTdp	is	able	to	suppress	TLR	signalling.		The	data	presented	here	does	not	support	BaTdp	acting	on	TLR-signalling.	However,	we	were	able	to	identify	a	possible	connection	between	BaTdp	expression	and	cellular	autophagy.		
6.2	Materials	and	methods	The	materials	and	methods	used	for	studying	cellular	localisation,	PAMP-induced	cytokine	secretion,	cellular	viability	and	apoptosis,	as	well	as	the	statistical	analysis	presented	in	this	chapter	are	all	as	previously	described	in	chapter	5.			
6.2.1	General	reagents	and	antibodies		 Polyclonal	rabbit	antibody	to	Microtubule-associated	protein	1A/1B-light	chain	3	B	(α-LC3B)	was	from	Cell	Signaling	Technology.	Polyclonal	rabbit	antibody	to	α-β	tubulin	was	from	Santa	Cruz	Biotechnology.		
6.2.2	Generation	of	mammalian	expression	constructs		 Mammalian	expression	plasmids	were	generated	using	identical	methodology	as	described	in	section	3.2.1	with	the	primers	listed	in	Table	6.1.	
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pCDNA-BaTdp	vector	was	obtained	from	Dr.	Abigail	Spear,	DSTL.	Site-directed	mutagenesis	was	performed	as	described	in	section	3.2.2	using	oligonucleotide	primers	(Eurofins	MWG	Operon)	BaTdp_G164A_F	(Fw)	5’-GGAAGCTAATGAAGCGTTAACAGTTCTTG-3’	and	BaTdp_G164A_R	(Rev)	5’-CAAGAACTGTTAACGCTTCATTAGCTTCC-3’.	The	underlined	bases	indicate	the	mutagenesis	site.	Mutagenesis	was	confirmed	by	DNA	sequencing.	The	G164	residue	of	BaTdp	corresponds	to	the	G601	residue	of	human	SARM.		
Table	6.1	Primers	used	for	BaTdp	plasmid	cloning.	
Construct	 Residues	 Nucleotide	sequence	(5’-3’)	 Vector	
GFP-BaTdp	 1-273	 GATCAAGCTTCGATGTATTATCATATTAG	
GATCGGTACCTTAATACGTAACTTTTAATCC	
pEGFP-C1	
BaTdp-FLAG	 1-273	 GATCAAGCTTATGTATTATCATATTAGAATTAA	
GATCGGTACCTTAATACGTAACTTTTAATCC		
pXJ40-FLAG	Underlined	sequences,	AAGCTT	and	GGTACC,	correspond	to	restriction	sites	HindIII	and	KpnI,	respectively.		
6.2.3	Measurement	of	autophagy		 The	protocol	for	measuring	autophagy	in	cells	was	adapted	from	(Harris	et	al.,	2009).	HEK293	cells	were	seeded	in	6-well	plates	at	5	x	105	cells	per	well	24	hours	before	transfection.	At	24	or	48	hours	post-transfection,	cells	were	washed	in	PBS	and	then	harvested	and	lysed	in	PBS	with	1%	SDS	at	RT	for	30	min	under	mild	agitation,	followed	by	boiling	at	95°C	for	10	min.	The	lysate	was	then	mixed	1:1	with	2X	SDS	loading	buffer,	further	boiled	at	95°C	for	5	min,	and	analysed	by	Western	blot	using	a	rabbit	polyclonal	α-LC3B	antibody.	Autophagy	was	followed	through	the	conversion	of	cytosolic	LC3-I	to	LC3-II,	the	latter	running	slightly	faster	during	separation	by	SDS-PAGE.	Cells	were	incubated	at	
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37°C	for	up	to	4	hours,	after	which	they	were	washed	twice	in	chilled	PBS,	and	analysed	for	LC3-II	content	by	Western	blot	as	described	above.		
6.3	Results	
6.3.1	BaTdp	co-localises	with	tubular	networks		 From	chapter	5,	we	observed	that	both	SARM	and	MyD88	appear	to	localise	to	cellular	mitochondria	when	expressed	in	mammalian	cells,	so	we	speculated	that	BaTdp	might	do	the	same.	To	study	the	cellular	localisation	of	BaTdp	expressed	in	mammalian	cells,	HEK	cells	grown	on	coverslips	in	12-well	plates	were	transfected	with	1	µg	pEGFP-BaTdp	and	pXJ40-FLAG-MyD88	using	Turbofect	reagent.	24	hours	post	transfection,	cells	were	washed	and	stained	with	mitotracker	dye,	followed	by	fixation	with	4%	PFA	and	mounting	on	microscopy	slides	in	DAPI-containing	mounting	medium.	As	shown	in	Figure	
6.1,	no	obvious	mitochondrial	localisation	was	observed	when	cells	were	viewed	under	fluorescence	microscope.		
	
Figure	6.1	BaTdp,	unlike	SARM,	does	not	localise	to	mitochondria.	HEK-TLR4	cells	were	co-transfected	with	plasmids	encoding	GFP-tagged	BaTdp	or	FLAG-tagged	MyD88.	After	24	h,	cells	were	treated	with	mitotracker	dye	to	stain	mitochondria	and	DAPI	to	stain	cell	nuclei,	followed	by	visualisation	using	fluorescence	microscopy.	All	scale	bars,	10	µm.	Original	magnification	X100.		 	
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The	protein	did	not	localise	in	a	similar	pattern	to	either	SARM	or	MyD88,	but	rather	it	localised	into	a	discrete	cytosolic	network	forming	patterns,	particularly	near	the	cell	membrane.	In	a	study	on	the	Brucella	encoded	Tdp	TcpB	by	Radhakrishnan	and	colleagues,	TcpB	was	found	to	co-localise	with	both	microtubules	and	the	plasma	membrane	(Radhakrishnan	et	al.,	2009),	prompting	us	to	investigate	whether	BaTdp	was	doing	the	same	here.	Microscopy	analysis	of	HEK-TLR4	cells	expressing	GFP-BaTdp	that	were	stained	with	α-β	tubulin	and	fluorescent	secondary	antibody	(Fig.	6.2)	revealed	a	clear	overlap	of	BaTdp	and	tubulin,	suggesting	that	BaTdp	targets	cytoskeletal	networks	when	expressed	in	mammalian	cells.	Radhakrishnan	and	colleagues	reported	a	noticeable	shrinkage	and	rounding	of	cells	following	TcpB	expression	in	HEK-cells	(Radhakrishnan	et	al.,	2009),	suggesting	a	cytotoxic	effect,	but	we	did	not	see	such	similar	morphological	changes	in	HEK	cells	following	BaTdp	expression.	
	
Figure	6.2	BaTdp	co-localise	with	tubulin.	HEK-TLR4	cells	were	transfected	with	plasmid	encoding	GFP-tagged	BaTdp.	After	24	h,	cells	were	stained	with	α-β	tubulin	antibody,	followed	by	secondary	staining	with	α-rabbit	IgG	Alexa	Fluor	568	conjugate	secondary	antibody	and	treatment	with	DAPI	to	stain	cell	nuclei.	Figure	shows	two	representative	cells.	All	scale	bars,	10	µm.	Original	magnification	X100.			
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6.3.2	BaTdp	expression	results	in	mild	reduction	of	cell	viability		 The	overall	cell	viability	of	HEK	cells,	expressing	BaTdp,	was	determined	by	MTT	cell	viability	assay.	Cells	were	grown	in	96-well	plates	and	transfected	with	increasing	amounts	of	pCDNA-BaTdp,	pCDNA-BaTdp	(G164A)	or	empty	pCDNA	vector	as	control	and	treated	with	MTT	reagent	for	four	hours	at	indicated	time	points,	followed	by	dissolving	the	formazan	crystals	in	10%	SDS,	10	mM	HCl	over	night.	Cell	viability	was	quantitated	by	reading	the	absorbance	at	590	nm	using	a	microplate	reader.	As	shown	in	Figure	6.3,	the	expression	of	BaTdp	was	associated	with	a	slight	but	not	significant	decrease	of	viable	cells,	compared	to	control	cells.			
	
Figure	6.3	MTT	cell	viability	assay	of	HEK293T	cells	expressing	BaTdp	or	BaTdp	
(G164A).	HEK293T	cells	were	transfected	with	plasmids	coding	for	either	WT	BaTdp	(A)	or	BaTdp	(G164A)	(B)	and	treated	with	MTT	dye	to	quantify	overall	cell	viability.	Formazan	crystals	were	solubilised	overnight	and	the	cell	viability	was	assessed	by	measuring	absorbance	at	590	nm.	Data	represent	the	means	±	SD	of	three	independent	experiments.		
6.3.3	BaTdp	expression	does	not	induce	cellular	apoptosis		 We	also	wanted	to	test	whether	BaTdp	expression	would	induce	apoptosis	in	mammalian	cells,	as	previously	shown	with	SARM	expression	in	chapter	5.	HEK293T	cells	were	transfected	with	pCDNA	vectors	coding	for	either	
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WT	BaTdp	or	G164A	mutant	protein,	as	well	as	empty	vector	as	a	negative	control.	As	shown	in	Figure	6.4,	there	was	no	indication	of	BaTdp	expression	being	associated	with	a	change	in	apoptotic	marker	Annexin	V,	suggesting	that	the	protein	is	not	pro-apoptotic.		
	
Figure	6.4	BaTdp	expression	does	not	induce	cellular	apoptosis.	HEK293T	cells	were	transfected	with	pCDNA-BaTdp	or	pCDNA-BaTdp	(G164A)	plasmids	and	double-stained	with	Annexin	V	and	7-AAD	24	or	48	hours	post	transfection,	followed	by	FACS	analysis	(A).	Dot	plots	are	representative	of	three	independent	experiments.	(B)	Statistical	analysis	of	three	independent	experiments.	Data	represent	the	means	±	SD.	NT,	non-transfected;	EV,	empty	vector.		
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6.3.4	BaTdp	expression	did	not	inhibit	LPS-mediated	cytokine	
activation	in	HEK-TLR4	cells		 As	shown	in	chapter	4,	the	BaTdp	TIR	domain	specifically	interacted	with	multiple	TLR	adaptor	proteins	in	vitro,	including	the	key	adaptor	MyD88.	This	may	be	an	indication	that	BaTdp	expression	in	mammalian	cells	would	disrupt	TLR-mediated	signalling.	To	evaluate	whether	BaTdp	expression	had	any	effect	on	the	activation	of	inflammatory	cytokines	in	HEK-TLR4	cells	following	LPS	stimulation,	cells	were	seeded	in	24-well	plates	and	transfected	with	various	amounts	of	pCDNA-BaTdp.	24	hours	post	transfection,	cells	were	stimulated	with	100	ng/mL	LPS	for	an	additional	24	hours,	followed	by	quantification	of	IL-8	and	TNFα	in	the	cell	supernatants	by	ELISA.	IL-6	content	was	also	quantified,	but	the	concentrations	were	below	the	detection	limit	in	all	samples	(data	not	shown).		 As	shown	in	Figure	6.5,	BaTdp	expression	had	no	apparent	effect	on	cellular	secretion	of	IL-8	or	TNFα.	This	is	in	contrast	to	SARM	expression,	which	efficiently	suppressed	LPS-mediated	activation	of	both	IL-8	and	TNFα,	and	further	suggests	that	unlike	SARM,	BaTdp	may	not	have	an	anti-inflammatory	effect	on	host	cells.	Furthermore,	the	G164A	mutation	in	the	predicted	BaTdp	BB-loop	region	did	not	affect	the	result	in	any	way.		
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Figure	6.5	BaTdp	expression	has	no	effect	on	LPS-mediated	TNFα	and	IL-8	
secretion	in	HEK-TLR4	cells.	HEK-TLR4	cells	were	transfected	with	increasing	amounts	of	pCDNA-BaTdp	(A)	or	pCDNA-BaTdp	(G164A)	(B)	plasmid.	24	hours	post	transfection,	cells	were	stimulated	with	100	ng/mL	LPS	for	an	additional	24	hours.	Cell	supernatants	were	collected	and	analysed	for	IL-8	and	TNFα	content.	Data	represent	means	±	SD	of	at	least	three	independent	experiments.			 From	the	results	shown	above,	it	would	appear	that	BaTdp	does	not	affect	TLR-mediated	immune	activation,	but	the	lack	of	effect	may	have	been	due	to	the	choice	of	receptor	used	for	immune	activation.	The	reason	for	using	HEK-TLR4	as	a	model	cell	line	is	that	TLR4	is	the	only	human	TLR	known	to	utilise	both	MyD88-	and	TRIF-mediated	signalling.	However,	the	PAMP	it	recognises	is	LPS,	which	B.	anthracis,	a	Gram-positive	bacterium,	does	not	express.	As	mentioned	in	section	1.4.7,	TLR4	also	recognises	anthrolysin	O,	expressed	by	B.	anthracis,	but	this	may	be	a	minor	mechanism	for	pathogen	detection	in	this	case.	To	ensure	
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that	the	inability	for	BaTdp	to	reduce	host	cell	secretion	of	inflammatory	cytokines	was	not	a	receptor-specific	effect,	we	further	decided	to	conduct	a	similar	experiment	using	HEK-TLR2	cells.		
6.3.5	BaTdp	expression	has	no	effect	on	cytokine	secretion	in	
HEK-TLR2	cells		 LTA	expressed	on	cellular	membranes	of	Gram-positive	bacteria	such	as	
B.	anthracis	is	one	of	the	main	PAMPs	recognised	by	TLR2,	which	makes	HEK-TLR2	a	well-suited	cell	line	to	study	any	suppressive	effect	BaTdp	may	have	on	TLR	mediated	immune	activation.	Although	this	receptor	only	signals	via	the	MyD88	dependent	pathway,	our	data	indicate	that	the	BaTdp	TIR	domain	interacts	specifically	with	MyD88-TIR	(section	4.3.3),	which	may	constitute	a	mechanism	of	action.		 HEK-TLR2	cells	were	grown	in	24-well	plates	and	transfected	with	increasing	amounts	of	plasmid	encoding	for	BaTdp,	as	well	as	G164A	mutant	protein,	and	incubated	for	24	hours	followed	by	stimulation	with	1000	ng/mL	LTA	for	an	additional	24	hours.	Secreted	amounts	of	IL-8	in	culture	supernatants	were	then	analysed	by	ELISA	(Fig.	6.6).	TNFα	levels	were	also	analysed,	but	results	suggested	that	the	content	was	below	the	detection	limit	(data	not	shown).		
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Figure	6.6	BaTdp	expression	has	no	effect	on	LTA-mediated	IL-8	secretion	in	HEK-
TLR2	cells.	HEK-TLR2	cells	were	transfected	with	increasing	amounts	of	pCDNA-BaTdp	(A)	or	pCDNA-BaTdp	(G164A)	(B)	plasmid.	24	hours	post-transfection,	cells	were	stimulated	with	1000	ng/mL	LTA	for	an	additional	24	hours.	Cell	supernatants	were	collected	and	analysed	for	IL-8	content.	Data	represent	means	±	SD	of	at	least	three	independent	experiments.			 Consistent	with	the	results	from	experiments	conducted	in	HEK-TLR4	cells,	BaTdp	expression	had	no	significant	effect	on	LTA	induced	IL-8	activation	in	HEK-TLR2	cells,	further	indicating	that	the	BaTdp	protein	may	not	have	an	immune	suppressive	function	when	expressed	in	mammalian	cells.	The	results	suggest	that	unlike	many	other	bacterial	Tdps,	BaTdp	does	not	have	an	anti-inflammatory	effect	on	host	cells,	leading	us	to	speculate	on	what	its	actual	function	is.		
6.3.6	BaTdp	expression	induces	autophagy	in	HEK293T	cells		 Given	that	BaTdp	appeared	to	localise	to	tubular	networks	when	expressed	in	mammalian	cells,	we	suspected	that	the	protein	may	act	on	autophagy-related	pathways.	This	is	one	of	the	main	internal	housekeeping	systems	for	maintaining	cellular	homeostasis	by	removing	unwanted	cytosolic	components	(Eskelinen,	2005),	and	tubulin	is	known	to	play	an	important	role	in	
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autophagosome	formation	in	mammalian	cells	(Geeraert	et	al.,	2010).	As	mentioned	in	chapter	1,	the	process	involves	the	generation	of	autophagosomes	surrounding	the	target	molecules,	which	then	fuse	with	a	lysosome	to	initiate	degradation	via	hydrolytic	enzymes.	A	key	marker	for	this	process	is	the	lipidation	of	cytosolic	LC3	(LC3-I)	to	form	LC3-II	(Kabeya	et	al.,	2000),	which	enables	the	protein	to	localise	to	the	autophagosome	and	autolysosome.	Monitoring	the	lipidation	of	LC3-I	by	Western	blot	analysis	is	an	established	method	for	detecting	cellular	autophagy	and	has	previously	been	used	successfully	with	HEK	cells	(Tanida	et	al.,	2005,	Tanida	et	al.,	2008).		To	test	whether	BaTdp	expression	in	mammalian	cells	was	associated	with	increased	autophagy	activity,	HEK293T	cells	were	transfected	with	pCDNA-BaTdp	plasmids.	24	or	48	hours	post-transfection,	cell	lysates	were	resolved	by	SDS-PAGE	and	analysed	for	LC3-content	by	Western	blot.	LC3-II	is	a	highly	hydrophobic	protein	that	is	only	partially	soluble	in	standard	lysis	buffers	(Tanida	et	al.,	2008),	so	1%	SDS	in	PBS	buffer	was	used	here	in	order	to	fully	extract	the	cellular	protein	content.	As	shown	in	Figure	6.7,	a	significant	increase	in	LC3-II	could	be	seen	in	cells	expressing	BaTdp	48	hours	post	transfection,	indicating	an	increase	in	autophagy.	The	G164A	mutation	was	associated	with	a	reduction	of	this	effect,	suggesting	that	this	residue	is	functionally	important.	However,	given	that	the	primary	antibody	used	for	detection	recognises	both	LC3-I	and	LC3-II,	we	were	surprised	to	see	that	the	amount	of	LC3-I	detected	by	Western	blot	analysis	was	very	low.			
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Figure	6.7	BaTdp	expression	induces	cellular	autophagy	in	HEK293T	cells.	(A)	HEK293T	cells	were	transfected	with	plasmid	encoding	for	either	WT	BaTdp	or	BaTdp	(G164A).	After	24	or	48	hours,	cells	were	lysed	in	PBS	containing	1%	SDS	followed	by	assessment	of	LC3B	content	by	Western	blot	analysis.	(B)	Immunoblots	were	analysed	by	densitometry	using	ImageJ	software	(Schneider	et	al.,	2012).	For	each	sample,	the	LC3B-II	value	was	normalised	against	the	corresponding	GAPDH	value.	Error	bars,	SD	of	triplicates.	*p	<	0.05.			 HEK293T	cells	expressing	GFP-tagged	BaTdp	were	also	immunostained	with	α-LC3B	antibody,	followed	by	secondary	staining	with	α-rabbit	IgG	Alexa	Fluor	568	conjugate	to	observe	LC3	content	of	cells	via	fluorescence	microscopy	(Fig.	6.8).	An	accumulation	of	LC3	could	be	seen	in	cells	expressing	GFP-BaTdp,	while	cells	expressing	free	GFP	or	transfected	with	empty	plasmid	control	displayed	nearly	undetectable	levels	of	LC3.	
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Figure	6.8	Accumulation	of	LC3	in	HEK293T	cells	expressing	GFP-BaTdp.	HEK293T	cells	were	transfected	with	plasmids	encoding	GFP-tagged	BaTdp	or	free	GFP	for	48	hours,	followed	by	immunostaining	with	α-LC3B	and	α-rabbit	IgG	Alexa	Fluor	568	conjugate	antibody	and	analysis	by	fluorescence	microscopy.	Cell	nuclei	were	stained	with	DAPI.	All	scale	bars,	10	µm.	Original	magnification	X100.	NT,	non-transfected	cell.		
6.4	Discussion		 From	the	results	presented	in	this	chapter,	it	is	clear	that	BaTdp	operates	in	a	distinctly	different	manner	compared	to	SARM.	Bacterial	Tdps	have	been	discovered	in	a	vast	number	of	species,	and	several	studies	have	confirmed	that	some	of	these	are	able	to	regulate	host	TLR-signalling	(Rana	et	al.,	2013).	However,	the	presence	of	Tdps	in	non-pathogenic	bacteria	suggests	that	these	proteins	may	also	have	other	functions.	Recently,	a	study	by	Patterson	and	colleagues	indicated	that	two	TIR-like	proteins	from	S.	aureus	(SaTlp1	and	SaTlp2)	do	not	inhibit	TLR	signalling,	but	rather	upregulate	host	immune	signalling	through	NFκB	activation	(Patterson	et	al.,	2014).	Askarian	and	colleagues	had	previously	been	able	to	demonstrate	that	another	S.	aureus	Tdp	(TirS)	was	able	to	inhibit	TLR2-mediated	NFκB	activation	in	vitro	(Askarian	et	
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al.,	2014).	It	seems	clear	that	bacterial	Tdps	do	not	possess	a	single	unified	function,	but	are	able	to	interact	with	various	different	host	mechanisms	for	different	purposes.		In	addition	to	the	data	presented	here,	our	collaborators	at	the	Defence	DSTL	performed	in	vivo	experiments	with	a	B.	anthracis	BaTdp	KO	strain.	No	significant	difference	in	the	median	lethal	dose	(MLD)	could	be	seen	between	the	two	strains	following	infection	of	mice	via	inhalation.	However,	after	analysing	the	bacterial	loads	of	lung,	spleen,	and	kidney	tissue	at	various	time	points,	it	became	evident	that	the	BaTdp	KO	strain	was	able	to	colonise	lung	tissue	at	a	faster	rate	than	the	WT	strain.	Both	at	72	and	96	hours	post-infection,	animals	infected	with	the	BaTdp	KO	strain	displayed	significantly	higher	bacterial	loads	in	the	lungs	than	those	infected	with	the	WT	strain,	although	at	later	time	points	there	were	no	noticeable	differences.	We	do	not	yet	know	if	this	is	functionally	relevant,	but	taken	together,	the	data	suggests	that	BaTdp	is	not	a	major	virulence	factor.	Although	the	results	presented	in	chapter	4	indicated	that	BaTdp	was	able	to	form	TIR-TIR	interactions	with	mammalian	TLR	adaptor	proteins	in	vitro,	we	found	no	indication	of	the	protein	suppressing	TLR-mediated	immune	activation	when	expressed	in	mammalian	cells.	It	is	possible	that	the	interactions	are	simply	too	weak	to	be	functionally	relevant,	but	it	is	also	important	to	point	out	that	those	experiments	were	conducted	with	truncated	proteins	featuring	only	the	isolated	TIR	domains.	Although	it	is	unlikely	that	the	full	length	proteins	fold	in	a	manner	that	does	not	allow	for	complex	formation,	e.g.	by	not	exposing	the	relevant	interaction	sites,	we	cannot	rule	out	this	possibility	which	would	explain	why	BaTdp	did	not	appear	to	co-localise	with	MyD88	when	both	protein	
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were	overexpressed	in	the	same	cell.	The	complex	cellular	environment	may	also	contain	yet	to	be	discovered	factors	inhibiting	BaTdp	from	targeting	MyD88,	which	would	explain	why	we	only	observed	an	interaction	in	a	minimal	buffer	system.	Of	particular	interest	is	our	observation	that	BaTdp	appeared	to	be	targeting	cytoskeletal	networks	when	expressed	in	mammalian	cells.	A	similar	effect	had	previously	been	described	for	TcpB	(Radhakrishnan	et	al.,	2009),	although	TcpB	has	also	been	found	to	suppress	TLR-mediated	immune	activation	(Cirl	et	al.,	2008,	Sengupta	et	al.,	2010).	Here,	we	showed	that	HEK	cells	expressing	BaTdp	displayed	significantly	increased	cellular	levels	of	lipidated	LC3B,	indicative	of	increased	autophagy.		During	Western	blot	analysis,	the	amount	of	unlipidated	LC3B	detected	was	surprisingly	low.	This	assay	typically	results	in	bands	corresponding	to	LC3-I	and	LC3-II	of	similar	intensity,	although	results	where	the	band	for	unlipidated	LC3	was	barely	detectable	has	previously	been	described	during	starvation	of	HeLa	cells	(Tanida	et	al.,	2005).	In	that	case,	the	result	could	be	improved	with	the	addition	of	protease	inhibitors	E64d	and	pepstatin	A	in	the	growth	medium,	which	is	something	that	may	have	made	the	results	presented	here	more	clear.	We	do	not	know	exactly	why	this	phenomenon	occurs.	Inconsistent	cellular	extraction	of	LC3-I	and	–II	during	sample	preparation	is	unlikely,	as	the	lipidated	form	is	expected	to	be	less	soluble	than	the	unlipidated	form.	It	is	possible	that	the	antibody	used	for	detection	has	a	higher	affinity	for	lipidated	LC3B,	in	which	case	an	increased	amount	of	antibody	used	could	have	helped.	Regardless	of	the	reason,	results	presented	would	have	been	more	convincing	if	a	positive	control	
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sample,	such	as	analysis	of	cells	undergoing	starvation-induced	autophagy,	had	been	included	in	both	the	Western	blot	and	immunofluorescence	analyses.	It	is	known	that	mammalian	cell	exposure	to	B.	anthracis	lethal	toxin	(LT,	comprised	of	LF	and	PA)	results	in	an	increase	of	cellular	autophagy	(Tan	et	al.,	2009),	but	this	was	suggested	to	be	a	regular	host-defence	response	as	inhibition	of	autophagy	with	3-methyladenine	resulted	in	accelerated	cell	death	of	LT-treated	HL-60	cells.	On	the	other	hand,	Kandadi	and	colleagues	have	reported	that	TLR4	KO	mice	displayed	some	protection	against	LT	challenge	(Kandadi	et	al.,	2012).	They	proposed	that	this	effect	was	due	to	a	reduction	of	TLR4-induced	autophagy,	as	cardiomyocytes	display	autophagic	cell	death	during	heart	failure	(Knaapen	et	al.,	2001)	and	TLR4-activation	is	known	to	cause	autophagy	(Xu	et	al.,	2007).		As	discussed	in	section	1.4.2,	some	pathogenic	bacteria	are	also	known	to	subvert	host	autophagy	in	order	to	induce	a	niche	environment	suitable	for	intracellular	replication.	For	example,	S.	aureus	has	been	shown	to	enter	into	autophagosomes	shortly	after	cellular	infection	where	it	proceeds	to	replicate	(Schnaith	et	al.,	2007).	However,	B.	anthracis	has	so	far	not	been	described	to	engage	in	similar	mechanisms.	It	is	possible	that	B.	anthracis	induces	BaTdp-mediated	host	cell	autophagy	either	as	a	way	to	evade	host	immune	system,	or	to	amplify	the	toxic	effect	of	LT	on	cardiac	function	during	later	stages	of	infection.	However,	further	studies	are	warranted	to	support	a	definitive	conclusion	on	the	functional	relevance	of	this	protein.		 	
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Chapter	7		
Final	discussion	
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7.1	Recombinant	expression	of	TIR	domain	proteins	Generation	of	high	quality	proteins	by	recombinant	expression	and	purification	is	a	fundamental	part	of	functional	and	structural	protein	studies.	TIR	domain	proteins	have	consistently	been	demonstrated	to	be	difficult	to	produce	and	isolate,	leading	researchers	to	develop	various	strategies	to	improve	both	expression	yields	and	in	vitro	protein	stability,	such	as	the	use	of	solubility	enhancing	tags	(Rana	et	al.,	2011,	Snyder	et	al.,	2013,	Zou	et	al.,	2014).	Expression	of	truncated	proteins	featuring	only	the	TIR	domain	has	so	far	been	the	preferred	method	for	structural	studies	of	this	domain,	likely	due	to	low	expression	yields	when	attempting	to	express	full	length	TIR	domain-containing	proteins	in	bacterial	systems.	For	example,	Spear	and	colleagues	reported	that	they	were	unable	to	express	a	sufficient	amount	of	soluble	full	length	YpTdp,	leading	them	to	study	the	isolated	TIR	domain	instead	(Spear	et	al.,	2012).	This	was	also	the	case	in	this	study,	where	no	soluble	expression	of	full	length	SARM	protein	could	be	obtained.	A	problem	with	this	strategy	is	that	we	do	not	know	if	the	protein	domain	adopts	a	different	overall	fold	as	a	truncated	version,	or	if	certain	parts	of	the	domain	that	are	not	exposed	in	the	full	length	protein	interfered	with	functional	assays.		Another	important	tool	for	the	improvement	of	recombinant	expression	is	to	design	fusion	proteins	by	connecting	the	target	protein	with	a	protein	tag.	In	this	study,	expressing	TIR	domain	proteins	as	fusion	proteins	with	GST-	or	GB1-tags	dramatically	improved	both	expression	yields	and	solubility.	However,	an	unavoidable	problem	with	this	strategy	is	that	the	tag	may	interfere	with	both	the	protein	folding	and	downstream	functional	assays.	A	commonly	observed	problem	is	also	the	formation	of	so-called	soluble	aggregates,	where	the	target	
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protein	is	misfolded,	but	remains	in	solution	due	to	the	large	solubility	tag	it	is	attached	to.		In	our	experience,	these	issues	are	difficult	to	overcome	with	TIR	domain	proteins,	and	instead	of	attempting	to	circumvent	them,	focus	on	quality	control	remained	the	key	concern.	The	final	product	needs	to	be	pure,	homogenous	and	most	importantly	active.	The	GEV2	vector	(Huth	et	al.,	1997),	coding	for	a	target	protein	N-terminally	fused	with	a	GB1-tag	and	C-terminally	with	a	His-tag,	in	particular	was	useful	for	generation	of	SARM-TIR,	YpTIR,	BaTIR	and	MyD88-TIR	protein	by	bacterial	expression.	High	purity	soluble	protein	could	typically	be	isolated	following	IMAC	and	SEC	purification,	and	this	system	may	be	suitable	as	a	generic	platform	for	recombinant	expression	and	purification	of	TIR	domains.			
7.2	Functional	role	of	SARM	Of	the	human	TIR	domain	proteins,	SARM	is	functionally	and	evolutionarily	unique.	Phylogenetic	analysis	of	the	human	SARM	amino	acid	sequence	indicated	that	the	protein	is	more	closely	related	to	bacterial	TIR	domain	proteins	than	mammalian	ones.	Functional	SARM	homologs	have	been	identified	in	a	wide	range	of	organisms,	including	invertebrate	species	such	as	the	horseshoe	crab	(Belinda	et	al.,	2008)	and	C.	elegans	(Couillault	et	al.,	2004).	SARM	displays	the	highest	degree	of	evolutionary	conservation	of	all	human	TIR	domain	proteins,	and	interestingly,	it	also	appears	to	be	the	most	dissimilar	on	a	functional	level.	While	it	is	well	established	that	the	TLRs	recognise	various	PAMPs	in	order	to	trigger	the	innate	immune	response,	and	that	cytosolic	TLR	adaptor	proteins	MyD88,	MAL,	TRIF	and	TRAM	mediate	immune	signalling	
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downstream	of	the	receptors,	the	functional	role	of	SARM	is	still	not	fully	understood.		Multiple	studies	have	indicated	that	SARM	has	an	anti-inflammatory	role,	acting	by	inhibiting	TLR3-	and	TLR4-activation	(Peng	et	al.,	2010,	Carty	et	al.,	2006).	However,	SARM-deficient	mice	displayed	significantly	lower	expression	of	pro-inflammatory	cytokine	TNFα	following	infection	with	West	Nile	virus	(WNV)	(Szretter	et	al.,	2009).	A	study	by	Kim	and	colleagues	also	demonstrated	that	both	mouse	and	human	myeloid	cells	express	little	to	no	SARM	(Kim	et	al.,	2007b),	which	is	inconsistent	with	the	idea	of	SARM	playing	a	dominant	role	in	innate	immune	regulation.	Recent	studies	have	also	indicated	that	SARM	plays	a	central	role	in	mediating	axonal	degeneration	(Osterloh	et	al.,	2012,	Gerdts	et	al.,	2013,	Gerdts	et	al.,	2015),	demonstrating	that	it	is	a	multifaceted	protein	with	possible	involvement	in	several	biological	processes.	The	data	generated	in	this	study	further	confirms	SARM’s	ability	to	act	as	an	immunosuppressive	protein.	SARM	expression	resulted	in	a	significant	reduction	of	the	secretion	of	multiple	proinflammatory	cytokines	in	HEK	cells	following	both	TLR2-	and	TLR4-mediated	immune	activation.	This	suggests	that	SARM	not	only	acts	on	the	TRIF-dependent	pathway	as	previously	demonstrated	(Carty	et	al.,	2006),	but	also	has	the	ability	to	act	on	the	MyD88-dependent	pathway.	Furthermore	the	research	also	showed	that	the	SARM	TIR-domain	binds	directly	to	the	MyD88	TIR	domain.	Both	binding	to	MyD88	and	the	immunosuppressive	effects	are	dependent	on	G601	in	the	SARM	BB-loop,	strongly	suggesting	that	this	motif	is	functionally	important.				
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7.3	Functional	role	of	BaTdp	It	is	now	well	established	that	TIR	domain	proteins	are	common	among	bacterial	species.	In	the	bioinformatics	study	conducted	here,	more	than	3000	TIR-	or	TIR-like	proteins	of	bacterial	origin	were	identified,	comprising	almost	one	third	of	all	proteins	in	these	families.	However,	the	exact	purpose	of	these	proteins	is	still	not	well	understood.	Some	bacterial	TIR	proteins,	such	as	the	
Brucella	encoded	TcpB	and	uropathogenic	E.	coli	encoded	TcpC	have	been	demonstrated	to	regulate	host	cell	immunity	by	suppressing	TLR	signalling	in	human	cells	(Cirl	et	al.,	2008).	However,	in	this	study	we	did	not	find	any	convincing	evidence	that	the	B.	anthracis	encoded	BaTdp	plays	a	major	role	in	host	immune	suppression,	or	overall	virulence.		Despite	the	protein	associating	with	multiple	human	TLR	adaptor	proteins	in	vitro,	BaTdp	expression	in	human	cell	lines	did	not	affect	the	cellular	activation	of	proinflammatory	cytokines	following	PAMP	stimulation.	BaTdp	also	did	not	appear	to	target	MyD88	when	overexpressed	in	HEK	cells,	but	rather	co-localised	with	microtubule	structures.	It	is	not	clear	why	full	length	BaTdp	would	not	bind	to	cytosolic	MyD88	in	the	cell	based	assays,	but	it	should	be	pointed	out	that	some	fundamental	differences	between	the	interaction	experiments	exist.	For	example,	as	the	GST	pull	down	studies	was	performed	with	truncated	versions	of	BaTdp	comprising	just	the	TIR	domain,	a	possible,	but	unlikely,	explanation	could	be	that	the	full	length	protein	folds	in	a	way	that	blocks	TIR-TIR	interactions.	The	pull	down	assay	also	does	not	provide	any	information	regarding	the	affinity	of	interactions,	and	results	should	therefore	be	used	with	caution.	
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Further	investigation	showed	that	BaTdp	expression	in	mammalian	cells	resulted	in	a	significant	increase	of	cellular	autophagy	activity.	While	autophagy	is	considered	a	host	defence	mechanism,	several	pathogenic	bacteria	have	been	described	to	exploit	this	process	in	order	to	facilitate	intracellular	replication	(Campoy	and	Colombo,	2009).	However,	to	date	there	is	no	evidence	of	B.	
anthracis	utilising	autophagy	for	this	purpose.	Although	our	findings	in	this	thesis	work	are	novel,	further	studies	are	needed	before	any	firm	conclusion	on	the	functional	relevance	of	this	effect	may	be	drawn.		
7.4	Therapeutic	targeting	of	TLRs	and	TLR	adaptor	proteins	Given	their	central	role	in	immune	activation,	it	is	not	surprising	that	the	TLRs	have	attracted	attention	as	potential	therapeutic	targets	(O'Neill,	2003,	Hennessy	et	al.,	2010,	Cook	et	al.,	2004).	One	of	the	main	functions	of	TLRs	is	to	induce	cytokine	expression,	which	is	linked	to	a	wide	range	of	inflammatory	conditions,	and	TLR	antagonists	have	been	proposed	as	viable	strategies	for	treatment	of	both	acute	and	chronic	inflammatory	diseases.	The	most	effective	treatment	for	chronic	inflammation	currently	available	revolves	around	blocking	certain	cytokines	with	monoclonal	antibodies	or	antibody-like	molecules.	However,	one	could	argue	that	as	the	TLRs	appear	earlier	in	the	signalling	cascade,	targeting	these	molecules	may	comprise	a	more	potent	therapeutic	strategy.		Drugs	targeting	TLR4	have	been	tested	in	clinical	settings	for	treatment	of	sepsis,	examples	include	Eritoran,	a	synthetic	LPS	analogue	that	targets	the	ECD	domain	of	TLR4	(Kim	et	al.,	2007a),	and	Resatorvid,	a	small	molecule	drug	that	targets	the	TLR4	TIR	domain	(Takashima	et	al.,	2009).	Although	both	drugs	
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showed	high	potential	in	in	vitro	and	early	phase	clinical	trials,	results	from	phase	2	or	3	trials	were	not	convincing	and	developments	of	both	drugs	were	suspended.	One	possible	explanation	for	the	drugs	inability	to	perform	in	a	clinical	setting	is	that	a	great	deal	of	redundancy	is	built	into	the	innate	immune	system.	Targeting	a	single	TLR	may	not	be	sufficient	for	treatment	of	infection-related	inflammatory	diseases,	as	the	pathogen	would	still	be	recognised	by	other	TLRs.	For	example,	gram-negative	bacteria	may	be	recognised	by	not	only	TLR4	(LPS),	but	also	TLR2	(lipoprotein),	TLR5	(flagellin)	TLR7	(RNA)	and	TLR9	(DNA).	Nevertheless,	a	monoclonal	anti-TLR4	antibody,	NI-0101,	is	currently	in	development	by	Novimmune	for	treatment	of	chronic	inflammation.	The	antibody	was	well	tolerated	during	the	phase	1	clinical	trial,	and	we	eagerly	await	the	results	from	subsequent	trials.		An	alternative	approach	to	targeting	the	actual	TLR	may	be	to	target	one	or	multiple	downstream	signalling	molecules.	All	human	TLRs	except	TLR3	couple	via	MyD88	to	induce	immune	activation,	suggesting	that	this	molecule	may	pose	an	attractive	target	for	modulation	of	immune	activation.	A	study	by	Isnardi	and	colleagues	concluded	that	while	MyD88-deficient	patients	showed	defects	in	establishing	B-cell	tolerance,	they	did	not	develop	any	autoimmune	diseases,	suggesting	that	blocking	TLR	signalling	likely	thwarts	development	of	autoimmunity	(Isnardi	et	al.,	2008).		An	immediate	problem	with	this	strategy	is	that	unlike	cytokines,	the	TLR	adaptors	such	as	MyD88	are	not	secreted	from	immune	cells,	hence	any	drug	targeting	these	proteins	would	need	to	cross	the	cellular	membrane.	Monoclonal	antibody	therapy	therefore	does	not	appear	to	be	a	viable	strategy	in	this	case.		
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Decoy	peptides	based	on	certain	structural	motifs	from	multiple	TIR	domain	proteins	have	recently	been	suggested	as	potential	therapeutics	based	on	their	ability	to	prevent	TIR-TIR	interactions.	By	fusing	these	peptides	to	cell	penetrating	peptide	sequences,	they	can	easily	be	internalised	by	cells	and	exposed	to	the	cytosolic	environment.	Toshchakov	and	colleagues	have	successfully	used	this	strategy	to	design	multiple	peptides	based	on	sequences	from	both	TLRs	(Toshchakov	et	al.,	2007)	and	TLR	adaptor	proteins	(Toshchakov	et	al.,	2005),	many	of	which	were	found	to	suppress	TLR	mediated	immune	activation	in	cellular	experiments.	A	small	molecule	designed	to	mimic	the	(F/Y)-(V/L/I)-(P/G)	consensus	sequence	in	the	BB	loops	of	multiple	TIR	domain	proteins	has	also	been	demonstrated	to	interfere	with	the	association	between	MyD88	and	IL1-R,	but	not	with	the	MyD88/TLR4	interaction	(Bartfai	et	al.,	2003).		In	this	study,	we	designed	a	peptide	based	on	the	SARM	BB-loop	motif	fused	with	the	cell	penetrating	Antennapedia	homeodomain	sequence.	The	peptide	could	be	found	in	the	cytosol	of	HEK	cells	after	just	30	minutes	of	treatment,	indicating	that	it	crosses	the	cellular	membrane	without	difficulty.	However,	despite	in	vitro	data	indicating	that	the	peptide	targets	MyD88,	only	a	minor	reduction	of	IL-8	activation	following	PAMP	stimulation	could	be	seen	in	cells	that	had	been	pre-treated	with	up	to	20	µM	of	the	peptide.	The	rationale	for	basing	the	peptide	on	the	SARM	BB-loop	motif	was	that	a	point	mutation	in	this	region	rendered	the	protein	unable	to	associate	with	both	MyD88	and	TRIF,	but	we	do	not	know	if	this	is	the	actual	binding	site,	or	what	parts	of	MyD88	and	TRIF	that	are	targeted.	While	this	platform	for	delivery	of	drugs	targeting	
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intracellular	proteins	appears	promising,	further	optimisation	of	the	SARM	sequence	is	required.		
7.5	Future	perspectives	In	order	to	further	advance	our	understanding	of	TIR	protein	dynamics	and	the	therapeutic	potential	of	targeting	TLR	pathways,	it	is	imperative	to	elucidate	the	interaction	profiles	of	TIR	domain	proteins	on	a	molecular	level.	With	regard	to	SARM,	a	bottleneck	in	this	study	has	been	that	we	do	not	know	the	molecular	structure	of	the	protein’s	TIR	domain.	We	have	assumed	that	the	SARM	TIR	domain	adopts	a	similar	overall	fold	as	the	TIR	domains	of	previously	solved	structures,	but	a	high-resolution	crystal	structure	of	the	SARM	TIR	domain	would	significantly	facilitate	further	studies.	In	this	study,	we	have	attempted	to	crystallise	the	SARM	TIR	domain,	but	were	unable	to	obtain	any	diffracting	protein	crystals	(data	not	shown).	Given	that	SARM	was	found	to	interact	with	several	TIR	adaptor	proteins,	it	is	possible	that	the	domain	can	be	stabilised	by	co-expression	and	co-crystallisation	with	another	TIR	protein,	such	as	MyD88,	which	could	form	the	basis	for	further	experiments	in	this	area.	To	support	further	development	of	SARM-derived	peptides	with	therapeutic	potential,	it	is	important	to	develop	a	better	understanding	of	mechanisms	that	are	used	for	SARM	association	with	other	TIR	proteins.	In	particular,	elucidation	of	the	binding	interface	between	SARM	and	MyD88	would	be	of	interest,	as	MyD88	is	the	key	adaptor	protein	downstream	of	the	TLRs.	HDXMS	and	2D-NMR	methodology	are	well	suited	techniques	for	this	application,	but	further	optimisation	of	the	experimental	conditions	are	required.	
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